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ABSTRACT 
ALTERED AXON INITIAL SEGMENT STRUCTURE AND FUNCTION IN 
INFLAMMATORY DISEASE 
 
By Kareem Clark, B.S. 
 
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor 
of Philosophy at Virginia Commonwealth University. 
 
Virginia Commonwealth University, 2017 
 
Director: Jeffrey L. Dupree, Ph.D. 
Associate Professor 
Department of Anatomy and Neurobiology 
 
     Axonal pathology is a key contributor to long-term disability in multiple sclerosis (MS), 
an inflammatory demyelinating disease of the central nervous system (CNS), but the 
mechanisms that underlie axonal insults remain unclear. While most axonal pathologies 
characterized in MS are a direct consequence of myelin loss, we propose that axonal 
pathologies also occur independent of demyelination. In support of this idea, we recently 
reported that mice that develop experimental autoimmune encephalomyelitis (EAE), a 
model commonly used to mimic the pathogenesis of MS, exhibit a structural and 
functional disruption of the axon initial segment (AIS), a subdomain of the axon that acts 
as the trigger-zone for action potential generation. Importantly, this disruption is 
independent of myelin loss. Although the mechanism responsible for AIS disruption 
remains unclear, we observed an attenuation of the AIS insult following treatment with a 
known scavenger of oxygen free radicals. To further investigate the role of oxidative 
stress in modulating AIS stability, we employed an in vitro model in which neurons were 
exposed to a spontaneous reactive oxygen and nitrogen species generator. Through this 
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approach, we demonstrated that oxidative stress is capable of AIS modulation acting 
through induction of cytosolic calcium (Ca2+) influx from both extracellular and intracellular 
sources, resulting in calpain protease activation. Furthermore, because rises in 
intracellular Ca2+ are central to these and other mechanisms of AIS disruption, we next 
investigated the cisternal organelle (CO), an AIS-localized Ca2+-regulating structure. 
Although this organelle could prove to be central to AIS modulation, very little is known 
about the mechanisms regulating its stability. Through this line of investigation, we 
provide the first evidence of pathological alteration to the CO in a disease state.  This 
disruption precedes loss of AIS protein clustering and axo-axonic GABAergic input in both 
EAE and MS postmortem tissue. Overall, these studies reveal a primary axonal insult, 
independent of myelin loss, in a disease classically characterized as a white-matter 
pathology. Instead, this insult is most likely driven by oxidative stress through local Ca2+ 
dysregulation at the AIS, providing novel therapeutic targets for MS. 
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CHAPTER ONE 
 
INTRODUCTION 
 
1.1 The Central Nervous System   
     The central nervous system (CNS), which integrates information and coordinates 
activity throughout the body, consists of two major structures: the brain and spinal cord, 
as opposed to the peripheral nervous system which consists of nerves that travel outside 
of the skull or spinal column (de Lahunta et al., 2016). This system is composed of gray 
and white matter which contain neuronal cell bodies and processes respectively (de 
Lahunta et al., 2016). Entry of circulating blood flow components into the CNS is restricted 
by a highly selective blood brain barrier (BBB). Additionally, a unique set of cell types 
reside in the CNS, including neuronal and glial cells, which include astrocytes, microglia, 
and oligodendrocytes (Zuchero and Barres, 2015).     
     Astrocytes are one of three main types of glial cells present in the CNS (Oberheim et 
al., 2012). These star-shaped cells have perhaps the most diverse set of functions 
including guiding laminar organization, providing neuronal trophic support, modulating 
synaptic activity, and maintaining BBB integrity. These cells are also interconnected 
through gap-junctions that aid in the synchrony during reactivity (Orellana et al., 2013). 
Microglia, a separate glial cell type, are the resident innate immune cells of the CNS. 
While the periphery contains a host of lymphocyte and macrophage related cells, the 
inflammatory response in the CNS is largely mediated by microglia (Kabba et al., 2017). 
These cells survey the surrounding CNS environment ready to respond to potential insults 
(Kabba et al., 2017). As effectors of the inflammatory response, these cells can exhibit a 
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spectrum of reactivity profiles depending on the nature of the insult. Microglia are capable 
of displaying either pro-inflammatory or resolving phenotypes which mediate destructive 
or reparative processes respectively (Tang and Le, 2016).  
     A third type of glial cell, oligodendrocytes, are critical for efficient neuronal firing activity 
(Simons and Nave, 2015). These cells form the myelin sheaths, fatty membranes which 
wrap around and insulate the axon and allow for rapid propagation of an action potential 
(AP) (Simons and Nave, 2015). These myelin forming glial cells are responsible for the 
establishment and maintenance of several neuronal subdomains along the axon that are 
crucial for AP transmission (Chang and Rasband, 2013). Oligodendrocytes arise from 
progenitor cells which develop into non-myelin forming immature oligodendrocytes. 
These pro-oligodendrocytes then mature and express critical myelin components 
necessary for initiation of myelination (Barateiro et al., 2016). While myelin consists of 
~70% lipids, proteins such as myelin basic protein (MBP), proteolipid protein (PLP), 
myelin oligodendrocyte glycoprotein (MOG), and myelin associated glycoprotein (MAG) 
are important for proper myelination (Jahn et al., 2009). As oligodendrocyte processes 
wrap around an axon, cytoplasm in the oligodendrocyte membranes is compressed 
towards the lateral edges of the myelin segments, resulting in regions of compacted and 
non-compacted myelin (Zuchero and Barres, 2015). While some axons are unmyelinated, 
AP conduction speed is significantly slower. Without myelin, axons typically have an AP 
conduction velocity of ~10 m/s, while compact myelinated axons can propagate at speeds 
around 100 m/s. (Salzer, 2003; Zalc, 2006). 
     While glial cells have important roles within the CNS, they serve primarily to support 
neurons, the functional units of the nervous system. Acting as the effectors of impulse 
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transmission, these cells control a vast array of physiological functions (Raichle, 2010). 
Neurons of the CNS can be subclassified into pyramidal cells or interneurons which 
exhibit excitatory or inhibitory neurotransmitter release respectively (Hu et al., 2014). 
Important for their firing function, neurons exhibit cellular polarity which involves the 
establishment of distinct cellular compartments such as the somatodendritic region, which 
receives input from other neurons, and the axonal compartment which transmits signals 
to other targets (Britt et al., 2016).  
 
1.2 Axonal Domains 
     A myelinated axon of the CNS contains distinct specialized domains including; the 
internode, juxtaparanode, paranode, node of Ranvier, and axon initial segment (AIS), 
which are diagramed in Figure 1.1 (modified from Susuki et al., 2013). These domains 
have similarities and differences with regards to protein composition, function, and 
mechanisms of establishment and maintenance (Buttermore et al., 2013).  
 
1.2.1 The Internode 
     Spanning a distance of about 99% of the myelinated segment length, the internode is 
the region of the myelinated axon where the myelin is most compact (Buttermore et al., 
2013; Salzer, 2003; Thaxton and Bhat, 2009). This domain contains axoglial interactions 
mediated by cell adhesion molecules (CAMs) called nectin-like proteins, which form 
junctions between the internodal axonal membrane and the overlying myelin sheath. 
These nectin-like proteins are important for both the initiation of myelin wrapping, as well 
as the maintenance of these axoglial interactions following myelination (Park et al., 2008, 
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Spiegel et al., 2007). The cytoskeletal network in the internode consists of the scaffolding 
proteins βII- and αII-spectrin, protein 4.1B, and the adaptor protein ankyrin B which form 
a complex that interacts with actin to establish and maintain neuronal polarity (Buttermore 
et al., 2013; Galiano et al., 2012). While ion channels are not clustered at the internode, 
they are diffusely distributed along the length of this domain (Freeman et al., 2016). 
Despite the lack of ion channel clustering, the internode plays a critical role in AP 
propagation through the maintenance of close axonal-myelin association of the protein 
interactions described above (Buttermore et al., 2013; Maurel et al., 2007; Salzer, 2003; 
Thaxton and Bhat, 2009).  
 
1.2.2 The Juxtaparanode 
     Flanking the internodes is an axonal domain that is crucial for repolarization following 
AP transmission known as the juxtaparanode. This domain contains a high density of 
delayed rectifier potassium channels which function to return the membrane potential to 
resting state following AP propagation and prevents its backpropagation (Buttermore et 
al., 2011; Rasband et al., 1998; Thaxton and Bhat, 2009). Similar to the internode, the 
juxtaparanode makes contact with the overlying myelin sheath via specific protein 
interactions. The protein complex, however, is distinct from that of the internodal axoglial 
interactions. Transmembrane cell adhesion molecule contactin associated protein-2 
(caspr-2) binds the CAM known as transient axonal glycoprotein-1 (tag-1) on the 
axolemma (Gollan et al., 2003; Thaxton and Bhat, 2009; Zoupi et al., 2013). Axonal caspr-
2 and tag-1 then form interactions with tag-1 expressed on the myelin membrane to form 
axoglial junctions (Traka et al., 2003; Zoupi et al., 2013). Similar to the internode, this 
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complex is linked to the cytoskeleton through the same scaffolding proteins αII- and βII-
spectrin, protein 4.1B, and the adaptor ankyrin B. The caspr-2/tag-1 complex is also 
important for the clustering of the rectifier potassium channels, as a mutation in either of 
these proteins results in diffusion of these channel clusters (Poliak et al., 2003; Thaxton 
and Bhat, 2009; Zoupi et al., 2013).  
 
1.2.3 The Paranode 
     Located immediately adjacent to the juxtaparanode is the paranodal axonal domain, 
which forms junctions with the lateral edges of myelin segments (Buttermore et al., 2013; 
Rosenbluth et al., 2013; Salzer, 2003; Thaxton and Bhat, 2009). The length of the 
paranode is highly conserved at ~3.5 µm (Shepherd et al., 2012). As myelin wraps around 
the axon, the cytoplasm contained in the oligodendrocyte process is forced to the edges, 
creating pockets of cytoplasm (non-compact myelin) in the glial membrane called 
“paranodal loops” (Buttermore et al., 2013; Snaidero et al., 2014). These loops make 
contact with the axonal membrane (axolemma) through protein interactions termed 
transverse bands or axoglial septate-like junctions which provide a barrier against lateral 
diffusion of the distinct axonal domains (Buttermore et al., 2011; Buttermore et al., 2013; 
Snaidero et al., 2014). The junctions between the axolemma and the paranodal myelin 
loops consist of 2 proteins on the axolemmal side: CAM caspr-1 which binds in cis with 
contactin (Buttermore et al., 2013) and a single transmembrane CAM  neurofascin 155 
(NF-155) on the glial side (Gollan et al., 2003). Additionally these axoglial interactions are 
stabilized by the spectrin, protein 4.1B, and ankyrin B actin scaffolding complex as in the 
internode and juxtaparanode (Faivre-Sarrailh and Devaux et al., 2013; Thaxton et al., 
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2011). The establishment and maintenance of the paranode is dependent on these 
interactions with the myelin membrane through this complex (Pillai et al., 2009). The 
paranodal domain, while crucial for myelin contact, does not contain functional ion 
channel clusters in the axolemma (Buttermore et al., 2013). Despite this, the paranode 
nevertheless plays an important role in AP propagation serving as a “fence,” demarcating 
nodal and juxtaparanodal ion channels and allowing for rapid saltatory conduction 
(Dupree et al., 1999; Rosenbluth et al., 2003; Thaxton and Bhat, 2009).  
 
1.2.4 The Node of Ranvier  
     The nodes of Ranvier are myelin-bare regions of the axon spanning approximately 1-
2 µm in length (Salzer, 1997). Saltatory conduction, the “jumping” of action potentials from 
node to node along the axon, is made possible by a high density clustering of voltage 
gated sodium channels at the node of Ranvier (Salzer, 2003; Arancibia‑Carcamo and 
Attwell, 2014). Without this clustering, AP conduction would be severely hindered. These 
sodium channels are anchored to the cytoskeleton through interaction with the nodal- and 
AIS-specific scaffolding protein ankyrin G (AnkG) (Buttermore et al., 2013; Thaxton and 
Bhat, 2009). AnkG associates with the spectrin-actin cytoskeleton through interactions 
with βIV-spectrin, which is also exclusively localized in the node and AIS (Berghs et al. 
2000; Buttermore et al., 2013; Komada and Soriano, 2002). The node of Ranvier also 
contains extracellular matrix (ECM) molecules such as the proteoglycans; brevican 
(Bekku et al., 2009) and versican (Dours-Zimmermann et al., 2009), as well as specific 
CAMs such as neurofascin-186 (NF-186) and neural cell adhesion molecule (NrCAM) 
(Davis et al., 1996; Eshed-Eisenbach and Peles, 2013), which also interact with the 
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scaffolding protein AnkG (Lustig et al., 2001; Rasband, 2010). Establishment and 
maintenance of nodal protein clustering is dependent on both extrinsic glial cues and 
intrinsic neuronal cues through initial clustering of NF-186 driven by myelin contact 
followed by recruitment of the AnkG scaffolding protein which clusters other scaffolding 
proteins and voltage gated ion channels (Yang et al., 2007; Zonta et al., 2008).  
 
1.2.5 The Axon Initial Segment 
     The AIS is the unmyelinated region of the axon, spanning about 35-45 µm distally from 
the soma, located between the axon hillock and the first myelin segment (Grubb and 
Burone, 2010; Rasband, 2010). The AIS provides two critical functions: serving as the 
trigger zone for AP initiation as well as establishing and maintaining neuronal polarity 
(Yosihmura and Rasband, 2014). Consistent with the AIS and the NOR both playing roles 
in AP transmission, their protein clusters are very similar in composition (Rasband, 2010). 
The AIS, like the node, contains a high density of voltage gated sodium channels which 
are ~40-50 times more densely clustered in the AIS compared to the somatodendritic 
domain (Rasband, 2010; Kole et al., 2008). Unlike the node, which assists in the 
propagation of action potentials, these AIS sodium channel clusters instead serve as the 
trigger zone for firing (Meeks et al., 2007). In addition to its role in AP initiation, modulation 
of the AP amplitude, duration, and frequency is made possible by a variety of voltage 
gated potassium channel subtypes (Kole et al., 2007; Sánchez-Ponce et al., 2012). The 
AIS also serves as a barrier between the somatodendritic and axonal compartments; thus 
maintaining neuronal polarity (Rasband, 2010). This AIS barrier, while not fully 
understood, is hypothesized to act as a sieve to filter out large cytoplasmic molecules 
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(Nakada et al., 2003; Rasband, 2010). Diffusion within the membrane is also restricted 
due to physical interactions with the AIS cytoskeletal and scaffolding proteins (El-Husseini 
et al., 2000; Rasband, 2010).  
     Establishing and maintaining the protein complexes that constitute the AIS is critical 
for both initiation and modulation of action potentials, as well as retaining neuronal 
polarity. Establishment and maintenance of this domain is under the sole control of 
cytoskeletal scaffolding protein AnkG, which is dubbed the “master organizer” of the AIS 
complex (Dzhashiashvili et al., 2007; Hedstrom, et al., 2007; Rasband, 2010). AnkG 
silencing and its removal from the mature AIS results in dismantling of the AIS, as 
detected through dispersion of sodium channels, βIV-spectrin, NF-186, and NrCAM 
immunolabeling (Hedstrom et al., 2008). AnkG is therefore, not only required for the initial 
recruitment and clustering of AIS proteins, but also for the long-term maintenance of this 
domain. The AIS, once established, is highly plastic, exhibiting alterations to ion channel 
localization and expression in response to neuronal activity. (Adachi et al., 2014; Grubb 
and Burrone 2010; Kaphzan et al., 2011; Kuba et al., 2012).  
   Although the node of Ranvier and the AIS contain very similar protein clusters, they are 
established and maintained through drastically different processes. In addition to the 
differences in roles that NF-186 and AnkG play in recruitment and stabilization of the two 
domains, as described above, perhaps the most extreme difference lies in the role of 
myelin contact. In fact, none of the nodal, paranodal, juxtaparanodal, and internodal 
domains can successfully form without glial contact (Dupree et al., 1999; Buttermore et 
al., 2013; Dzhashiashvili et al., 2007; Eshed-Eisenbach and Peles, 2013; Susuki et al., 
2013; Thaxton and Bhat, 2009). The AIS, however, is formed intrinsically through AnkG 
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restriction to the proximal end of the developing axon, completely independent of 
myelination (Bennett and Baines, 2001; Galiano et al., 2012).     
 
1.3 Axonal Domains in Injury and Disease 
     As described above, the nodal and initial segment domains are responsible for critical 
functions such as AP firing and neuronal polarity maintenance (Nelson et al., 2017). 
Because of these vital functions, pathological disruption of these domains yields severe 
downstream consequences responsible for a wide array of CNS insults (Nelson et al., 
2017). 
 
1.3.1 The Nodal Domains in Injury and Disease 
     As detailed above, the major regulator of the nodal axonal domain stability is myelin 
integrity. For this reason, nodal disruption is characteristic of all CNS insults with 
demyelination as a pathogenic feature. Our laboratory and others have demonstrated 
loss of nodal protein clustering as a downstream consequence of demyelination in mouse 
models of MS and postmortem MS tissue (Dupree et al., 2004; Coman et al., 2006; Howell 
et al., 2010; Pomicter et al., 2010; Zoupi et al., 2013). Following loss of myelin contact on 
the axon, voltage gated ion channels, as well as cytoskeletal scaffolding molecules, 
diffuse away from the domains at which they were clustered (Arancibia-Carcamo and 
Attwell, 2014). Interestingly, nodal clustering can be re-established upon remyelination. 
In the cuprizone demyelinating model of MS, mice that were withdrawn from the cuprizone 
treatment display endogenous remyelination which paralleled reestablishment of nodal 
ion channel and scaffolding protein clustering (Dupree et al., 2004). Similarly, analysis of 
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partially remyelinated lesions in MS postmortem tissue revealed similar restoration of 
nodal clustering (Coman et al., 2006). Other demyelinating disorders of the CNS that 
include nodal domain disruption include optic neuritis, phenylketonuria, Tay-Sachs, 
Gaucher disease, and other leukodystrophies (Mehndiratta and Gulati, 2014). 
     Interestingly, there is evidence of nodal domain dysfunction in CNS disorders that lack 
detectible myelin loss. For example, mutations in ion channels as well as cytoskeletal 
scaffolding proteins at the NOR, paranode and juxtaparanode are implicated in several 
psychiatric disorders including epilepsy, bipolar disorder and autism (Susuki, 2013). 
Additional myelin-independent mechanisms of nodal domain disruption, in the form of 
reduced ion channel expression and localization, occurs in disorders involving the 
peripheral nervous system, such as amyotrophic lateral sclerosis (ALS) (Shibuya et al., 
2011). Traumatic brain injury, as induced through mild fluid percussion, can also result in 
intrinsic disruption of nodal domains through neuronal calpain activation and proteolytic 
cleavage of critical nodal scaffolding components (Reeves et al., 2010). Unlike the myelin-
dependent nodal pathologies, restoration of nodal structure and function following insult 
has yet to be demonstrated. 
 
1.3.2 The Axon Initial Segment in Injury and Disease 
     While nodal axonal domains are crucial for AP propagation, AIS function is perhaps 
more crucial to neuronal firing as the site of AP initiation (Adachi et al., 2014).  Unlike the 
nodal axonal domains, the AIS does not require myelin for establishment of the domain 
(Nelson et al., 2017). The role of myelination in maintenance of AIS integrity, however, 
has only very recently been investigated by our lab (see Chapter 2; Clark et al., 2016) 
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and others (Hamada and Kole, 2015). Other CNS insults, however, are known to induce 
structural and functional alterations to this domain. AIS disruption is prominent, and 
thought to be a causative factor, in several animal models of epilepsy (Marco et al., 1997, 
Wimmer et al., 2010; Harty et al., 2013; Liu et al., 2017). These findings are consistent 
with the role of the AIS as a modulator of neuronal firing (Kole et al., 2008). Additionally, 
traumatic brain injury (TBI), as modeled by blast wave exposure and mild central fluid 
percussion, induces reductions in AIS length, which correlate to functional changes in AP  
generation (Baalman et al., 2013; Greer et al., 2013; Vascak et al., 2017). Disrupted AISs 
are also observed in close proximity to Amyloid-β plaques in models of Alzheimer’s 
disease (León-Espinosa et al., 2012; Marin et al., 2016). These changes in models of 
Alzheimer’s disease are believed to result from decreased AnkG expression by increased 
levels of specific microRNAs (Sun et al., 2014). These structural changes correlated to 
impairment of the selectivity function of the AIS allowing macromolecules such as 
pathogenic forms of Tau into the somatodendritic compartment (Li, et al., 2011; Zempel 
et al., 2017). AIS structure is also a downstream consequence of ischemic injury as 
induced through middle cerebral artery occlusion, focal cortical, and focal white matter 
stroke (Schafer et al., 2009; Hinman et al., 2013). Similarly, excitotoxicity to high levels of 
purinergic and glutamate signaling also result in alterations to the AIS complex (Del 
Puerto et al., 2015; Benned-Jensen et al., 2016) As detailed below, AIS dismantlement 
under ischemic and excitotoxic conditions involves activation of a calcium activated 
protease revealing an important role for calcium regulation at the AIS in the maintenance 
of domain stability. 
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1.4 The Role of Calcium at the AIS 
     As described above, all established mechanisms of AIS alterations under CNS insults 
involve Ca2+ dysregulation and activation of downstream Ca2+-dependent enzymatic 
processes. Understanding mechanisms of Ca2+ entry and storage is, therefore, vital to 
addressing these pathologies in an array of CNS conditions.  
 
1.4.1 Extracellular Ca2+ Entry 
     Influx of extracellular Ca2+ at the AIS is achieved through a variety of membrane 
channels that involve both voltage as well as ligand-gated entry (Rao et al., 2007; Simms 
et al., 2014). Voltage-gated Ca2+ channels (VGCCs), which remain closed at resting 
membrane potential, require a depolarizing shift in order for Ca2+ influx to occur (Simms 
et al., 2014). These channels respond to membrane depolarization through a 
conformational change of the channel subunits, which allows pore formation and entry 
of Ca2+ down its concentration gradient (Catterall et al., 2011). Multiple subfamilies of 
VGCCs are classified according to a variety of properties including; strength of voltage-
dependence, conductance of ion flow, and sensitivity to pharmacological antagonists 
(Catterall et al., 2011). These VGCC subfamilies include Cav1, Cav2, and Cav3, which 
are further classified into channel subtypes correlating with the type of Ca2+ current they 
conduct. Additionally, each VGCC subfamily is also described based on the degree of 
changes to membrane potential required for activation: either low-voltage activated 
(LVA) or high-voltage activated (HVA). These subfamilies include L-type, N-type, P/Q-
type, T-type and R-type currents (Catterall et al., 2011; Simms et al., 2014). 
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     T-type VGCCs, belonging to the Cav3 subfamily, are classified separately from all 
other subfamilies as LVA, since they open in response to small depolarizing currents 
(Cain et al., 2013). Three subtypes of T-type VGCCs are identified each with a unique 
pore forming subunit (Cain et al., 2013). These include Cav3.1, Cav3.2, and Cav3.3 (Cain 
et al., 2013). While T-type channels are the only LVA type of VGCCs described, they are 
not the only type classified differently from the HVA channels. R-type channels (Cav2.3), 
despite belonging to the Cav2 subfamily of VGCCs, share activation and inactivation 
properties with both HVA and LVA channels, lending them to an intermediate-voltage 
activated classification (Guéguinou et al., 2014). Both T- and R-type VGCCs are present 
at the AIS of hippocampal neurons, neocortical pyramidal cells, cerebellar Purkinje cells, 
as well as cartwheel interneurons of the dorsal cochlear nucleus (Bender and Trussell, 
2009, Bender et al., 2010, Grubb and Burrone, 2010). AIS expression of these channels, 
however, seems to vary among cell type as T-type channels are excluded from the AIS-
like region of retinal bipolar cells, and are instead localized exclusively to the 
somatodendritic compartment. While T- and R-type VGCCs are expressed in a variety 
of neuronal cell types axonally and/or somatodendritically (Puthussery et al., 2013), their 
localization at the AIS in other CNS regions remains to be investigated.  
     The Cav2 subfamilies of VGCCS contain P/Q-type and N-type VGCCs are both HVA 
channels further characterized as Cav2.1 and Cav2.2, respectively (Nimmrich and Gross, 
2012; Adams et al., 2013). While N-type channels were named for their ubiquitous 
expression in the “nervous” system, P/Q-type VGCCs were originally identified in 
cerebellar Purkinje cells but later found to be expressed in a variety of other CNS regions 
(Gazulla and Tintore, 2007).  Among several neuronal functions, these channel subtypes 
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are important for vesicle release of specific neurotransmitters at synaptic terminals 
(Molderings et al., 2000; Nimmrich and Gross, 2012). They are also localized at the AIS 
where their proposed function is in the modulation of AP wave form and spike timing (Yu 
et al., 2010).  
     Another type of HVA channels, L-type VGCCs, belong to the Cav1 subfamily 
(Furukawa, 2013). These subtypes are named for their “long-lasting” duration of 
activation, and are extensively characterized in cardiomyocytes (Eisner et al., 2014). 
Neuronal L-type VGCCs, however, are expressed and involved in a variety of neuronal 
functions such as regulating synaptic transmission and plasticity at the somatodendritic 
compartment. Interestingly, while L-type VGCCs are heavily involved in modulating AIS 
plasticity and injury in a variety of CNS insults as described below, they are absent at the 
AIS plasma membrane (Griggs et al., 2017; Jamann et al., 2017). These are not the only 
non-AIS localized Ca2+ channels that influence domain stability. Purinergic (P2X7) and 
glutamate (NMDA) receptors, which are non-selectively permeable to cations including 
Ca2+, also reside in the somatodendritic compartment where they are thought to influence 
AIS Ca2+ levels through changes in membrane potential and subsequent activation of 
AIS-localized VGCCs (Del Puerto et al., 2015; Benned-Jensen et al., 2016). 
 
1.4.2 Intracellular Ca2+ Stores: The Cisternal Organelle 
     While cell surfaced localized channels are important for extracellular Ca2+ entry, local 
storage at the AIS is also critical for buffering cytoplasmic Ca2+ levels (Benedeczky et 
al., 1994). The AIS contains a unique Ca2+ storing structure known as the cisternal 
organelle (CO), which is a specialized form of smooth endoplasmic reticulum (Bas Orth 
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et al., 2007). Insight into the function of the CO is largely gained from the nature of the 
proteins expressed at this structure. The CO contains annexin 6 (A6), sarco-endoplasmic 
reticulum Ca2+-ATPase (SERCA), and Inositol 1,4,5-trisphosphate (IP3) receptor type 1 
(IP3R1); all suggesting a role for the CO in the sequestration and release of Ca2+ at the 
AIS (Benedeczky et al., 1994; Sánchez-Ponce et al., 2011). The CO maintains its 
stability through interactions with the actin cytoskeleton via synaptopodin and α-actinin, 
which are actin-associated proteins crucial for CO establishment and maintenance (Bas 
Orth et al., 2007; Sánchez-Ponce et al., 2011; Sánchez-Ponce et al., 2012). The AIS and 
CO seem to be reciprocally dependent for stability, as loss of AIS clustering disrupts CO 
integrity, and proper CO localization drives AIS plasticity during development (Sánchez-
Ponce et al., 2011; Schlüter et al., 2017). Overall, while the CO appears to be important 
for local Ca2+ regulation at the AIS, alterations to CO integrity under pathological 
conditions have yet to be demonstrated. 
 
1.4.3 The Role of Ca2+ in AIS Plasticity and Injury 
     The AIS, while a highly stable complex, undergoes homeostatic alterations in length 
and positioning along the axon as a response to changes in neuronal activity (Jamann 
et al., 2017). For example, overstimulation of hippocampal neurons results in relocation 
of the AIS complex in an anterograde direction along the axon (Grubb and Burrone, 
2010). Additionally, several studies have demonstrated AIS length changes in response 
to neuronal activity (Jamann et al., 2017). Input deprivation results in lengthened AISs 
while increased stimulation induces shortening of the complex (Evans et al., 2015). All 
reported mechanisms of activity-dependent AIS plasticity are also dependent on Ca2+. 
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More specifically, this involves Ca2+ flow specifically through L-type VGCCs and 
subsequent activation of calcineurin, a Ca2+-dependent phosphatase that destabilizes 
interactions between AIS proteins such as AnkG and voltage gated ion channels (Evans 
et al., 2013). Overall, these Ca2+ dependent AIS alterations are thought to serve as a 
mechanism for fine tuning neuronal excitability in response to synaptic input (Jamann et 
al., 2017). 
     In addition to neuronal activity, changes to AIS protein clustering can also be induced 
through pathological insult as described above (Buffington and Rasband, 2011). The 
mechanisms of AIS dismantlement under ischemic and excitotoxic conditions, like that 
induced through homeostatic plasticity, is driven by Ca2+ influx (Stoler et al., 2016). 
Instead of calcineurin, these mechanisms of AIS injury involve proteolytic cleavage of 
critical AIS proteins including AnkG, βIV spectrin and voltage gated sodium channels by 
calpain, a Ca2+ activated cysteine protease (Schafer et al., 2009; Del Puerto et al., 2015; 
Benned-Jensen et al., 2016). Unlike calcineurin-mediated homeostatic AIS plasticity, 
calpain-dependent proteolysis of the AIS is thus far reported to be irreversible (Schafer 
et al., 2009). It remains unclear how Ca2+ influx selectively triggers calcineurin- versus 
calpain-driven AIS modulation.  
 
1.5 Multiple Sclerosis: Definition and Epidemiology 
1.5.1 Definition and Diagnosis 
     Multiple Sclerosis (MS) is an immune-mediated disease of the CNS in which myelin, 
the protective insulating sheath surrounding neuronal fibers is targeted for degeneration 
(Hemmer et al., 2015). Patients typically present with an initial episode of neurological 
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symptoms lasting at least 24 hours, known as a clinically isolated syndrome (CIS). While 
not all cases of CIS lead to a diagnosis of MS, about ~80% of these cases manifest into 
the disease within several years following the initial event (Brownlee and Miller, 2014). 
Following a CIS, MS can present as one of three types of disease courses: relapsing-
remitting (RRMS), secondary-progressive (SPMS), or primary-progressive (PPMS). With 
85% of MS patients initially diagnosed with RRMS, this is the most common form of the 
disease (Gallo et al., 2015). The RRMS disease course consists of periods of worsening 
neurologic symptoms, or “relapses,” interspersed between periods of symptom 
alleviation, or “remissions” (Gallo et al., 2015). Most patients initially diagnosed with 
RRMS will eventually develop SPMS, in which there is a steady progression of 
neurological deficits over time (Lassmann et al., 2012). A third form of MS, known as 
PPMS, presents with worsening clinical symptoms from the start, lacking the periods of 
remission characteristic of RRMS or the early stages of SPMS (Rice et al., 2013). During 
sudden relapses, PPMS can be also subclassified as “active”, a disease course formally 
referred to as progressive-relapsing MS (PRMS) (Ontaneda and Fox, 2015). 
     No matter the disease course, all diagnoses of MS must meet a specific set of clinical 
criteria (Katz Sand, 2015). Neurological function can be assessed clinically through 
several types of evoked potential testing (Kraft, 2013). Recording electrodes placed on 
the scalp record brain activity following presentation of visual or somatosensory 
stimulations which should yield impaired nerve conduction in MS patients (Kraft, 2013). 
While these tests can identify general neurological deficits, further criteria are necessary 
to rule out a diagnosis of a variety of other CNS diseases (Katz Sand, 2015). A diagnosis 
of MS must also present with regions of CNS myelin loss, termed lesions or plaques, as 
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visualized through Magnetic Resonance Imaging (MRI). Furthermore, a patient 
diagnosed with MS must demonstrate “dissemination of lesions in both space and time” 
according to the McDonald diagnostic criteria for MS (Milo and Miller, 2014). Additionally, 
patients diagnosed with MS also frequently present with oligoclonal bands, which are 
immunoglobulins present in the cerebrospinal fluid (CSF). These immunoglobulins, while 
originally thought to represent autoantibodies against certain CNS components, appear 
to present only as a secondary consequence of the disease, but remain valuable 
biomarkers nonetheless (Milo and Miller, 2014).  
 
1.5.2 Epidemiology 
     MS is estimated to affect 2.3 million individuals worldwide, with about 300,000 of those 
cases found in the United States (Schiess and Calabresi, 2016). Most patients are 
diagnosed between the ages of 20 and 50 (~85% of cases), with pediatric and geriatric 
cases of MS representing about 3-10% and 1-10% of diagnoses, respectively (Buhse et 
al., 2015; Cappa et al., 2017; Tenembaum, 2017). Diagnosing MS in children, however, 
is confounded by transient demyelinating events that may occur early in life, as well as 
the difficulty in identifying lesion progression through both space and time as described 
above (Kamate et al., 2010; Tenembaum, 2017). As with most autoimmune diseases 
(Fairweather et al., 2008), there is also an unequal predominance of MS based on sex, 
with an approximate 3:1 female to male prevalence of the disease (Bove and Chitnis, 
2013) potentially a consequence of  differential effects that sex hormones have on 
immune system function (Golden and Voskuhl, 2016). 
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1.5.3 Risk Factors 
     While the specific causes of MS are unclear, several risk factors, both environmental 
and genetic, are believed to be associated with the disease (Belbasis et al., 2015; 
Didonna et al., 2015). Interestingly, disease prevalence is higher among individuals 
residing in temperate climates such as those found in Canada, the northern United States, 
New Zealand, southeastern Australia and Europe. Low rates of incidence are observed 
among inhabitants of tropical climates, indicating an environmental component may 
contribute to MS development (Marrie, 2004). One hypothesis for this phenomenon is 
that living farther away from the equator, where exposure to sunlight is reduced, results 
in lower vitamin D production, a well-documented risk factor for MS (Lucas et al., 2015). 
There is strong evidence for a correlation between vitamin D levels and MS prevalence 
with levels typically lower in MS patients experiencing more severe disabilities (Simpson 
et al., 2017). Supporting this correlation, clinical trials have demonstrated that 
supplementing with vitamin D yields favorable immunomodulatory effects including 
suppressed lymphocyte reactivity and pro-inflammatory cytokine production (Røsjø E et 
al., 2015; Sotirchos et al., 2016; Muris et al., 2016B). No clinical trials to date, however, 
have successfully demonstrated a significant reduction in the frequency and severity of 
MS symptoms following vitamin D supplementation (Muris et al., 2016A). 
     Another heavily investigated environmental risk factor associated with MS 
development is exposure to the Epstein-Barr virus (EBV) (Wingerchuk, 2011). EBV 
correlates with a large number of MS cases with an increased incidence risk estimated 
around four-fold (Sundström et al., 2008; Wingerchuk, 2011; Burnard et al., 2017). Studies 
have found evidence of EBV infection in the serum and CNS of MS patients; including 
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increased antibody titers to the virus and virally infected T- and B-lymphocytes (Ascherio 
and Munger, 2007; Serafini et al., 2007; Farrell et al., 2009). Additionally, patients display 
an impaired EBV-specific lymphocytic response, suggesting that the MS immune system 
is inadequately equipped to control the virus, unlike that of healthy individuals (Jilek et al., 
2012; Laurencea and Benito-León, 2017). Despite this support for a link between EBV 
and MS development, mounting counter-evidence casts doubt on this hypothesis. Clinical 
trials have found no association between increased EBV antibody levels and the risk of 
developing MS following a CIS; a finding contradictory to its proposed role as a risk factor 
(Munger et al., 2015).  
     While MS is not considered a hereditary disease, familial and ethnic relationships have 
been identified (Hollenbach and Oksenberg, 2015). Existing evidence supports the 
involvement of a genetic component in the development of MS potentially acting to create 
a pre-disposition that would result in enhanced susceptibility to other disease triggers 
such as those described above. Supporting this idea, risk gene CYP24A1, which encodes 
an enzyme involved in vitamin D degradation, was found to be overexpressed in MS 
(Shahijanian et al., 2013). This may explain the extensive vitamin D deficiencies 
associated with severe neurological deficits in MS (Simpson et al., 2017). A variant of a 
critical allele of the HLA-DRB1 gene, which encodes a type of MHC class II cell surface 
receptor, has also been demonstrated in MS patients (Alcina et al., 2012). This receptor 
is crucial for proper recognition of the EBV by T-lymphocytes providing a possible 
explanation for the increased risk of EBV infection in MS patients (Kumar et al., 2013). 
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1.6 Multiple Sclerosis: Murine Models 
     While multiple sclerosis is strictly a human disease, key pathological features such as 
inflammation, demyelination, remyelination, and neuronal insults can be closely 
recapitulated in murine models (Kipp et al., 2017). The most commonly utilized mouse 
models of MS include toxin-induced demyelinating models, viral-induced demyelinating 
models, and experimental autoimmune/allergic encephalomyelitis (EAE) (Kipp et al., 
2017).  
 
1.6.1 Toxin-Induced Demyelinating Models 
     Because demyelination is a hallmark pathological feature of MS (Filippi et al., 2016), 
recapitulating this in mouse models is essential for uncovering the mechanisms 
underlying white matter injury and repair. This is effectively achieved through the use of 
toxin-induced demyelinating models such as the cuprizone and lysolecithin models. The 
cuprizone toxin, which is regularly administered through chow, yields detectible myelin 
loss around 1-2 weeks on cuprizone treatment with peak demyelination by 5-6 weeks of 
exposure (Denic et al., 2011). CNS targets of cuprizone-induced demyelination include 
white matter tracts such as the corpus callosum, striatum, and anterior commissure, but 
also grey matter areas such as the cerebral cortex, hippocampus and cerebellum (Herder 
et al., 2011). Lysolecithin, which is administered through focal stereotactic injection into 
specific CNS regions of interest, induces demyelination much sooner, with myelin loss 
appearing hours after injection (Torre-Fuentes et al., 2017). Unlike cuprizone, lysolecithin-
induced demyelinating insults are limited to the site of injection which commonly include 
the spinal cord or corpus callosum (Torre-Fuentes et al., 2017). While both toxins yield 
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substantial myelin loss, the mechanisms underlying these white matter insults remain 
unclear. 
     Cuprizone, a copper chelating agent, results in the death of oligodendrocytes 
presumably through impairment of mitochondrial enzymes responsible for cellular 
respiration (Torre-Fuentes et al., 2017). In contrast to cuprizone, lysolecithin, is thought 
to stimulate demyelination through disruption of myelin membranes rather than induction 
of oligodendrocyte death. (Höflich et al., 2016). In addition to providing a means of 
examining the downstream consequences of myelin loss, the toxin-induced models also 
allow for the investigation of remyelination mechanisms as both models display 
endogenous myelin repair following removal of the toxins (Baker and Amor, 2015). These 
demyelinating models, however, lack peripheral immune system involvement, a major 
component of MS pathogenesis, which involves autoimmune lymphocyte reactivity and 
CNS infiltration (Filippi et al., 2016). While this may be viewed as a pitfall of the models 
in their deviation from MS pathogenesis, it can also effectively be exploited to uncover 
mechanisms of demyelination and remyelination in a more pure environment. Despite the 
lack of peripheral inflammatory involvement, the inflammatory environment of the CNS is 
altered in both models. This includes increased reactivity and recruitment of microglia, 
the resident innate immune cells of the CNS, to lesion sites where they seem to promote 
myelin debris clearance and remyelination (Rawji and Yong, 2013). Overall, the toxin-
induced models are commonly used to investigate mechanisms of demyelination and 
remyelination, such as those present in MS, but fail to recapitulate the peripheral 
inflammatory component of the autoimmune disease. 
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1.6.2 Viral-Induced Demyelinating Models 
     As described above, development of MS is linked to certain viral infections (Mecha et 
al., 2013). To examine the viral contribution to MS pathogenesis, viruses such as Murine 
Hepatitis virus, Semliki Forest virus, and Theiler's murine encephalomyelitis virus (TMEV) 
are employed. TMEV, the most commonly studied demyelination-inducing virus, is a 
mouse pathogen capable of infecting neuronal and glial cells resulting in the activation 
and recruitment of peripheral lymphocytes into the CNS (DePaula-Silva et al., 2017). 
Intracerebral injection of TMEV leads to the induction of a late-onset demyelinating 
disease with motor deficits and myelin loss not evident until 4-5 weeks post injection 
(McCarthy et al., 2012). As with the toxin-induced models, the mechanisms that trigger 
demyelination remain unknown with possibilities including demyelination as a secondary 
consequence to axonal damage, direct viral effects on oligodendrocytes, or macrophage 
mediated phagocytosis (Mecha et al., 2013). Unlike the cuprizone model, the majority of 
the demyelinating lesions are restricted to the spinal cord despite initial intracerebral 
infection. The chronic inflammatory environment, however, is present in a variety of CNS 
regions and closely mimics that of MS (Olson, 2014). A major advantage of the viral-
induced demyelinating models is that, much like MS, the disease persists for the entire 
lifespan of the animals making it most useful for studying effective therapies for the 
chronic progressive forms of MS (DePaula-Silva et al., 2017). Because of this, effectively 
studying mechanisms of remyelination is challenging since white matter recovery is 
limited in the viral-induced models of MS (Oleszak et al., 2004). 
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1.6.3 Experimental Autoimmune Encephalomyelitis 
     EAE is the most commonly utilized mouse model of MS, and arguably the most 
successful in our understanding of disease pathogenesis since at least three of the 
approved therapies were developed solely through the use of this model (Denic et al., 
2011). EAE is induced through subcutaneous injection of myelin proteins accompanied 
by pertussis toxin and an adjuvant to ignite an inflammatory response (Beeton et al., 
2007). Immunized myelin proteins in this model include myelin oligodendrocyte 
glycoprotein (MOG), myelin basic protein (MBP), or proteolipid protein (PLP) (Badawi and 
Siahaan, 2013). Interestingly, induction of EAE with each of these proteins results in 
distinct disease courses with MOG- and MBP-induced EAE displaying a course closer to 
primary progressive MS with PLP more closely recapitulating the relapsing-remitting form 
(Badawi and Siahaan, 2013).  
    Within 1-2 weeks following induction, EAE mice display motor deficits that can present 
as mild or severe (Beeton et al., 2007). Similar to the viral-induced models, demyelination 
is limited to the spinal cord, but lymphocyte infiltration and microglial reactivity is prevalent 
throughout the CNS (Fletcher et al., 2010; Luo et al., 2017). With extensive peripheral 
and central inflammatory involvement, EAE is arguably the most successful at 
recapitulating the inflammatory environment associated with MS (Kipp et al., 2017). 
Furthermore, pathogenesis of this model, much like MS, is T-cell driven, as transfer of 
EAE-activated T-cells into Naïve mice results in adoptive progression of the disease 
(Rangachari and Kuchroo, 2013). The central role of the autoimmune component in EAE 
distinguishes this model from the toxic models of demyelinating disease which utilize 
more artificial triggers to recapitulate MS symptoms (Denic et al., 2011). Although EAE is 
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the most widely utilized murine model of MS, it is not without its pitfalls. While lymphocytic 
CNS infiltration is successfully replicated in EAE, the prominent T-cell subtype 
contributing to disease progression of this model is CD4+, with CD8+ T-cells known to 
play the predominant role in MS pathogenesis (Babbe et al., 2000; Kipp et al., 2017). 
Despite leading to the development of several currently prescribed MS drugs, EAE also 
has an incredibly high rate of failure for potential therapies, which showed promise in the 
model but proved ineffective in clinical trials (Sriram and Steiner, 2005). Overall, these 
models, along with their advantages and disadvantages, provide close recapitulation of a 
variety of pathogenic components associated with MS. 
 
1.7 Multiple Sclerosis: The Inflammatory Environment 
1.7.1 Peripheral Inflammation 
     While MS is considered an autoimmune disease of the CNS, the inflammatory 
response in MS is initiated in the periphery and thought to drive the early phase of disease 
(Hemmer et al., 2015). Effectors of the inflammatory response associated with MS 
pathogenesis include antigen presenting cells (APCs), T-cells, and B-cells. While T-cells 
are the primary peripheral immune cell type driving MS pathogenesis, their activity is 
dependent on APCs (Sie and Korn, 2017). Peripheral APCs, including macrophages, 
monocytes and dendritic cells, are involved in activating T-cells in the periphery through 
phagocytosis and presentation of myelin antigens on MHC class II receptors along with 
costimulatory molecules (Chastain et al., 2011). This process is necessary for 
development and pathogenesis of both the TMEV and EAE models of MS (Greter et al., 
2005; Chastain et al., 2012). Ultimately, this method of T-cell activation results in 
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maturation into specific T-cell subsets depending on the costimulatory signals presented 
alongside the antigen (Breed et al., 2017). 
     T-cells, which play a major role in the adaptive immune response, are CD3+ 
lymphocytes that mature in the thymus to yield one of three subsets: CD4 expressing 
helper T-cells (Th),  CD8 expressing cytotoxic T-cells, and the more enigmatic CD4-/CD8- 
gamma delta T-cells (Germain, 2002; Wiest, 2016). Helper T-cells, upon activation by 
APCs, further mature into effector subsets including Th1, Th2, Th17 and regulatory T-
cells (Tregs) which are classified based on cytokine profiles. Th1 cells, which mount 
responses against bacterial infections under non-autoimmune conditions, release pro-
inflammatory cytokines such as IFN-gamma (IFN-γ), Interleukin (IL)-2, and tumor 
necrosis factor beta (TNF-β) (Zhu et al., 2010). In contrast, Th2 cells, which normally 
protect against parasitic infection, release several immunosuppressive cytokines 
including IL-10 and IL-4 (Allen and Sutherland, 2014). The Th1 to Th2 balance appears 
critical for MS pathogenesis, as alleviation of disease symptoms is achieved by shifting 
the balance towards the resolving Th2 population (Oreja-Guevara et al., 2012; Aharoni, 
2014). Th17 cells, named for their effector cytokine IL-17, are a distinct pro-inflammatory 
subset of helper T-cells that play a large role in pathogen clearance at mucosal 
membranes but are heavily implicated in a variety of autoimmune disorders upon 
dysregulation (Tabarkiewicz et al., 2015). While these autoimmune functions have proven 
effective for tumor regression, this T-cell subset plays a detrimental role in MS 
pathogenesis (Brucklacher-Waldert et al., 2009; Bailey et al., 2014). Autoreactive Th17 
cells in MS permit CNS lymphocytic infiltration through breakdown of BBB tight junctions, 
and promotion of lymphocyte adhesion to the vascular endothelium (Kebir et al., 2007; 
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Brucklacher-Waldert et al., 2009). While still ongoing, clinical trials targeting the Th17 
population in MS have shown promise (Dos Passos et al., 2016). Whereas Th1 and Th17 
subsets are considered to exhibit pro-inflammatory effector functions, Tregs function to 
suppress these subsets and promote resolution of the inflammatory response; producing 
a variety of anti-inflammatory cytokines such as Transforming growth factor beta (TGF-
β), IL-35, and IL-10 (Duffy et al., 2017). Because modulating the proper T-cell subset 
balance has proven essential for successful disease alleviation in models and clinical 
trials, these cells are of interest for MS therapeutic strategies (Danikowski et al., 2017). 
Interestingly, Tregs are significantly downregulated in MS with those present exhibiting 
dysfunctional receptor expression and cytokine release (Danikowski et al., 2017). Most 
current MS therapies do not target the Treg population but on-going clinical trials are 
aiming to achieve this (Danikowski et al., 2017). Additionally, while much less is known 
about gamma delta T-cells, they are capable of suppressing the Treg population, thus 
exacerbating the autoimmune response. Consistent with a downregulated Treg 
population, the gamma delta T-cell population is significantly increased in MS lesions 
(Paul et al., 2015). Finally, CD8+ T-cells, which normally possess anti-tumor and anti-viral 
functions, are the predominant T-cell subtype found in MS plaques (Sinha et al., 2015). 
The role for these cytotoxic T-cells, however, is controversial with conflicting evidence 
supporting both a pathogenic, as well as an immune regulatory role in MS (Salou et al., 
2015). CD8+ T-cells appear detrimental to MS pathogenesis as they secrete factors 
involved in BBB disruption, and are sufficient to adoptively transfer EAE, which presents 
as a more severe form than that of the donor animal (Salou et al., 2015). Supporting a 
regulatory role, CD8+ T-cells, are important for EAE recovery and display higher activity 
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levels during phases of remissions rather than relapses in MS (Denic et al., 2013; Sinha 
et al., 2015). 
     In addition to T-cells, B-cells are also critical for adaptive immunity with antibody 
production being the most notable function during the inflammatory response (Hoffman 
et al., 2016). B-cells are responsible for the production of CSF oligoclonal 
immunoglobulins, one of the hallmarks of MS clinical diagnosis (Bankoti et al., 2014). 
These cells produce autoantibodies against myelin and axonal specific proteins within 
CNS plaques, and direct the T-cell population toward pro-inflammatory effector functions 
(Rawes et al., 1997; DeVries, 2004; Wootla et al., 2011). Further supporting a pathogenic 
role for B-cells in MS, depletion of B-cells in clinical trials resulted in significant 
improvement of MS disability (Cree et al., 2005; Hauser et al., 2008). Overall, these 
lymphocytes and macrophages, while activated peripherally, infiltrate the CNS where they 
ultimately contribute to plaque formation and disease progression (Larochelle et al., 
2011). 
 
1.7.2 Central Inflammation 
     The CNS, once thought to be immune privileged, is now known to undergo immune 
surveillance by lymphocytes residing in the meninges (Louveau et al., 2015). Despite this 
connection to the peripheral immune system, Microglia serve as the major regulators of 
the CNS inflammatory response (Fernandes et al., 2014). Interestingly, microglia in MS 
adopt a biphasic response, serving as either pro-inflammatory or resolving, depending on 
their location within the diseased CNS (Luo et al., 2017).  
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     Microglia in EAE and the TMEV-induced models display a pro-inflammatory 
phenotype, classically referred to as M1, which contributes to a destructive environment 
such as that found in actively demyelinating MS lesions (Gao and Tsirka, 2011). These 
microglia release a litany of pro-inflammatory cytokines such as IFN-γ, TNF-α, IL-6, IL-
12, and IL-23 and overexpress enzymes that contribute to oxidative stress such as 
inducible nitric oxide synthase (iNOS) and nicotinamide adenine dinucleotide phosphate 
oxidase (NOX) (Rawji and Yong, 2013). These cytotoxic cytokines and free radical 
generating enzymes contribute to extensive damage to surrounding neurons and glial 
cells (Yamasaki et al., 2014). In addition to direct effects on neurons and 
oligodendrocytes, these pro-inflammatory microglia also act to re-stimulate T-cells that 
were activated in the periphery through presentation of new myelin antigens and 
costimulatory molecules (Croxford et al., 2002). 
     In contrast, microglia in toxin-induced demyelinating models such as cuprizone display 
an immunosuppressive phenotype, classically labeled as M2, which contributes to the 
reparative environment found in remyelinating, or “shadow”, plaques (Clemente et al., 
2013). These microglia release resolving and neurotrophic factors such as IL-4, IL-10, 
and TGF-β (Tang and Le, 2016). Additionally, these microglia promote remyelination of 
demyelinated axons both through the clearance of myelin debris, and the secretion of 
factors necessary for recruitment and maturation of oligodendrocyte progenitors (Miron 
et al., 2013). 
     Interestingly, microglia are not the only antigen presenting cells in the CNS. 
Astrocytes, while not traditionally considered immune cells, perform immunomodulatory 
functions (Claycomb et al., 2013). In animal models of MS for example, astrocytes 
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enhance proliferation rate and activation of myelin-specific T-cells by phagocytosis and 
presentation of myelin antigens (Nair et al., 2008). Additionally, they indirectly promote 
myelin damage and T-cell activation through the recruitment of other APCs, such as 
dendritic cells, to sites of damaged myelin (Claycomb et al., 2013). 
     Overall, modulation of the inflammatory response in MS is crucial, and a common 
target of all currently approved therapies (Dargahi et al., 2017). The lack of a cure, 
however, suggests the necessity for a solution more intricate than dampening the 
systemic inflammatory response. This is highlighted by several failed clinical trials which 
aimed to suppress pro-inflammatory cytokines previously implicated in disease 
pathogenesis in animal models (Denic et al., 2011), but either failed to alleviate or 
worsened MS deficits (Anon, 1999; Panitch et al., 1987; Segal et al., 2008; Longbrake 
and Racke, 2009). 
     In order to investigate the contribution of central inflammation in the models used in 
this study, we treated mice with an anti-inflammatory drug termed 3,4-dihy 
dihydroxybenzohydroxamic acid, Didox (Molecules for Health Inc., Richmond, VA). Didox 
was originally purposed as a tumor suppressive drug due to its function as a potent 
ribonucleotide reductase inhibitor (Inayat et al., 2010; Matsebatlela et al., 2015; Shah et 
al., 2015). This drug, however, has also proven effective in suppressing central 
inflammation through inhibition of the peripheral T-cell response, free radical scavenging, 
and reduction of the pro-inflammatory NFkB pathway (Matsebatlela et al., 2015). Due to 
these immunosuppressive properties, Didox will be utilized in these studies to investigate 
the contribution of the inflammatory environment on our pathologies of interest.  
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1.8 Chapter Summary 
     Ultimately, while our lab has previously demonstrated disruption of nodal domains 
under the pathological conditions associated with MS, stability of the compositionally 
similar AIS under these conditions has not been investigated. In the subsequent chapters 
we explore this unaddressed potential neuropathology utilizing a variety of approaches 
including MS mouse models, primary neuronal cultures, and postmortem human tissue. 
In Chapter 2 we exploit two separate mouse models of MS, the cuprizone and EAE 
models, to investigate AIS stability under distinct hallmark conditions of MS pathogenesis 
(Dargahi et al., 2017), demyelination and inflammation, respectively. In an attempt to 
address AIS insults in a wide variety of CNS pathologies, Chapter 3 includes a study 
utilizing a primary neuronal in vitro system of oxidative stress to investigate potential 
mechanisms of reactive oxygen and nitrogen species (ROS/RNS)-induced AIS 
modulation. Finally, in Chapter 4 we examine the cisternal organelle, the enigmatic 
structure responsible for local Ca2+ regulation at the AIS. This includes investigation of 
the mechanisms regulating its stability as well as the consequences of its disruption in 
MS and its inflammatory model. 
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Figure 1.1. Schematic of Axonal Domains. A myelinated axon exhibits five domains 
critical for action potential initiation and propagation. The axon initial segment (AIS) is the 
proximal unmyelinated portion of the axon. The node of Ranvier (N) is the unmyelinated 
IN IN 
Modified from: Susuki et al., 2013 
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gap between the myelin segments. The node is flanked by the paranode (PN), the region 
where the lateral edges of the myelin segments contact the axon. The juxtaparanode (JP) 
is located adjacent to the paranodal domains, while the internode (IN) is the axonal region 
underlying the majority of the compacted myelin segments.     
 
 
 
 
 
 
 
 
 
CHAPTER TWO 
 
COMPROMISED AXON INITIAL SEGMENT INTEGRITY IN EAE IS PRECEDED BY 
MICROGLIAL REACTIVITY AND CONTACT 
 
Clark et al., 2016. Glia 
 
2.1 Abstract 
     Axonal pathology is a key contributor to long-term disability in multiple sclerosis (MS), 
an inflammatory demyelinating disease of the central nervous system (CNS), but the 
mechanisms that underlie axonal pathology in MS remain elusive. Evidence suggests that 
axonal pathology is a direct consequence of demyelination, as we and others have shown 
that the node of Ranvier disassembles following loss of myelin. In contrast to the node of 
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Ranvier, we now show that the axon initial segment (AIS), the axonal domain responsible 
for action potential initiation, remains intact following cuprizone-induced cortical 
demyelination. Instead, we find that the AIS is disrupted in the neocortex of mice that 
develop experimental autoimmune encephalomyelitis (EAE) independent of local 
demyelination. EAE-induced mice demonstrate profound compromise of AIS integrity with 
a progressive disruption that corresponds to EAE clinical disease severity and duration, 
in addition to cortical microglial reactivity. Furthermore, treatment with the drug didox 
results in attenuation of AIS pathology concomitantly with microglial reversion to a less 
reactive state. Together, our findings suggest that inflammation, but not demyelination, 
disrupts AIS integrity and that therapeutic intervention may protect and reverse this 
pathology.   
 
2.2 Introduction 
     Multiple Sclerosis (MS) is an immune-mediated inflammatory disease of the central 
nervous system (CNS) characterized by lymphocytic infiltration (Greer, 2013) and focal 
demyelination (Popescu et al., 2013). In addition to myelin loss, axonal pathology is 
prevalent and postulated to be responsible for irreversible clinical disability (Trapp et al., 
1998). Although present at all stages of MS (Criste et al., 2014), axonal pathology is 
generally considered a consequence of demyelination (Black et al., 2007; Waxman, 
2008). Consistent with this view, deterioration of the node of Ranvier (NOR), the 
specialized axonal domain required for action potential propagation (Susuki and 
Rasband, 2008), is a consequence of myelin loss in MS (Coman et al., 2006; 
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Desmazieres et al., 2012; Howell et al., 2010) and mouse models of CNS demyelination 
(Dupree et al., 2004) and inflammation (Zoupi et al., 2013).  
     Here, we examined the effect that demyelination has on another specialized axonal 
domain- the axon initial segment (AIS), which clusters many of the same proteins as the 
NOR (Buffington and Rasband, 2011). The AIS is located distal to the soma, contains a 
high density of ion channels including voltage-gated sodium (Nav+) channels (Kole et al., 
2008) and is responsible for action potential initiation and modulation (Buffington and 
Rasband, 2011).  Mice incapable of clustering AIS proteins develop ataxia and fail to 
initiate action potentials (Zhou et al., 1998). The Nav+ channels clustered at the AIS are 
linked to the spectrin-actin cytoskeleton through interactions with the scaffolding protein 
ankyrin-G (AnkG) (Buffington and Rasband, 2011). AnkG is considered the master 
organizer of the AIS, as it is required for the establishment and maintenance of AIS protein 
clusters and neuronal polarity (Hedstrom et al., 2008; Jenkins and Bennett, 2001). While 
the establishment of the AIS is well defined (Galiano et al., 2012), the mechanisms that 
regulate AIS stability remain poorly understood. AIS protein clustering is compromised in 
a variety of neuropathological models including stroke (Schafer et al., 2009; Hinman et 
al., 2013) and traumatic brain injury (Baalman et al., 2013; Greer et al., 2013) while protein 
clustering is preserved following demyelination (Hamada and Kole, 2015). To our 
knowledge, however, this is the first study to investigate AIS stability in an immune-
mediated CNS model of inflammation. 
     Our findings, consistent work of Hamada and Kole (2015), show that local 
demyelination is not sufficient to trigger disruption of AIS protein clusters, indicating that 
the mechanisms that maintain the node/paranode are distinct from those that maintain 
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the AIS. In contrast, we provide the first evidence that AIS clustering is lost in an 
inflammatory model of MS. AIS disruption is preceded by microglial reactivity and 
correlates with increased microglia/AIS contact and expression of pro-inflammatory 
factors. Moreover, we report that pharmacological intervention can prevent and reverse 
these microglial changes and lead to the protection of AIS integrity. 
 
2.3 Materials and Methods 
Animals 
     Five and 11 weeks old c57bl/6 mice were purchased from Jackson Laboratories (Bar 
Harbor, ME) and maintained in the Virginia Commonwealth University Division of Animal 
Resources (VCU DAR) or the McGuire Veterans Affairs Medical Center  
(VAMC) vivariums, respectively, which are both AAALAC accredited facilities. Treatments 
were initiated after the mice acclimated for one week resulting in treatment initiation at six 
and 12 weeks of age. Food and water were provided ad libitum. In addition, 12 weeks old 
Thy1-YFP-H mice [B6Cg-TgN (Thy1-YFP-H)2Jrs, stock number 003782 obtained from 
the Jackson Laboratories] were obtained from an established colony maintained in the 
VCU DAR. All procedures were conducted in accordance with the methods outlined in 
approved VCU and McGuire VAMC IACUC protocols. 
 
The Cuprizone Model 
     To induce cortical demyelination, ground chow (5001 Rodent Diet; PMI Nutrition 
International, LLC, Brentwood, MO) was mixed with cuprizone (Bis(cyclohexanone) 
oxaldihydrazone; Sigma-Aldrich, St. Louis, MO; 0.2% w/w) as previously described 
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(Dupree et al., 2004).  Briefly, six weeks old mice were maintained on a ground chow diet 
without (0%; n=7) or with (0.2% w/w) cuprizone for 1 (n=6), 3 (n=6) or 5 (n=6) weeks. 
These durations were chosen based on previous studies that reported initial signs of 
cortical demyelination occur following 3.5 weeks and maximum demyelination occurs 
following 5 weeks of cuprizone exposure (Fjaer et al., 2013).  An additional group was 
maintained on cuprizone for 5 weeks followed by 3 weeks of normal (non-cuprizone; n=6) 
chow, allowing remyelination. Table 2.1 outline treatment duration and the number of 
mice per treatment group.   
 
The Chronic EAE Model 
     To evaluate AIS integrity in an inflammatory environment, we induced the chronic 
model of experimental autoimmune encephalomyelitis (EAE) as previously described 
(DeVries et al., 2012; Secor McVoy et al., 2015; Dupree et al., 2015). Briefly, 12 weeks 
old c57bl/6 mice or Thy1-YFP-H mice were injected subcutaneously over each shoulder 
with 50 L of a solution containing 3 mg/mL myelin oligodendrocyte glycoprotein peptide 
35–55 (MOG35–55, MEVGWYRSPFSRVVHLYRNGK) (AnaSpec, Inc., Fremont, CA)  
emulsified with complete Freund’s adjuvant containing 2 mg/mL of heat-killed M. 
tuberculosis (Invitrogen Life Technologies, Grand Island, NY). Mice were also injected 
intraperitoneal (i.p.) on the same day with 300 ng Pertussis toxin (PT) (List Biological 
Labs, Campbell, California) in 200 µL phosphate buffered saline (PBS) with a booster PT 
injection 48 hours later. Clinical motor symptoms were scored daily and recorded as 
follows: 0= no signs, 1.0= limp tail, 2.0= loss of righting reflex, 3.0= paralysis of single 
hind limb and 4.0= paralysis of both hind limbs. 
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     Mice achieved peak clinical symptoms at ~15 days post injection (Fig. 2.1A). 
Immunohistochemical analysis was conducted at two time points along the EAE disease 
course; an early inflammatory time point (3 days post peak clinical symptoms; ~18 days 
post induction) and a late inflammatory time point (9 days post peak clinical symptoms; 
~24 days post induction) as indicated in Figure 2.1A. As illustrated, not all mice achieved 
the more severe clinical scores (Fig. 2.1A). We have exploited this variation in model 
progression and grouped the mice into 2 categories based on clinical scores which 
provided a clinical score-to-structural disruption analysis. Within each time point, mice 
were categorized as either EAE 1&2 (Early n=4; Late n=3) or EAE 3&4 (Early n=4; Late 
n=7) based on daily scoring. Only animals that maintained consistent scores for the period 
of 3 or 9 days post peak score were used in the study.  Table 2.2 displays the clinical 
scores and the number of mice used in each group.   
 
Didox Administration    
     Didox (N-3,4-tridhydroxy-benzamide), a ribonucleotide reductase inhibitor supplied by 
Molecules for Health, Inc., (Richmond, VA), is a multifunctional compound that inhibits 
DNA replication and T-cell proliferation, reduces oxidative injury and attenuates 
microglia/macrophage production of inflammatory factors (Bhave et al., 2013; Inayat et 
al., 2010; Matsebatlela et al., 2015; Turchan et al., 2003). Based on prior optimization 
studies to determine drug dose, frequency, and route of administration (DeVries et al., 
2012, Elford et al., 2013), 200 µl of carboxymethylcellulose containing 550 mg/kg of didox 
was administered via oral gavage to a separate cohort of mice (n=4) at the Early time 
point. Vehicle control mice (n=4), also at the Early EAE time point, were administered 200 
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µl of carboxymethylcellulose solution by oral gavage. The vehicle solution contained 0.5% 
(w/v) carboxymethylcellulose, 0.9% (w/v) sodium chloride, 0.4% (w/v) polysorbate 30, and 
0.9% (w/v) benzyl alcohol in deionized water. Administration of didox or vehicle was 
continued daily for 6 days (Fig. 2.1B). 
 
Antibodies 
     Axon initial segments (AISs) were visualized using mouse monoclonal antibodies 
directed against ankyrin-G (AnkG) (NeuroMab, Davis, CA; N106/36, 1:200) and the Nav+ 
channel isoform 1.6 (Nav1.6) (NeuroMab; K87A/10, 1:100)  Microglia were labeled with a 
rabbit polyclonal antibody directed against the ionized calcium binding adaptor molecule-
1 (IBA-1) (Wako Chemicals, Richmond, VA; 1:1000). An antibody directed against myelin 
basic protein (MBP) (Covance, Chantilly, VA, 1:1000) was used to assess myelin integrity 
in the EAE-induced and cuprizone treated mice. Neurons were identified using the NeuN 
antibody (Millipore; Billerica, MA; 1:1000). To distinguish nodes of Ranvier from 
potentially fragmented AISs, an antibody directed against Caspr (anti-guinea pig; 
generous gift from Dr. Manzoor Bhat, University of Texas San Antonio) was used to label 
paranodes. To assess inflammatory molecular profiles of reactive microglia, antibodies 
directed against tumor necrosis factor alpha (TNFα) (abcam; Cambridge, MA, 1:200), 
inducible nitric oxide synthase (iNOS) (BD Biosciences; San Jose, CA, 1:200), and 
macrophage colony stimulating factor (M-CSF) (Santa Cruz Biotechnology; Dallas, TX, 
1:200) were used. All secondary antibodies were obtained from Invitrogen Life 
Technologies (Grand Island, NY; AlexaTM Fluor) and used at a dilution of 1:500. 
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Tissue Preparation      
     Mice were deeply anesthetized using 0.016 mL/gm body weight of a 2.5% solution of 
avertin (2, 2, 2 tribromoethanol) (Sigma-Aldrich; St. Louis, MO) in 0.9% sodium chloride 
(Sigma-Aldrich, St. Louis, MO) and transcardially perfused with 4% paraformaldehyde 
(Ted Pella, Redding, CA) (Dupree et al., 1999; Shepherd et al., 2012). Following perfusion 
the cortex was cryopreserved in 0.1 M PBS containing 30% sucrose for 48 hours, frozen 
in Optimal Cutting Temperature compound, and serially sectioned at 40 µm in a coronal 
orientation using a Leica CM 1850 cryostat. The cortical region spanning 1.1 mm anterior 
to bregma to 2.5 mm posterior to bregma was serially sectioned. Fifteen sets of six 
sections were collected and placed on ProbeOn Plus slides (Fisher Scientific, 
Loughborough, UK) and stored at -80°C.  Additionally, a single mouse brain was 
sectioned transversely to assess microglia/AIS interactions from a different orientation.  
 
Immunohistochemistry 
     Slides were immunolabeled with the appropriate primary and secondary antibodies as 
described (Dupree et al., 1999; Shepherd et al., 2012; Pomicter et al., 2010) with the 
modification that 0.5%  Triton X-100 was used for AnkG  labeling and 1% Triton X-100 
was used for MBP labeling. Nuclear stain BisBenzimide (Sigma-Aldrich, St. Louis, MO, 
1:1000) was used to identify cortical layers. Slides were mounted with Vectashield™ 
(Vector Laboratories, Burlingame, CA); and imaged using confocal microscopy. 
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Confocal Microscopy/Quantitation 
Image Collection 
     All images were collected using a Zeiss LSM 710 confocal laser scanning microscope 
(Carl Zeiss Microscopy, LLC, Thornwood, NY) housed in the VCU Department of 
Anatomy and Neurobiology Microscopy Facility. Confocal z-stacks, each spanning an 
optical distance of 25m, using a pin hole of 1 Airy disc unit and Nyquist sampling were 
collected from neocortical layer V for each of the six sections per mouse resulting in 12 
images per animal for AIS quantitation and 24 images per animal for microglial 
morphological scoring. Images were taken with a 40X oil-immersion objective with a 
numerical aperture of 1.3; optical slice thickness was 0.49 µm, using a scan average of 
2. X, Y and Z image dimensions were 212.43 µm x 212.43 µm x 25.00 µm, respectively. 
The gain and offset values were kept constant for all images. Spectral unmixing was 
employed to remove auto-fluorescence that resulted from lipofuscin and interfered with 
AIS quantitation. All quantitative analyses of AISs were limited to the AnkG-labeled slides 
since labeling intensity and consistency were superior with the AnkG antibody as 
compared to the Nav1.6 antibody. Although not quantified, Nav1.6 labeled sections were 
used to confirm, qualitatively, the changes in AIS integrity.  
 
AIS Quantitation   
     AIS length measurements and counts were performed using ImageJ analysis software 
by manually tracing initial segments from maximum intensity projection images resulting 
in the analysis of >1000 AISs per Naïve mouse. To eliminate AISs that extended beyond 
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the boundaries of the captured field of view (FOV), which would result in an artificial 
shortening of the segment, AISs touching any of the six edges of the collected z-stack 
were excluded from analysis. To compare the number of AISs, the data are presented as 
percent of Naïve (% Naïve ± SEM). To compare AIS length, the average length of the 
AISs in micrometers is presented as mean ± SEM. We also determined AIS length as a 
percent of AIS length from Naïve mice and these data are presented as % Naïve ± SEM. 
After determining normal distribution of the data sets using normal quantile (Q-Q) plots, 
one-way ANOVAs with Tukey’s Honest Significant Difference (HSD) post hoc tests were 
performed for both mean AIS number and length comparisons. All graphing and statistical 
analyses were performed using GraphPad Prism version 6.03 for Windows (GraphPad 
Software, San Diego, CA). 
 
Neuronal Number Quantitation 
     To compare neuron number, neuronal nuclei were immunolabeled with the NeuN 
antibody (Mullen et al., 1992) and NeuN+ cells were counted in three Naïve mice and 
three EAE 3&4 mice at the Late time point. Double immunolabeling with AnkG was also 
performed to determine the percent of NeuN+ cells with and without an associated AIS. 
Three confocal images per mouse were collected using a 20X objective with a numerical 
aperture of 1.4 and a pinhole of 1 Airy disc unit, resulting in ~900 neurons analyzed per 
Naïve mouse. A two-tailed T-test with Welch’s correction was performed on the average 
number of NeuN+ cells using GraphPad Prism version 6.03 for Windows. 
 
Quantitation of Microglial Morphology 
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     Microglial morphology was quantified using a modification of a method previously 
published (Hutson et al., 2011; Taetzsch et al., 2015). Briefly, microglia, as identified by  
IBA-1 immunolabeling in  confocal Z-stacks, were scored with values ranging from “0” to 
“3” based on cell morphology wherein a stage “0” represents a ramified, surveying 
microglia, and a stage “3” represents an amoeboid form, consistent with reactivity. 
Microglia exhibiting each morphological stage are presented in Supplementary Figure 
S2.1. Categorizing characteristics included cell body size as well as process thickness, 
length and branching complexity as described (Hutson et al., 2011; Taetzsch et al., 2015); 
quantification was conducted blindly and independently by two individuals resulting in 
scoring of approximately 250 cells per mouse. Results of microglial phenotype 
quantitation varied by <10% per mouse between the two blinded evaluators. The findings 
from the two blinded evaluators were averaged, and the data presented as morphological 
stage distribution graphs as a percent of the total microglia present. For statistical 
analysis, two-way ANOVAs with Tukey’s HSD post hoc tests were performed using 
GraphPad Prism software version 6.03 for Windows. 
 
Quantitation of Microglial-AIS Interactions 
     Contact between microglia and AISs was quantified using Volocity™ 3D Image 
Analysis Software version 6.3 allowing each confocal z-stack to be observed in three 
dimensions.  The number of microglia, AISs, and contact points in each double 
immunolabeled z-stack was counted manually. Contact points along the six edges of the 
z-stacks were excluded from analysis. Data are presented as the number of contact 
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points per FOV as a percent of Naïve. One way ANOVAs with Tukey’s HSD post hoc 
tests were performed using GraphPad Prism version 6.03 for Windows. 
    The z-stacks used for the quantitation of microglia and AIS contact were also used for 
production of isosurfaced images. These images were generated as a 3D-reconfiguration 
of the optical slices to facilitate visual assessment. 
 
Isolation of Mouse Cortical Microglia 
     Isolation of adult cortical microglia was performed as described (Taetzsch et al., 2015). 
Briefly, Naïve, cuprizone treated (3 wk), and EAE induced (Early 1&2) mice were perfused 
with 50mL of ice-cold PBS.  After removal of the meninges, cerebral cortices of three mice 
were pooled per sample (3 mice = 1 n) and suspended in Hank’s balanced salt saline 
solution (HBSS) without CaCl2 and MgCl2 (Corning, Corning, NY). A single-cell 
suspension was prepared using the Miltenyi Neural Tissue Dissociation Kit (Miltenyi 
Biotec, San Diego, CA). Myelin depletion was performed by suspension in 30% isotonic 
Percoll™ (GE Healthcare Life Sciences, Pittsburgh, PA) followed by a spin at 700xg 
(4oC). Isolation of microglia was performed using CD11b microbead labeling (Miltenyi, 
San Diego, CA) followed by passage of the cells through MACS LS columns and magnetic 
separator (Miltenyi, San Diego, CA). 
 
Quantitative Reverse Transcriptase Polymerase Chain Reaction 
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     Total RNA was extracted from CD11b+ isolated cells using a Qiagen RNeasy mini kit 
(Qiagen, Germantown, MD). Contaminating DNA was eliminated through treatment with 
Ambion DNase I (Invitrogen Life Technologies, Grand Island, NY). iScript Reverse 
Transcription Supermix (BioRad, Hercules, CA) was used to create cDNA from the 
isolated RNA (0.3 μg/sample). Quantitative RT-PCR was performed with a CFX96 
(BioRad, Hercules, CA) RT-PCR detection system using 1 μL of cDNA, SsoFast 
Evagreen Supermix (BioRad), and forward and reverse primers (500 nM). Cycling 
parameters were one cycle at 95°C (5 min), 40 cycles of 95°C (5 sec) and 56°C (5 sec) 
followed by a melt curve measurement consisting of 5 sec 0.5°C incremental increases 
from 65°C to 95°C. The fold changes in expression of the genes M-CSF (forward: 5’- 
CGAGACCCTCAGACATTGGA -3’; reverse: 5’- TGGTGAGGGGTCATAGAATCC -3’), 
iNOS (forward: 5’-TCCAGAATCCCTGGACAAGCTGC-3’; reverse: 5’-
TGCAAGTGAAATCCGATGTGGCCT-3’), and TNFα (forward: 5’-
GCCCACGTCGTAGCAAACCACC-3; reverse: 5’-CCCATCGGCTGGCACCACTA-3’) in 
CD11b+ cells were calculated using the formula RQ = 2−ΔΔCt, using Cyclophilin A 
(forward: 5’- CTAGAGGGCATGGATGTGGT -3’; reverse: 5’- 
TGACATCCTTCAGTGGCTTG -3’) as an endogenous reference gene. For statistical 
analysis, two-way ANOVAs with Tukey’s HSD post hoc tests were performed using 
GraphPad Prism software for Windows (v6.03). 
 
2.4 Results 
Axon initial segments are not disrupted following cuprizone-induced 
demyelination  
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     Our laboratories (Dupree et al., 2004; Coman et al., 2006) and others (Howell et al., 
2010; Zoupi et al., 2013) have shown that demyelination results in the loss of NOR protein 
clustering. Here, we investigated the effect that demyelination has on another axonal 
domain -- the AIS. Consistent with previous studies (Skripuletz et al., 2008) and as shown 
in Figure 2.2, mice maintained on a normal diet (Fig. 2.2A) or a cuprizone diet for 1 week 
(Fig. 2.2B) revealed robust MBP labeling in cortical grey matter, while extensive reduction 
was observed following 3 (Fig. 2.2C) and 5 (Fig. 2.2D) weeks of cuprizone exposure (Fig. 
2.2D). Mice that were maintained for 5 weeks on cuprizone followed by 3 weeks of normal 
chow revealed increased MBP labeling consistent with remyelination (Fig. 2.2E). 
     To assess AIS number and length in the control, 1, 3 and 5 weeks cuprizone treated 
and recovered (5+3 weeks) mice, AISs were immunolabeled for AnkG (Fig. 2.2F-J) and 
Nav1.6 (not shown). Consistent with the findings of Hamada and Kole (2015), who 
showed that AnkG, Nav1.6 and βIV spectrin maintained AIS clustering following cuprizone 
treatment, no significant difference was observed among any of the groups as compared 
to the Naïve with regard to either AIS number (Fig. 2.2K; Table 2.1) or length (Fig. 2.2L; 
Table 2.1), indicating that unlike the NOR, AIS maintenance is independent of 
myelination. 
 
Axon initial segments are shortened following Early EAE  
     Although cuprizone treatment provides an excellent model to study demyelination and 
subsequent remyelination, the inflammatory aspects of MS are better studied by 
exploiting the EAE model. Following EAE induction, we analyzed AIS number and length 
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in cortical layer V of EAE mice at the Early disease stage (3 days post peak; Fig. 2.1A). 
For comparison, EAE mice were grouped according to clinical disease severity as mild 
(scores 1&2 or EAE 1&2) or severe (scores 3&4 or EAE 3&4).  No change in AIS number 
was observed among either of the Early groups (Fig. 2.3A-C, G; Table 2.2) and no 
difference in the mean AIS length was observed between Naïve (19.9 ± 0.3m; Table 
2.2) and Early EAE 1&2 (17 ± 1.6 µm; Table 2.2) animals. In contrast, the Early EAE 3&4 
mice showed significantly shorter mean AIS lengths (13.4 ± 0.4m; Table 2.2) as 
compared to both the Naïve and the Early EAE 1&2 groups (compare Fig. 2.3C against 
Fig. 2.3A, B; Fig. 2.3H). As shown in Figure 2.3, AIS labeling was frequently discontinuous 
in the Early EAE 3&4 mice suggesting that AIS clustering was modestly compromised at 
this stage of disease.  
 
 
 
Axon initial segments are lost during Late EAE  
     Our findings from the Early EAE mice indicate that AISs are structurally vulnerable (i.e. 
AIS shortening); however, recent studies have shown that the AIS is a highly dynamic 
structure with regard to length (Evans et al., 2013; Grubb and Burrone, 2010). Therefore, 
to determine whether the changes in length observed in the EAE mice during the Early 
stages of disease were maintained, we assessed AIS morphology in the EAE mice at 9 
days post peak clinical score (Late EAE).   
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     In contrast to the mice at the Early EAE stage, EAE-induced mice at the Late stage 
presented significantly fewer AISs in both the EAE 1&2 (Fig. 2.3E) and the EAE 3&4 
group (Fig. 2.3F) compared to the Naïve (Fig. 2.3D).  As shown in Figure 2.3G and Table 
2.2, approximately 60% of the AISs were lost in the Late EAE 1&2 group while nearly 
75% of the AISs were lost in the Late EAE 3&4 mice, with a statistically significant 
difference between the latter two groups.   
    For the above data, AIS counts from all sections spanning the entire anterior to 
posterior axis of the brains were combined. To determine whether AIS stability was 
different along the anterior-posterior axis, counts were compared between comparable 
regions with regard to their location. Consistent with the compiled findings, AISs were 
equally susceptible to disruption at each bregma location along the anterior-posterior axis 
(Supplementary Figure S2.2).    
    With the loss of AISs, AnkG-labeled puncta were more readily observed. To determine 
whether these puncta were remnants of disrupted AISs or possibly nodes of Ranvier, we 
double labeled EAE brain sections for AnkG and the paranodal protein Caspr (Bhat et al., 
2001; Peles and Salzer, 2000). As shown in Figure 2.3F inset, these AnkG-positive 
puncta were flanked by Caspr labeling indicating that these structures were preserved 
nodes of Ranvier. 
     As with the Early group, we also measured AIS lengths in the Late group (Fig. 2.3H). 
The average AIS length for the Late EAE 1&2 mice was 12.0 ± 0.3 µm (Table 2.2), which 
was significantly shorter than that of the Early group with similar clinical scores (17.0 ±1.6 
µm for Early EAE 1&2). The average AIS length for the EAE 3&4 mice in the Late group 
was 16.0 ± 0.6 µm, which was significantly shorter than that of the Naïve (19.9 ± 0.3 µm). 
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Although the AISs from the Late EAE 3&4 mice were significantly shorter than those of 
the Naïve group, the mean AIS length of the Late EAE 3&4 mice  was significantly longer 
than that of the Early EAE 3&4 mice (compare 13.4 ± 0.4 µm for Early versus 16.0 ± 0.6 
µm; p=0.0071). At first glance these findings appear to suggest that the Early stage of the 
disease resulted in greater AIS disruption, with regard to length; however, the average 
length for the Late mice reflects AISs that remained intact. As shown in Figure 2.3, about 
75% of the AISs were lost in the Late EAE 3&4 group. These findings suggest that the 
AISs of cortical neurons have differential vulnerabilities and that the AISs that were not 
lost were less susceptible to shortening. 
 
AIS loss is not due to demyelination, neuronal death, or axonal transection 
     Our findings demonstrated that AIS integrity of cortical layer V neurons was 
significantly compromised in EAE. To determine whether AIS disruption was a primary 
insult and not a result of upstream neuropathology, we assessed the neuronal population 
as well as myelin and axonal integrity. While EAE is primarily an inflammatory model, 
demyelination is consistently reported in the spinal cord (Dupree et al., 2015), cerebellum 
(Noor et al., 2015), parahippocampus (Sun et al., 2015), corpus callosum and cortical 
regions (Mangiardi et al., 2011). However, unlike the cuprizone model (Fig. 2.2) cortical 
demyelination is less prominent. In order to assess the extent of demyelination in our 
mice, we performed MBP immunolabeling on both Early and Late EAE animals and 
observed no reduction in intensity (Fig. 2.4A-C). The absence of cortical myelin loss was 
also confirmed by western blot analyses for the myelin proteins cyclic nucleotide 
phosphodiesterase and MBP (Supplementary Figure S2.3). 
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    Studies have reported a reduced number of cortical layer V neurons in EAE (Burns et 
al., 2014; Spence et al., 2014). In order to determine if the AIS disruption observed in this 
study was a consequence of neuronal loss, we performed counts based on NeuN labeling 
(Fig. 2.4D, E). Counts revealed no difference in the neuronal populations (Fig. 2.4F; Late 
EAE 3&4 was 104% of the Naïve). In addition to total neuronal counts, we also quantified 
the number of NeuN-positive cells with or without an associated AIS.  96.2% ± 0.4% of 
neurons counted in the Naïve had an associated AIS which was reduced to 27.7% ± 3.7% 
of neurons in the Late EAE 3&4 mice, consistent with the findings reported in Figure 2.3G. 
Lastly, we induced EAE in Thy1-YFP mice to assess axonal transection and 
degeneration. Neither pathology was observed even in neurons with deteriorated AISs at 
a Late EAE 3&4 stage (Fig. 2.4G, H). Together these findings suggest that AIS loss is not 
due to demyelination, neuronal death or axonal transection.  
     
 
Microglia exhibit reactive morphology during both Early and Late EAE 
     Baalman et al. (2015) recently reported that AISs within the cortex are contacted by 
microglia. Presently, the role that these cells play in AIS structure/function is not known 
but may involve AIS structural modulation. Therefore, we focused our attention on the 
role that microglia, the resident innate immune cells of the CNS, play in changes in AIS 
organization. 
     In the spinal cord of EAE-induced mice, reactive microglia clear myelin debris (Lewis 
et al., 2014). In the cortex of EAE-induced mice where demyelination is limited, the role 
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of reactive microglia is not as well characterized. It should be noted that while microglia 
were identified as IBA-1 positive cells, peripheral monocyte-derived macrophages, which 
infiltrate the CNS in EAE, are IBA-1 positive also. However, based on their distinct 
morphology, as previously described (Yamasaki et al., 2014), we will refer to IBA-1 
positive cells as “microglia.”  
     As shown in Figure 2.5A and 2.5D, surveying (non-reactive) microglia, identified by 
the presence of long, thin, highly branched processes and small cell bodies, were 
prevalent throughout cortical layer V of Naïve mice.  Following EAE induction, however, 
the percent of microglia that exhibited a reactive phenotype, as revealed by thicker and 
shorter branches and large cell bodies, was significantly increased in both the Early (Fig. 
2.5B, C, G, H) and Late (Fig. 2.5E, F, I, J) stages regardless of disease severity, as shown 
by the shift towards more reactive morphologies. Importantly, microglial reactivity was 
observed in the Early EAE 1&2 mice indicating that microglial reactivity preceded AIS 
disruption.   
 
Microglia are reactive in cuprizone treated mice    
     Because microglial reactivity paralleled AIS disruption in the EAE model, we 
investigated the state of microglial reactivity in the cuprizone model in which AIS integrity 
was not altered. The cuprizone model is generally described as a model of demyelination, 
without inflammation, at least with regard to T-cell infiltration due to an intact blood-brain-
barrier (McMahon et al., 2002). However, reactive microglia play a critical role in both MS 
and the cuprizone model acting as phagocytes to clear myelin debris (Gudi et al., 2014). 
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In our cuprizone treated mice, we found that microglia exhibited morphologies consistent 
with reactivity only during periods of active demyelination—3 and 5 weeks of cuprizone 
treatment (Fig. 2.6C, D, G, H). Following 1 week of cuprizone treatment, a time point 
when demyelination was not observed (Fig. 2.2B), microglia displayed ramified 
morphologies (Fig. 6B, 6F) resembling the microglia in the untreated mice (Fig. 2.6A, F). 
Following termination of cuprizone exposure (5+3 wks Cup), the microglia returned to 
their ramified morphology during a period of repair (Fig. 2.6E, I).   
 
Microglial-AIS interactions increase with disease progression in both the cuprizone 
and EAE models 
    The presence of reactive microglia, not only in EAE but also in cuprizone mice, negated 
our hypothesis that the presence of reactive microglia alone is sufficient to cause AIS 
disruption. Since a recent paper reported that a subset of microglia contact the AIS 
(Baalman et al., 2015), consistent with these cells playing a role in AIS plasticity, we 
quantified microglia/AIS contact in the two models proposing that a difference in the 
frequency of interaction between the AIS and the microglia would shed light on the role 
that these cells play in the observed AIS breakdown (EAE) and preservation (cuprizone). 
    For this analysis we utilized Volocity™ to quantify microglial/AIS contact while 
preserving 3-dimensional relationships since the use of collapsed projection images can 
provide misleading associations. In both the cuprizone (Fig. 2.7B, H) and the EAE (Fig. 
2.7C, I) models, our quantitative analyses revealed a significant increase in the number 
of microglial/AIS contact points per FOV as compared to Naïve mice (Fig. 2.7A) and this 
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increase paralleled and preceded both myelin loss (cuprizone; 1 wk - 122.9 ± 4.3%; 3 wk 
– 145.3 ± 5.9%; 5 wk – 216.4 ± 8.5%; 5+3 wk – 179.7 ± 6.3%; all values are expressed 
as percent of Naïve) and AIS breakdown (EAE; Early 1&2 – 153.8 ± 22.5%; Early 3&4 – 
185.0 ± 5.9%; Late 1&2 – 205.6 ± 33.9%; Late 3&4 – 169.4 ± 31.2%; all values are 
expressed as percent of Naïve) (Fig. 2.7H, I). Interestingly, the types of contact were 
highly varied with some of the microglia extending processes that ran along the AIS (Fig. 
2.7D, F) while other processes completely ensheathed the AIS (Fig. 2.7E). 
 
Reactive microglia in cuprizone-treated and EAE-induced mice exhibit different 
molecular profiles 
     Based on the above findings, there is a significant increase in the percent of AISs that 
are contacted by microglia in both the cuprizone and EAE models as compared to control 
but no difference in the extent of contact was noted between the models. Therefore, 
increased microglial contact is not sufficient to explain the difference in AIS integrity 
observed in the EAE and cuprizone models. We further proposed that the reactive 
microglia in these two models exhibit different molecular profiles resulting in functional 
diversity. To test this hypothesis, we double immunolabeled brain sections from 
cuprizone-treated and EAE-induced mice with IBA-1 and tumor necrosis factor alpha 
(TNFα), inducible nitric oxide synthase (iNOS), or macrophage colony stimulating factor 
(M-CSF) at the earliest time points when microglial morphology was altered and prior to 
pathology (3 wk cuprizone, Fig. 2.6; Early 1&2 EAE, Fig. 2.5). TNFα and iNOS are pro-
inflammatory factors produced by reactive microglia (Block et al., 2007; Haji et al., 2012; 
Miron et al., 2013); M-CSF regulates microglial proliferation and survival (Elmore et al., 
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2014). As shown in Figure 2.8, microglia from Naïve mice exhibit minimal labeling for 
these three markers (Fig. 2.8A, E, I), consistent with the surveying state of microglia in 
Naïve mice. In contrast, cuprizone treated mice (Fig. 2.8B, F, J) exhibited minimal labeling 
for TNFα and iNOS (comparable to Naïve) but elevated labeling for M-CSF. Interestingly, 
microglia in EAE induced mice (Fig. 2.8C, G, K) presented elevated labeling for TNFα, 
and iNOS while M-CSF labeling was comparable to Naïve. These results were confirmed 
using quantitative RT-PCR of cortical microglia isolated from Naïve, cuprizone (3 wk) and 
EAE mice (Early 1&2) (Fig. 2.8D, H, L). Therefore, consistent with previous work 
(reviewed by Rawji and Yong, 2013), we propose that the reactive microglia found in each 
model are phenotypically distinct, and play functionally distinct roles. 
 
EAE-induced AIS disruption is attenuated with anti-inflammatory treatment 
     Since AIS disruption was preceded by microglial reactivity (Fig. 2.5), we proposed that 
reactive microglia may be involved. To test this hypothesis, we administered an anti-
inflammatory drug to the EAE 3&4 mice at the Early time point, predicting that the 
inhibition of microglial reactivity would result in sparing of the AIS. For this approach we 
used didox, a drug that readily crosses the blood brain barrier (Fiqul et al., 2003), 
scavenges free radicals (Mayhew et al., 2002), down regulates NFƙB activity (Inayat et 
al., 2002) and inhibits microglial reactivity and the production of pro-inflammatory factors 
that are produced by macrophages/microglia (Matsebatlela et al., 2015).  Treatment with 
this drug resulted in an attenuation of the EAE clinical scores (Fig. 2.1B).  
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     In addition to the attenuation of clinical scores and consistent with our hypothesis, 
didox treatment also resulted in a significant reduction in microglial reactivity based on 
morphological analysis (Fig. 2.9A-D) and microglia/AIS contact (Figure 2.9E-H). Although 
reversion back to a surveying phenotype was not complete in the didox treated animals 
(Fig. 2.9C, C’, D), microglia/AIS contact reverted to near Naïve levels (Fig. 2.9G, H). 
Therefore, our findings indicate that didox inhibited progressive AIS deterioration and 
reversed AIS pathology with regard to length, and almost completely attenuated the 
reactive microglial morphology.  Furthermore, didox treatment attenuated the elevated 
microglial expression of TNFα (Supplementary Fig. S2.4A-D), and iNOS (Fig. 2.9I-L) 
consistent with a return to a surveying phenotype.  
     Moreover, Early EAE 3&4 mice treated with didox (Fig. 2.10C) displayed, at the Late 
stage, AISs with lengths that were indistinguishable from Naïve (compare 19.5 ± 0.9 µm 
for didox; 19.9 ± 0.3 µm for Naïve; Fig. 2.10A; Table 2.2) indicating that didox treatment 
reversed AIS pathology observed in the Early EAE 3&4 group. Didox treated mice also 
exhibited significantly longer AISs than the vehicle control (16.8 ± 1.2 µm; Fig. 2.10B, 
2.10E; Table 2.2) and EAE 3&4 Early and Late mice (13.4 ± 0.4 µm, and 16.0± 0.6, 
respectively; Table 2.2). In addition, the loss of AISs was significantly attenuated with a 
preservation of 68.4% ± 5.5% of the AISs following didox treatment compared to the 
preservation of only 27.7% ± 0.5% in the vehicle control group and only 28.5 ± 0.5% in 
the Late EAE 3&4 (Figs. 2.10D, Table 2.2).  
 
2.5 Discussion 
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     In contrast to the NOR, here we show that protein clustering in the AIS is not lost 
following demyelination but is disrupted following inflammation.  Initially, AIS length is 
reduced followed by a significant loss in AIS number in later disease stages. Although the 
mechanism of disruption is unknown, microglial reactivity and increased microglial/AIS 
contact preceded AIS pathology. Additionally, treatment with didox, a drug known to 
reduce macrophage/microglia inflammation (Matsebatlela et al., 2015), resulted in 
suppression of microglial reactivity, reversal of AIS shortening and prevention of AIS 
breakdown. Finally, we provide evidence that the roles that microglia play in 
demyelinating and inflammatory disease are dependent on their expression profiles. 
   
AIS integrity is not compromised by demyelination 
     Axonal function requires maintenance of the NORs and the AISs (Buttermore et al., 
2013). The maintenance of these domains, however, differs with respect to myelin 
dependency as we (Dupree et al., 1999; 2004) and others (Bhat et al., 2001; Ishibashi et 
al., 2002; Pillai et al., 2009; Rasband et al., 1999; Rosenbluth et al., 2003; Suzuki et al., 
2004) have shown that myelin contact is critical for NOR maintenance. For example, 
cuprizone-induced demyelination resulted in complete loss of nodal and paranodal 
clustered proteins (Dupree et al., 2004). In contrast, we now show that AIS maintenance 
is not dependent on myelin as cortical demyelination did not alter AIS number or length 
consistent with work by Hamada and Kole (2015). Therefore, while the NOR and AIS 
maintain clusters of similar proteins (Buffington and Rasband, 2011), the mechanisms 
responsible for domain maintenance are distinct. 
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AIS integrity is compromised following EAE disease induction    
     Although we are the first to report AIS disruption in EAE, we are not the first to report 
AIS vulnerability following disease or injury. Schafer et al. (2009) reported a significant 
loss of cortical and striatal AISs following ischemia in vivo, and showed that AIS 
deterioration resulted from calpain activity. Although calpain inhibitors prevented AIS 
deterioration, reversal of the pathology was not achieved. Similarly, Hinman et al. (2013) 
reported AIS shortening following ischemia and showed sprouting of immature AISs 
suggesting the potential for AIS replacement but not repair.   
      Following traumatic brain injury (TBI), AISs were significantly shortened consistent 
with altered neuronal excitability (Baalman et al., 2013) and developed amyloid precursor 
protein-containing axonal swellings (Greer et al., 2012; 2013).  Although the mechanisms 
responsible for AIS disruption following TBI are unclear, cytoskeletal disruption has been 
observed (Buki and Povlishock, 2006; Povlishock et al., 1999). Similar to the findings of 
Schafer et al. (2009), spectrin and AnkG are degraded following TBI (Buki et al., 1999; 
Reeves et al., 2010), which is accompanied by calpain activation suggesting that related 
mechanisms underly AIS breakdown in distinct models. 
   
Is the axon a primary target of pathology in MS? 
     Demyelination is a hallmark feature of MS (Lassmann, 1999), but axonal insults are 
also prevalent in this disease (Kornek and Lassmann, 1999). The formation of axonal 
swellings, reduced levels of Na+/K+ ATPase, synaptic damage, axon transection, and 
disruption of nodal domains are among the known axonal pathologies associated with 
MS and its models (Black et al., 2007; Dutta et al., 2011; Howell et al., 2010; Peterson et 
59 
 
al., 2001; Pomicter et al., 2010). These axonal pathologies, which contribute to disability 
progression (Dutta and Trapp, 2011), are postulated as consequential to demyelination; 
however, the axon may also be a primary target (Calabrese et al., 2015).  For instance, 
MS plaque load does not correlate with axonal loss (DeLuca et al., 2006); analysis of 
post-mortem MS tissue reveals axonal swellings and end bulbs located in normal 
appearing white matter (Kutzelnigg et al., 2005; Nikić et al., 2011) and axonal number is 
reduced in regions lacking demyelination in MS and EAE (Bjartmar et al., 2001; Recks et 
al., 2013). Similarly, our findings suggest that axonal pathology results from a 
demyelination-independent mechanism further suggesting that the axon may be a 
primary target in inflammatory disease. 
 
Are microglia responsible for inflammation-dependent AIS disruption? 
     Microglia are reactive in MS and play a role in the progression of the disease (Rawji 
and Yong, 2013). EAE progression closely correlates with microglial reactivity and 
inhibition of these inflammatory cells attenuates disease course (Bhasin et al., 2007; 
Heppner et al., 2005). Triggers for microglial reactivity in MS include oligodendrocyte 
stress and demyelination (Hendrickx et al., 2014; Huizinga et al., 2012; Lassmann et al., 
2001); however, microglial reactivity also occurs in the absence of demyelination (Marik 
et al., 2007) and, consistent with our findings, these cells may directly target axons in MS 
and its animal models (Nikić et al., 2011; Rawji and Yong, 2013).  
     Baalman et al. (2015) recently established a relationship between microglia and the 
AIS by reporting that a subpopulation of microglia contact the AIS during development 
and maintain this contact throughout adulthood suggesting a role in AIS organization. 
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Interestingly, following TBI reactive microglia lost AIS contact. Our results further confirm 
the existence of microglia/AIS contacts in the Naïve cortex but demonstrate that these 
contacts are increased in a pathological environment-- either inflammatory (EAE) or 
demyelinating (cuprizone model). Our results also highlight a differential response to TBI 
and EAE induction concerning AIS stability. Indeed, Baalman et al. (2013) reported that 
following blast injury, the AIS is only modestly, yet significantly, shortened whereas in 
EAE our results show a dramatic early shortening followed by AIS loss, the latter being 
preceded by an increase in microglia/AIS contact.  
     In EAE, reactive microglia release pro-inflammatory factors including reactive oxygen 
species (ROS) (Guemez-Gamboa et al., 2011), and TNFα (Haji et al., 2012). Each of 
these factors is capable of increasing intraneuronal calcium levels by triggering calcium 
channel currents specifically through L-type calcium channels (Furukawa and Mattson, 
1998; Das et al., 2011; Guemez-Gamboa et al., 2011; Sama and Norris, 2013; Vogel et 
al., 2015). Thus, both TNFα and ROS have the potential to contribute to AIS modulation, 
since L-type calcium channels are crucial for plasticity at the AIS (Grubb and Burrone, 
2010). Moreover, neurons in EAE-induced mice exhibit elevated calcium levels with a 
corresponding increase in calpain activity and axonal cytoskeletal pathology that is 
ameliorated by calpain inhibition (Guyton et al., 2005, 2009). Calpain inhibitors also 
reduce symptomatic severity in EAE mice (Das et al., 2013) potentially through anti-
inflammatory and neuroprotective mechanisms (Trager et al., 2014). This scenario of AIS 
disruption is consistent with our data suggesting that pro-inflammatory microglia can 
trigger a cascade that drives this disruption.   
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Is microglial function dependent on their inflammatory profile? 
     Although an easy culprit for AIS disruption, reactive microglia were also abundant in 
the cuprizone model where AISs were not compromised. However, reactive microglia in 
the EAE and cuprizone models presented with different inflammatory profiles providing a 
viable explanation for distinct functions (Hanisch and Kettenmann, 2007). Consistent with 
AIS disruption, numerous studies have implicated iNOS and TNFα as mediators of 
neurodegeneration (Block et al., 2007; Glass et al., 2010).  In contrast, an up-regulation 
of M-CSF, a growth factor involved in proliferation and survival of microglia and 
macrophages (Stanley et al., 1997), promotes remyelination in demyelinating mouse 
models through the recruitment of microglia to lesioned sites, followed by oligodendrocyte 
progenitor differentiation (Döring et al., 2015). While these distinct expression profiles are 
consistent with microglia playing different roles in these models, it is important to point 
out that TNFα and iNOS also have neuroprotective roles (Arnett et al., 2001; 2002; Liu et 
al., 1998) and that anti-inflammatory cytokines may also have differential expression 
patterns in these models (Janssens et al., 2015) indicating the complex nature of these 
cells. 
 
Is AIS disruption reversible? 
     In the ischemic injury model (Schafer et al., 2009), calpain inhibitors preserved AIS 
integrity; however, AIS repair was not observed suggesting an irreversible pathology 
(Schafer et al., 2009).  Here, AIS length was restored following didox treatment. AISs alter 
their length during development (Gutzmann et al., 2014) and in response to changes in 
presynaptic input (Kuba et al., 2010) indicating that the AIS is a dynamic domain. 
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However, the present study is the first to report a therapeutic attenuation of AIS pathology. 
It remains to be determined if the more severe consequences, such as complete loss of 
AIS protein clustering, as observed in Late EAE, can be reversed. 
 
     In summary, we report that AIS integrity was preserved in the demyelinated cortex, 
but significant disruption was observed in the non-demyelinated cortex of EAE-induced 
mice suggesting that the AIS is a potential primary axonal target during inflammation. 
Morphological analyses at two distinct time points along the disease course indicates AIS 
shortening is an early event that is followed by loss of AIS protein clustering. Importantly, 
AIS pathology, potentially mediated by reactive microglia, appears both preventable and 
reversible through therapeutic intervention. Taken together, our results open new 
perspectives into the understanding of disability progression in inflammatory 
demyelinating disease such as MS, with potential innovative therapeutic avenues. 
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Figure 2.1. Clinical Progression of EAE model. Mean clinical scores of the EAE mice 
used in this study are graphed showing the consistent progression of the disease of each 
clinical score group (EAE 1&2 and EAE 3&4) as well as the time points at which these 
groups were analyzed (Early and Late; arrows) (A). Treatment with the anti-inflammatory 
didox at the Early time point resulted in reduced EAE clinical scores, while treatment with 
the vehicle carboxymethylcellulose had no effect on EAE progression (B). 
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Figure 2.2. AISs are not disrupted following cuprizone-induced demyelination. 
Cortical demyelination was assessed by immunolabeling for MBP (A–E). No myelin loss 
was detected following 1 week of cuprizone treatment (B). Note a slight reduction in MBP 
labeling following 3 weeks of cuprizone exposure (compare A and C) with a continued 
decrease in labeling by 5 weeks of treatment (D). Following an additional 3 weeks without 
cuprizone, MBP labeling increased consistent with remyelination (E). Ankyrin-G labeling 
of cortical layer V axon initial segments (AIS) revealed no difference among mice that 
were maintained on ground chow without cuprizone (F) and mice maintained on 
cuprizone for 1 week (G), 3 weeks (H), 5 weeks (I), or 5 weeks with an additional 3 weeks 
of recovery (J). Quantitative analysis confirmed that neither AIS number (K) nor AIS 
length (L) was altered following cortical demyelination at any exposure time point or as 
compared to untreated (Naïve) mice. 
 
 
 
 
 
67 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.1: 
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Figure 2.3. AIS length is reduced in early stages of EAE while the number of AISs 
is decreased in the late stages of disease. In Early disease stage (3 days post peak 
clinical symptoms), AISs in cortical layer V neurons of Naïve (A) and EAE 1&2 (B) mice 
were abundant, presented with uniform length and rarely revealed discontinuous labeling 
indicative of fragmentation (yellow arrows). In contrast, AISs of layer V cortical neurons 
in Early EAE 3&4 mice (C) were frequently reduced in length (white arrows) and 
fragmented (yellow arrows). Quantitative analysis confirmed the immunohistochemical 
observations. No difference in AIS number was observed among the Early EAE groups 
(G). Although no difference in AIS length was observed between Naïve and Early EAE 
1&2 mice (H), a significant shortening was observed with the Early EAE 3&4 mice 
compared to Naïve animals (H). In contrast, the Late EAE 1&2 mice (E,G) exhibited a 
significantly reduced number of AISs with a continued progression in AIS loss observed 
in the Late EAE 3&4 mice (F,G). While there was a significant decrease in AIS length for 
the Late EAE 1&2 mice, a significant but less dramatic shortening was observed for the 
Late EAE 3&4 mice as compared to the Naïve animals (H). Note that with the loss of AISs 
(Panel F), punctate AnkG labeling was observed. Double labeling for AnkG and the 
paranodal marker Caspr (see F inset; AnkG – red; Caspr – green) revealed that these 
puncta were nodes of Ranvier that were not disrupted following EAE induction. (Asterisks 
with no associated bracket represent a significant difference from the Naïve group; 
*P = 0.0001, ** P = 0.008). 
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Figure 2.4. Disrupted AISs in EAE are not the consequence of demyelination, 
neuronal death or axonal transection. Based on immunohistochemical labeling for 
MBP, no difference in cortical myelin was observed among Naïve (A), Early EAE 3&4 
mice (B) or Late EAE 3&4 mice (C). The density of neuronal cell bodies, as determined 
by NeuN immunolabeling (D–F) also remained constant, indicating AIS loss is not a result 
of cell death. Note the presence of numerous NeuN/AnkG double positive cells in Panel 
D while most NeuN positive cells in Panel E lack AnkG labeling (white arrowheads) 
Immunolabeling of AnkG (red) in Thy1-YFP (green) mice induced with EAE (Late 3&4) 
revealed intact axons following disruption of the AIS protein clustering (H; white rectangle) 
while Naïve Thy1-YFP mice revealed robust AnkG labeling in the AIS (G; white 
rectangle). 
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Figure 2.5. Microglia exhibit a reactive morphology at Early and Late stages of EAE. 
Microglia in Naïve mice (A,D) exhibited small cell bodies with long, thin and highly 
branched processes indicative of a surveying phenotype (white arrows). In contrast, 
microglia from Early and Late EAE 1&2 (B,E) and EAE 3&4 (C,F) mice displayed enlarged 
cell bodies with short, thick processes with reduced branching consistent with cells in a 
state of reactivity (yellow arrows). Distribution graphs of microglial morphological stages 
provide quantitative evidence confirming this significant shift from the Naïve (G-J). 
(*P = 0.0001, ** P = 0.003). 
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Figure 2.6. Microglia exhibit a reactive morphology during periods of demyelination 
in the cuprizone model. Based on immunohistochemical labeling for IBA-1, mice 
maintained on normal chow (no cuprizone) exhibited ramified microglia (A), indicative of 
a surveying role. Scoring of microglial morphology indicated that the cells remained 
ramified following 1 week of cuprizone treatment (B,F). Following 3 (C,G) and 5 (D,H) 
weeks of treatment, microglia exhibited an amoeboid morphology consistent with 
reactivity. Removal of cuprizone from the diet resulted in a shift in the presented 
morphologies consistent with untreated mice (E,I). (*P = 0.0001, ** P = 0.006). 
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Figure 2.7 Microglia exhibit increased contact with the AIS in Cuprizone treated and 
EAE induced mice. Double immunolabeling of IBA-1 and AnkG revealed an increase in 
the percent of AISs contacted by microglia in both the cuprizone (B) and EAE (C) models 
temporally corresponding with microglial reactivity (H,I). Confocal z-stacks were analyzed 
in 3D to rule out apparent contact points in 2D as demonstrated by the inset AIS (A′) 
which was rotated 90° along the X-axis, revealing no microglial contact (A′′). Examples of 
microglial-AIS interactions are depicted with reactive microglia making contact onto one 
(F) or more AISs (D, E). Processes frequently aligned along the AIS (white arrows, D,F). 
Transverse sections of the cortex revealed microglial processes wrapping completely 
around AISs cut in cross section (E, yellow arrows). The number of contact points per 
FOV as a percent of the Naïve was significantly increased following 3 and 5 weeks of 
cuprizone treatment, with a slight, but significant, decrease in contact following 3 weeks 
of recovery (no cuprizone) (H). Similarly, microglial-AIS interactions were increased along 
with EAE progression (I). Panels F and F′ present the same microglia but display anterior 
(F) and posterior (F′) views. The image in Panel F′′ was generated with the software 
Volocity™ from the z-stack of images used to compile the images in F and F′. The 
Volocity™ generated image provides shadowing to display the image with 3 dimensions 
providing a better depiction of the microglia and neuron interaction. (Asterisks with no 
associated bracket represent a significant difference from the Naïve group; * P = 0.0001, 
** P = 0.01). 
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Figure 2.8. Microglia present distinct phenotypes in Cuprizone vs. EAE. Double 
immunolabeling at the onset of microglial reactivity (3 weeks for cuprizone and Early 1&2 
for EAE), for IBA-1 (green) in combination with either TNFα (A-C; red), iNOS (E-G; red), 
or M-CSF (I-K; red) indicated distinct phenotypes of the reactive microglia between the 
two models. Labeling intensities for TNFα were elevated in the microglia from both models 
(B,C). Labeling intensities for iNOS were elevated, as compared to Naïve, only in the 
microglia of the EAE mice (G), while M-CSF labeling intensities were elevated only in the 
microglia of the cuprizone treated mice (J). Immunohistochemistry results were confirmed 
by qRT-PCR of cortical microglia isolated from Naïve, cuprizone and EAE mice (D, H, L) 
(Asterisks represent a significant difference from the Naïve group; * P = 0.0001). 
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Figure 2.9 Didox treatment attenuates microglial reactivity and AIS-contact. 
Microglia in the Naïve mice (A,D) were not reactive based on their morphology (white 
arrows) while the microglia in the vehicle-treated animals were reactive as evidenced by 
large cell bodies and thick processes with limited branching (B,D). Although didox 
treatment attenuated microglial reactivity (white arrows) (C,D), treatment did not result in 
a complete reversion as reactive microglia (yellow arrow) were also detected in the didox 
treated animals (C′,D). In addition to reactivity, didox treatment also attenuated the 
increased microglial-AIS contact (G,H) while carboxymethylcellulose vehicle treatment 
maintained the enhanced number of contact points (F,H) as compared to the Naïve (E,H). 
Importantly, didox administration to EAE mice attenuated the elevated labeling intensities 
of iNOS (K) consistent with didox attenuation of microglial reactivity. iNOS 
immunolabeling (J) and mRNA expression (L) in the vehicle treated group remained 
increased compared to the Naïve group (I,L) (Asterisks with no associated bracket 
represent a significant difference from the Naïve group; * P =0.0001, ** P =0.02, *** P 
=0.002). 
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Figure 2.10 Didox treatment attenuates AIS disruption. Naïve mice exhibited 
numerous AISs (A). Initiating didox treatment at the Early stage of disease in EAE 3&4 
mice resulted in inhibition of AIS loss (C,D). In contrast to the didox treated mice, animals 
maintained on the vehicle, carboxymethylcellulose, displayed continued AIS 
degeneration (B,D,E). In addition to AIS preservation, Early EAE 3&4 mice treated with 
didox revealed a reversal of AIS shortening by the Late EAE stage. These are the first 
data to indicate a therapeutic reversal of AIS pathology. 
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Table 2.2: 
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Figure S2.1. Microglia present distinct morphologies consistent with state of 
reactivity.  Microglia present unique morphology representing specific stages of reactivity 
as visualized through IBA-1 immunolabeling (B). Surveying microglia are scored as a 
Stage 0. Increasing cell body size, shorter and thicker processes and fewer processes 
are indicative of higher stage scores and are equated to cells with a higher level of 
reactivity. 
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Figure S2.2. AISs are consistently disrupted throughout the anterior/posterior axis 
following EAE induction.  Comparison of the number of AISs among all treatment 
groups at each position along the anterior/posterior axis revealed no difference in AIS 
susceptibility to disruption. Although all 6 locations were separately compared, only the 
results of those quantitative comparisons for the most anterior (bregma +1.1 mm) and 
posterior (bregma -2.5 mm) positions are shown. Note the findings for each distinct 
anterior/posterior location precisely mirror the compiled data (Figure 2.3). 
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Figure S2.3 Western blot analysis revealed no cortical demyelination in EAE mice.  
Western blot analyses of isolated cortices from Naïve and Late EAE 3&4 mice revealed 
no difference in the levels of the myelin proteins CNP (A) and MBP (C).  Quantitative 
densitometry confirmed the absence of myelin protein loss.   
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Figure S2.4 Didox treatment attenuates TNFα expression in EAE induced mice.  
Immunolabeling (A-C) and RNA expression (D) for TNFα indicated low levels of cytokine 
expression in the Naïve and EAE induced mice treated with didox while EAE induced 
mice that received only the vehicle carboxymethylcellulose maintained high levels of both 
the protein and RNA. 
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CHAPTER THREE 
 
OXIDATIVE STRESS INDUCES DISRUPTION OF THE AXON INITIAL SEGMENT 
 
Clark et al., ASN Neuro (In Revision) 
 
3.1 Abstract 
     The axon initial segment (AIS), the domain responsible for action potential initiation 
and maintenance of neuronal polarity, is targeted for disruption in a variety of central 
nervous system (CNS) pathological insults. Previous work in our laboratory implicates 
oxidative stress as a potential mediator of structural AIS alterations in two separate 
mouse models of CNS inflammation, as these effects were attenuated following reactive 
oxygen species scavenging and NADPH oxidase 2 ablation. While these studies suggest 
a role for oxidative stress in modulation of the AIS, the direct effects of reactive oxygen 
and nitrogen species (ROS/RNS) on the stability of this domain remain unclear. Here we 
demonstrate that oxidative stress, as induced through treatment with 3-
morpholinosydnonimine (SIN-1), a spontaneous ROS/RNS generator, drives a reversible 
loss of AIS protein clustering in primary cortical neurons in vitro. Pharmacological 
inhibition of both voltage dependent and intracellular calcium (Ca2+) channels suggests 
that this mechanism of AIS disruption involves Ca2+ entry specifically through L-type 
voltage dependent Ca2+ channels and its release from IP3-gated intracellular stores. 
Furthermore, ROS/RNS-induced AIS disruption is dependent upon activation of calpain, 
a Ca2+-activated protease previously shown to drive AIS modulation. Overall, we 
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demonstrate for the first time that oxidative stress, as induced through exogenously 
applied ROS/RNS, is capable of driving structural alterations in the AIS complex. 
 
3.2 Introduction 
     The axon initial segment (AIS) is a specialized region of the axon located at the 
junction between the somatodendritic and distal axonal domains that is essential for both 
action potential generation, and the maintenance of neuronal polarity (Hedstrom et al., 
2008; Buffington and Rasband, 2011). This complex consists of cytoskeletal scaffolding 
proteins ankyrin-G (AnkG) and βIV-spectrin, which cluster the high density of voltage-
gated ion channels required for action potential initiation and modulation (Jenkins and 
Bennett, 2001). The AIS is a highly dynamic and plastic structure regulated by changes 
in neuronal activity (Yamada and Kuba, 2016), but its integrity is compromised 
consequential of a variety of pathological central nervous system (CNS) insults. These 
include models of epilepsy (Wimmer et al., 2010; Harty et al., 2013), ischemic injury 
(Schafer et al., 2009; Hinman et al., 2013), traumatic brain injury (Baalman et al., 2013; 
Greer et al., 2013; Vascak et al., 2017), Alzheimer’s disease (León-Espinosa et al., 2012; 
Sun et al., 2014; Marin et al., 2016; Zempel et al., 2017), and multiple sclerosis (Hamada 
and Kole, 2015; Clark et al., 2016). While the AIS is frequently and extensively targeted 
for disruption in CNS pathology, the mechanisms underlying altered stability of this 
domain have not been fully elucidated. 
     Our laboratory has previously demonstrated that AIS integrity is targeted for disruption 
in inflammatory environments. For example, induction of experimental autoimmune 
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encephalomyelitis (EAE), a model commonly used to mimic the inflammatory component 
of MS (Kipp et al., 2017), resulted in severe disruption of the AIS domain, which was 
preceded by and correlated with microglial reactivity and increased contact (Clark et al., 
2016). Similarly, peripheral injection of lipopolysaccharide (LPS), a classic model of 
systemic inflammation, was sufficient to drive the loss of AIS protein clustering, which 
was reversed following resolution of the inflammatory response (Benusa et al., 2017). In 
both of these inflammatory models, treatment with Didox, a novel scavenger of reactive 
oxygen and nitrogen species (ROS/RNS) (Mayhew et al., 2002; Turchan et al., 2003; 
Matsebatlela et al., 2015), prevented and reversed the AIS pathology (Clark et al., 2016; 
Benusa et al., 2017). Additionally, LPS injection in mice deficient in the major ROS 
producing enzyme NADPH oxidase 2 (Pollock et al., 1995) resulted in the complete 
preservation of the AIS (Benusa et al., 2017). Together, these data highlight a potential 
role for ROS and RNS in the alteration of AIS protein clustering; however, direct evidence 
that ROS/RNS are capable of driving AIS disruption is lacking. Here, to address this void 
in our understanding, we investigate the effect of exogenously applied ROS/RNS on AIS 
stability in primary cortical neurons in vitro, utilizing the spontaneous ROS/RNS generator 
SIN-1 (Singh et al., 1999). 
     Our findings demonstrate that oxidative stress, induced through exogenous 
application of ROS/RNS, is sufficient to drive structural disruption of the AIS protein 
complex. Pharmacological inhibition of voltage-dependent calcium channels (VDCCs), 
intracellular calcium (Ca2+) stores, and enzymatic activity suggests this mechanism of 
ROS/RNS-induced AIS disruption to involve cytosolic Ca2+ entry extracellularly through 
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L-type VDCCs, and intracellularly from IP3-gated store release, as well as calpain 
protease activation. 
 
3.3 Materials and Methods 
Animals 
     Timed pregnant embryonic day 14 (E14) c57bl/6 mice were purchased from Charles 
River (Wilmington, MA) and maintained in the Virginia Commonwealth University Division 
of Animal Resources (VCU DAR) or the McGuire Veterans Affairs Medical Center (VAMC) 
vivariums, respectively, which are both AAALAC accredited facilities. Timed pregnant 
mice were maintained in the facilities until pups were removed on embryonic day 15. 
Animals were maintained on an alternating 12 hour light and dark cycle and food and 
water were provided ad libitum. All procedures were conducted in accordance with the 
methods outlined in approved VCU and McGuire VAMC IACUC protocols. 
 
Primary Neuronal Cultures 
     Primary cortical neuron cultures were prepared from cerebral cortices of E15 mouse 
pups. Timed pregnant females were anesthetized with isoflurane and sacrificed by 
decapitation. Pups were removed and decapitated to allow for removal of the brains.  
Following removal of the meninges, cortices were incubated on ice in Accutase® Cell 
Detachment Solution (Innovative Cell Technologies, San Diego, CA) and dissociated 
step-wise using 1000 µL and 200 µL-sized pipette tips. Cells were counted and diluted in 
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plating medium consisting of Neurobasal® medium (Thermo Fisher Scientific, Waltham, 
MA; Formulation detailed in Supplementary Table S3.1) supplemented with glutamate 
(25 µM, Sigma-Aldrich, St. Louis, MO), glutamine (0.5 mM, Thermo Fisher Scientific, 
Waltham, MA), Antibiotic-Antimycotic (Thermo Fisher Scientific, Waltham, MA), and B-
27® supplement (Thermo Fisher Scientific, Waltham, MA). Cells were then plated at a 
density of 3000 cells/cm2 on poly-d-lysine (1 mg/mL; Sigma-Aldrich, St. Louis, MO) coated 
glass coverslips (12 mm) in 24-well plates. Following cell attachment, wells were filled 
with the medium described above, in which the B-27® supplement was replaced with B-
27® supplement minus antioxidants (Thermo Fisher Scientific, Waltham, MA). All 
experiments were performed starting at 12 days in vitro (DIV).  
 
SIN-1 and Pharmacological Treatments  
     12 DIV neurons were treated with spontaneous ROS/RNS generator SIN-1 (3-
Morpholinosydnonimine hydrochloride, Sigma-Aldrich, St. Louis, MO) diluted in the 
maintenance media described above at concentrations ranging from 0.1-100 μM and 
analyzed 3, 6, 12, 24, or 72 hours post-treatment. All pharmacological reagents were 
added simultaneously with SIN-1 and included EGTA (0.001-2 mM), NiCl2 (0.1-50 μM), 
(S)-(−)-Bay K8644 (0.00001-50 μM), MK-801 (0.001-50 μM), 2-APB (0.1-50 μM) and FK-
506 (0.001-50 μM) obtained from Sigma-Aldrich (St. Louis, MO) as well as ω-Conotoxin 
MVIIC (0.001-50 μM), nifedipine (0.001-50 μM), ryanodine (0.001-50 μM) and MDL 28170 
(0.001-50 μM) obtained from Tocris Bioscience (Avonmouth, Bristol, England). Stock 
dilutions of all pharmacological reagents were prepared in DMSO (Thermo Fisher 
Scientific, Waltham, MA) with subsequent dilutions performed in culture medium, except 
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for EGTA, NiCl2 and ω-Conotoxin MVIIC in which all dilutions were performed in culture 
medium. While a larger concentration range of pharmacological inhibitors and activators 
was tested, only non-cytotoxic concentrations are reported. All SIN-1 and 
pharmacological treatments were performed in three separate cell culture preparations 
(n=3). Within each preparation, three technical replicates at the 24 hour time point were 
performed.  
Measurement of Calpain Activity 
     Calpain activity was quantified using a fluorometric assay kit (Biovision, Milpitas, CA) 
according to the manufacturer's instructions. Briefly, neurons were treated with the 
extraction buffer provided by the manufacturer to extract cytosolic proteins while 
preventing the auto-activation of calpain during the extraction procedure. The neuronal 
supernatant was then incubated with a calpain substrate (Ac-LLY-AFC) which fluoresces 
at 505 nm upon cleavage. Fluorescence intensities at each SIN-1 concentration were 
measured on a spectrophotometric microplate reader and compared against an untreated 
sample at each time point. Six coverslips of neurons were pooled at each time point and 
SIN-1 concentration. Data from these measurements are presented as relative 
fluorescence units (RFU) as a percent increase over untreated samples. A total of three 
separate culture preparations (n=3), each run in three technical replicates, were 
compared at each measurement. Statistical comparisons were made by repeated 
measures one-way ANOVA with a Dunnett’s multiple comparisons post-hoc test. All 
graphing and statistical analyses were performed using GraphPad Prism version 6.03 for 
Windows (GraphPad Software, San Diego, CA). 
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Immunofluorescence 
     Cells were immunolabeled with the appropriate primary and secondary antibodies (see 
below) as described previously (Shepherd et al., 2012; Clark et al., 2016; Benusa et al., 
2017) with the modification that cells were fixed with 4% paraformaldehyde (Ted Pella, 
Redding, CA) for 5 minutes and permeabilized with -20oC methanol (Fisher Scientific, 
Waltham, MA). Slides were mounted with Vectashield™ mounting medium with DAPI 
(Vector Laboratories, Burlingame, CA); and imaged using confocal microscopy. 
 
Antibodies 
     Axon initial segments were visualized using mouse monoclonal antibodies directed 
against ankyrin-G (AnkG) (NeuroMab, Davis, CA; N106/36, 1:200) or βIV-spectrin (a 
generous gift from Dr. Matthew Rasband, Baylor College of Medicine; 1:500). Neurons 
were identified using an antibody directed against NeuN (Millipore; Billerica, MA; 1:1000). 
All secondary antibodies for immunofluorescence were purchased from Invitrogen Life 
Technologies (Grand Island, NY; AlexaTM Fluor) and used at a dilution of 1:500.  
 
Confocal Microscopy/Quantitation 
Image Collection 
     All images were collected using a Zeiss LSM 710 confocal laser scanning microscope 
(Carl Zeiss Microscopy, LLC, Thornwood, NY) housed in the VCU Department of 
Anatomy and Neurobiology Microscopy Facility. Confocal z-stacks, each spanning an 
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optical distance of 10 m, using a pin hole of 1 Airy disc unit and Nyquist sampling were 
collected from three technical replicate coverslips (12 mm) per treatment and time point 
resulting in 12 images per experimental group for AIS quantitation (~ 600 neurons per 
treatment group). All comparisons were made using three independent culture 
preparations (n=3). Images were taken with a 20X objective with a numerical aperture of 
1.4; optical slice thickness was 0.49 µm, using a scan average of 2. X, Y and Z image 
dimensions were 212.43 µm x 212.43 µm x 10.00 µm, respectively. The gain and offset 
values were kept constant for all images.  
 
AIS Quantitation   
     AIS stability was determined using ImageJ analysis software by manually counting 
initial segments from maximum intensity projection images resulting in the analysis of 
>600 AISs per experimental treatment and time point. The number of neurons in a FOV 
was also determined in the same images used for AIS analysis by counting NeuN-positive 
cells. Data are presented as the percent of NeuN-positive cells with an associated AIS as 
a percent of the control. One-way ANOVAs with Tukey’s Honest Significant Difference 
(HSD) post hoc tests were performed for these comparisons. All graphing and statistical 
analyses were performed using GraphPad Prism version 6.03 for Windows (GraphPad 
Software, San Diego, CA). 
 
 
Cell Viability Quantitation 
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     The extent of neuronal survival following SIN-1 treatment was determined using a 
propidium iodide (PI) exclusion assay to identify non-viable cells. Prior to 
paraformaldehyde fixation, cells were treated with a 0.01 mg/mL propidium iodide 
(Molecular Probes, Eugene, OR) solution for 10 minutes. Cells were then fixed and 
immunolabeled for NeuN as described above. The number of PI-positive and NeuN-
positive cells was manually counted from maximum intensity projection images using 
ImageJ analysis software. Data are presented as the percent of NeuN-positive cells 
negative for PI as a percent of the control (% neuronal survival). One-way ANOVAs with 
Tukey’s Honest Significant Difference (HSD) post hoc tests were performed for these 
comparisons. All graphing and statistical analyses were performed using GraphPad Prism 
version 6.03 for Windows (GraphPad Software, San Diego, CA). 
 
Measurement of ROS Production 
     Quantification of neuronal ROS production induced by SIN-1 treatment was performed 
using the CellROX® Green Reagent kit (Thermo Fisher Scientific, Walthanm, MA) 
according to the manufacturer's instructions. Briefly, 12 DIV primary cortical neurons 
grown on coverslips were treated with SIN-1 at concentrations ranging from 0.1-100 μM 
and analyzed 3, 6, 12, 24, or 72 hours post treatment. Cells were incubated for 30 minutes 
at 37oC with CellROX® Reagent at a concentration of 5 μM. Coverslips were rinsed with 
PBS and mounted on slides with Vectashield™ hard set mounting medium with DAPI 
(Vector Laboratories, Burlingame, CA); and imaged using confocal microscopy as 
described above. The CellROX® green fluorescence intensity was measured from 
maximum intensity projection images using ImageJ analysis software. Data from these       
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measurements are presented as the percent fluorescence increase over the untreated at 
each SIN-1 treatment concentration and time point. Data from these measurements are 
presented as relative fluorescence units (RFU) as a percent increase over untreated 
samples. A total of three separate culture preparations (n=3) were compared at each 
measurement. Statistical comparisons were made by repeated measures one-way 
ANOVA with a Dunnett’s multiple comparisons post-hoc test. All graphing and statistical 
analyses were performed using GraphPad Prism version 6.03 for Windows (GraphPad 
Software, San Diego, CA). 
 
3.4 Results 
ROS/RNS generator, SIN-1, induces primary neuronal oxidative stress in vitro 
     In order to directly test the effect of ROS/RNS on AIS stability, we treated primary 
cortical neurons in vitro with the NO and superoxide donor SIN-1 (Singh et al., 1999; 
Trackey et al., 2001; Rocchitta et al., 2005; Zhaowei et al., 2014). Optimal SIN-1 treatment 
conditions were first determined using a combination of cell death analysis, and a ROS 
production assay to identify SIN-1 concentrations that generated ROS/RNS without 
inducing cortical neuron death. Our first step was to administer the SIN-1 reagent, ranging 
in concentrations from 0.1 µM to 100 µM consistent with previous studies (Trackey et al., 
2001; Rocchitta et al., 2005; Zhaowei et al., 2014), to determine the maximum SIN-1 
concentration that could be tolerated by the cultured cells. Neuronal survival was 
assessed by the propidium iodide exclusion assay 24 hours post-treatment, a time point 
consistent with previous SIN-1 cytotoxicity studies (Trackey et al., 2001). As shown in 
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Figure 3.1 A-F and M, significant cell death was observed at the highest concentrations 
(50 µM and 100 µM) while no cell loss occurred at the concentrations of 25 µM and below. 
Specifically, the percent of NeuN positive cells that were also propidium iodide negative 
(defined as % neuronal survival) 24 hours after the addition of SIN-1 was 90.7% ± 6.6% 
(0.1 µM), 84.0% ± 5.9% (1 µM), 91.6% ± 4.9% (10 µM) and 89.0% ± 9.5% (25 µM).  
Significant neuronal loss, however, was detected at SIN-1 concentrations of both 50 µM 
(54.4% ± 12.5%, p=0.0004; Fig. 3.1M) and 100 µM (4.1% ± 0.42%, p<0.0001; Fig. 3.1F, 
M). Therefore, these findings indicated that 25 µM was an appropriate concentration for 
SIN-1 treatment to ensure that cell death was not induced. 
    Our initial studies to identify optimal SIN-1 concentrations were conducted at the 24 
hour time point based on previous work (Trackey et al., 2001). However, to better 
understand the profile of ROS/RNS production in our culture system, we employed the 
CellROX® Green assay, a fluorogenic cell-permeable probe which fluoresces upon 
oxidation by ROS (Isaev et al., 2016; Liu et al., 2014), to quantify levels of neuronal ROS 
over time. No significant increase in neuronal ROS levels was detected 3 (Fig. 3.1H, N) 
and 6 hours (Fig. 3.1I, N) post SIN-1 treatment, at a concentration of 25 µM (the highest 
non-cytotoxic concentration), as compared to the untreated cultures (Fig. 3.1G, N). 
However, by 12 hours (Fig. 3.1J, N) post SIN-1 addition, ROS levels were significantly 
increased with the levels highest at 24 hours (Fig. 3.1K, N) post SIN-1 treatment. By 72 
hours (Fig. 3.1L, N) post SIN-1 addition, ROS production returned to baseline levels 
indicating a resolution of the oxidative insult. With an established time course of SIN-1 
induced oxidative stress through the CellROX® assay, we next asked whether AIS 
integrity was compromised as a result of this insult. 
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Exogenously applied ROS/RNS induce AIS disruption in vitro 
    In order to assess the effects of exogenously applied ROS/RNS on AIS stability, 
primary cortical neurons were treated with SIN-1 at all of the non-cytotoxic concentrations 
tested above (0.1-25 µM) and subsequently double immunolabeled for AnkG and NeuN 
at 3, 6, 12, and 24 hours post-treatment. Data are presented as the percent of neurons 
(defined as NeuN+ cells) with an associated AIS (defined as AnkG+). Representative 
images for only the 25 µM SIN-1 treatments are shown for each time point (Fig. 3.2B-F). 
No significant alteration in AIS integrity was observed at any of the tested SIN-1 
concentrations (0.1-25 µM) 3 hours (Fig. 3.2B, G), 6 hours (Fig. 3.2C, H), or 12 hours 
(Fig. 3.2D, I) post-treatment as compared to the non-treated cultures (Fig. 3.2A). 
Similarly, at 24 hours (Fig. 3.2J), neither 0.1 µM nor 1 µM of SIN-1 was sufficient to induce 
disruption of the AIS. However, AIS loss was observed 24 hours after SIN-1 addition at 
concentrations of 10 µM (Fig. 3.2J; p=0.034) and 25 µM (Fig. 3.2E, J; p=0.003) with a 
significant reduction in the percent of neurons with an associated AIS of 29.0% ± 5.2% 
and 43.2% ± 3.7% respectively. Results from AnkG quantitation were confirmed by 
immunolabeling for βIV-spectrin, another AIS protein crucial for domain stability (data not 
shown). 
     Since the CellROX® assay indicated a return to baseline levels of ROS/RNS by 72 
hours, we next analyzed AIS integrity at this late time point to determine whether the 
ROS/RNS-induced AIS disruption is reversible. Interestingly, recovery was observed 72 
hours following SIN-1 treatment at both the 10 µM (Fig. 3.2K) and 25 µM (Fig. 3.2F, K) 
concentrations. To ensure that the recovery in the percentage of AIS+ cells was not due 
107 
 
to a loss of neurons that lacked positively labeled AISs, the relative number of NeuN+ 
cells was compared between the treated and non-treated groups. No significant 
difference was observed between groups (data not shown) indicating that NeuN+ cells 
that lost their AISs did not die, but recovered from the SIN-1 treatment and restored their 
AIS. This recovery at 72 hours post-treatment corresponds to a return to baseline of 
neuronal ROS levels as shown in Figure 3.1L & N. Overall, these data provide a time-
course for ROS/RNS-induced AIS disruption in our in vitro system, allowing for 
subsequent pharmacological manipulations to elucidate the underlying mechanism. All 
further experiments were performed 24 hours following treatment of 25 µM SIN-1, the 
time point of peak AIS loss, and the highest non-cytotoxic concentration of SIN-1, 
respectively.                                                                                                                                                                    
 
ROS/RNS-induced AIS disruption requires extracellular Ca2+ 
     Calcium (Ca2+) is central to most previously identified mechanisms of AIS modulation, 
during both activity-dependent plasticity (Yamada and Kuba, 2016), as well as 
pathological insult (Stoler and Fleidervish, 2016). In order to determine if ROS/RNS-
induced AIS disruption involves extracellular Ca2+ entry, neurons were pre-treated with 
the non-membrane permeable Ca2+-chelating agent EGTA, prior to SIN-1 addition. EGTA 
pre-treatment at concentrations of 0.001 mM and 0.01 mM were not sufficient to prevent 
the AIS disruption previously observed (Fig. 3.3D), and SIN-1 treated cells exposed to 
these concentrations were indistinguishable from those without EGTA (Fig. 3.3B, D). 
EGTA concentrations of 1 mM (Fig. 3.3D) and 2 mM (Fig. 3.3C, D), however, were 
capable of attenuating the AIS disruption, resulting in the preservation of 81.9% ± 0.8% 
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(p=0.0004) and 94.9% ± 0.7% (p<0.0001) of neurons with an associated AIS, 
respectively, as compared to the 62.3% ± 1.6% percent observed with SIN-1 treatment 
alone. Similar to other previously established models of AIS plasticity and injury (Schafer 
et al., 2009; Stoler and Fleidervish, 2016; Yamada and Kuba, 2016), these data 
demonstrate that extracellular Ca2+ is central to AIS disruption; however, we implicate 
ROS/RNS as upstream activators of this degenerative pathway.  
 
L-type voltage-dependent calcium channels are required for ROS/RNS-induced AIS 
disruption 
     While the importance of extracellular Ca2+ entry was demonstrated with EGTA, the 
site of Ca2+ entry into the cell during ROS/RNS-induced AIS modulation remains unclear. 
To address this, we pre-treated neurons with a series of inhibitors to the known types of 
voltage-dependent calcium channels prior to SIN-1 treatment (Catterall, 2011). Inhibition 
of T and R-type VDCCs by NiCl2 (Evans et al., 2013; Bhattacharjee et al., 1997) revealed 
no significant attenuation of SIN-1 induced AIS disruption at the range of concentrations 
tested (0.1-50 µM; Fig. 3.4C, G).  Similarly, no AIS protection was observed following 
application of the P, Q and N-type VDCC inhibitor ω-Conotoxin MVIIC (0.0001-1 µM; Fig. 
3.4D, H). Concentrations of these inhibitors higher than those presented resulted in 
significant neuronal death (data not shown). Additionally, specific inhibition of L-type 
VDCCs with nifedipine (Nguemo et al., 2013) at concentrations of 0.001-0.1 µM was not 
sufficient to protect AIS integrity. However, attenuation of SIN-1 induced AIS disruption 
was observed following pre-treatment with the L-type specific VDCC inhibitor at 
concentrations of 1 µM and 10 µM (Fig. 3.4E, I) resulting in the preservation of 88.3% ± 
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3.66% (p=0.0147) and 92.1% ± 4.3% (p=0.0055) of AISs respectively, as compared to 
the 60.2% ± 3.9% percent observed with SIN-1 treatment alone. 
     We then asked whether Ca2+ flow through L-type VDCCs in the absence of SIN-1 was 
sufficient to drive disruption of the AIS. To address this, a selective irreversible activator 
of L-type channels, (S)-(-)-Bay K 8644 (Ravens and Schöpper, 1990; Fusi et al., 2017), 
was used at concentrations ranging from 0.00001–1 µM with AIS assessment performed 
24 hours post-treatment. This treatment resulted in a significant reduction in the percent 
of neurons with an associated AIS at concentrations of 0.1 µM and 1 µM by 22.6% ± 3.9% 
(p=0.0002) and 32.5% ± 3.9% (p<0.0001) respectively (Fig. 3.4F, J). Importantly, these 
concentrations of (S)-(-)-Bay K 8644 did not result in neuronal death as determined by 
the propidium iodide exclusion assay described above (data not shown). Overall, these 
data suggest that ROS/RNS-mediated disruption of the AIS involves extracellular Ca2+ 
flow specifically through L-type VDCCs, and that activation of these channels, 
independently of SIN-1, is sufficient to drive similar AIS alterations.  
 
ROS/RNS-mediated AIS modulation involves IP3-gated Ca2+ stores 
     Because AIS stability is heavily dependent on the level of intracellular of Ca2+ (Stoler 
and Fleidervish, 2016; Yamada and Kuba, 2016) and on the function of VDCCs for 
ROS/RNS-mediated AIS disruption, we next asked if release from intracellular stores is 
involved in this SIN-1 induced insult. Prior to SIN-1 addition, neurons were pre-treated 
with inhibitors to both ryanodine and inositol 1,4,5-trisphosphate (IP3) receptors, the two 
major mediators of Ca2+ release from intracellular stores (Marks, 1997; Evans et al., 
2013). Inhibition of ryanodine receptors with ryanodine at concentrations of 0.001-10 µM 
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did not result in protection of the AIS from SIN-1 induced disruption (Fig. 3.5C, E). 
Concentrations greater than 10 µM resulted in significant neuronal death (data not 
shown). Conversely, pre-treatment with IP3 receptor inhibitor 2-Aminoethoxydiphenyl 
borate (2-APB) was capable of significantly preserving AIS integrity in a dose dependent 
manner at concentrations of 10 µM and 20 µM, resulting in the preservation of 80.4% ± 
7.3% (p=0.0290) and 95.1% ± 2.7% (p=0.0002) of neurons with an intact AIS respectively 
(Fig. 3.5D, F). Interestingly, low concentrations of 2-APB (<10 µM) result in the release 
of Ca2+ from IP3-gated intracellular stores (DeHaven et al., 2008), a possible explanation 
for the exacerbated effect of SIN-1 on the AIS at the 0.1 µM concentration (Fig. 3.5F; 
p=0.0010). Taken together, these data highlight an important role for Ca2+ release from 
IP3, but not ryanodine-sensitive intracellular stores in ROS/RNS-induced AIS disruption.  
 
Calpain, but not calcineurin activity, is involved in ROS/RNS-induced AIS 
disruption 
     While Ca2+ from both extracellular and intracellular sources appears to play a critical 
role in ROS/RNS-mediated AIS disruption, the downstream mediator of this AIS 
modulation remains unknown. Previously described mechanisms of AIS plasticity and 
injury have implicated two Ca2+-activated enzymes as critical regulators of AIS stability 
(Evans et al., 2013; Schafer et al., 2009). These include calcineurin, a Ca2+-activated 
phosphatase responsible for disassembly of the AIS protein complex in models of activity-
dependent plasticity (Evans et al., 2013), as well as calpain, a Ca2+-activated protease 
whose substrates include critical structural and functional AIS proteins (Schafer et al., 
2009). In order to assess the contribution of each potential AIS modulator in ROS/RNS-
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induced AIS disruption, pharmacological inhibitors of each were employed prior to SIN-1 
addition. Inhibition of calcineurin with FK-506 (Evans et al., 2013) in the presence of SIN-
1 was insufficient to prevent AIS disruption at all concentrations tested (0.001-10 μM) 
(Fig. 3.6C, E). Concentrations greater than 10 µM resulted in significant neuronal death 
(data not shown).  
     Treatment with the well-established calpain inhibitor MDL 28170 (Schafer et al., 2009; 
Donkor, 2015), however, prevented AIS loss in a dose-dependent manner, at 
concentrations of 1 μM and 10 μM, yielding preservation of 83.3% ± 0.6% (p<0.0001) and 
96.8% ± 0.8% (p<0.0001) of AISs respectively (Fig. 3.6D, F). A fluorescent activity assay 
was used to determine the time-course of calpain activity, at the time points tested in 
Figure 3.2, in order to correlate with SIN-1 induced AIS loss and recovery. While elevated 
calpain activity was observed at 12 hours post SIN-1 treatment (69.4% ± 4.8% increase 
over untreated; p=0.0036; Fig. 3.6G), peak activity was observed at 24 hours (255.5% ± 
14.9% increase over untreated; p<0.0001; Fig. 3.6G); the time point at which AIS loss is 
greatest (Fig. 3.2E, J). Interestingly, by 72 hours post SIN-1 treatment, calpain activity 
returned to baseline levels (34% ± 9.9% increase over untreated; Fig. 3.6G), 
corresponding to the point at which neuronal ROS levels have returned to baseline (Fig. 
3.1L, N) and AIS recovery is achieved (Fig. 3.2F, K). Overall, these data implicate a role 
for calpain, but not calcineurin, as an effector of AIS disruption downstream of oxidative 
stress. 
 
3.5 Discussion 
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     Previous work from our lab implicated oxidative stress as a mediator of AIS disruption, 
since free radical scavenger treatment was sufficient to protect and recover the domain 
in an inflammatory mouse model of MS (Clark et al., 2016). Additionally, ablation of NOX2, 
a major source of ROS/RNS production in the CNS, was sufficient to preserve AIS 
integrity in an LPS model of systemic inflammation (Benusa et al., 2017). While these 
studies suggested a role for oxidative stress in AIS modulation, the direct effects of 
reactive oxygen and nitrogen species on AIS stability remained unclear. The present 
study demonstrates for the first time that oxidative stress, induced through exogenous 
ROS/RNS application, drives structural alterations of the AIS. Additionally, 
pharmacological inhibition of both voltage-dependent and intracellular Ca2+ channels 
suggests that Ca2+ entry through L-type VDCCs and its release from IP3-gated stores is 
involved in ROS/RNS-mediated AIS modulation. Furthermore, this AIS insult is 
dependent upon calpain, but not calcineurin, activity.   
 
The Role of ROS/RNS in Axonal Pathology 
     The data presented in this study highlight a role for ROS/RNS in disruption of the AIS 
protein complex, but other axonal targets of oxidative stress have been described. These 
include the F-actin cytoskeleton (Hung et al., 2011; Sakai et al., 2012), axonal growth 
cones (Munnamalai and Suter, 2009; Munnamalai et al., 2014), and microtubule-
associated stabilizers and motors (Stroissnigg et al., 2007; Carletti et al., 2011; Redondo 
et al., 2015). Reactive oxygen and nitrogen species have also been associated with the 
pathogenesis of many CNS insults including axonal loss in peripheral nerve and spinal 
cord injury (Kuo et al., 2017; Maggio et al., 2017), hyperphosphorylation of tau in 
113 
 
Alzheimer’s disease (Sepulveda-Diaz et al., 2015), loss of cortical connections following 
ischemia (Rosenzweig and Carmichael, 2013), and demyelination and axonal 
degeneration in MS (Forte et al., 2007; Qi et al., 2007). 
     Because oxidative stress is a key contributor to many CNS pathologies (Lewén et al., 
2000; Smith et al., 2013; Méndez-Armenta et al., 2014; Islam, 2017), it is likely that this 
mechanism of ROS/RNS-induced AIS modulation may underlie many models of CNS 
injury. Our laboratory has recently identified AIS disruption in both an inflammatory model 
of multiple sclerosis (Clark et al., 2016), as well as a model of systemic inflammation 
(Benusa et al., 2017), which was prevented and/or reversed upon free-radical scavenger 
treatment. Additionally, other labs have reported alterations in AIS stability in models of 
epilepsy (Wimmer et al., 2010; Harty et al., 2013), ischemic injury (Schafer et al., 2009; 
Hinman et al., 2013), traumatic brain injury (Baalman et al., 2013; Greer et al., 2013; 
Vascak et al., 2017), and Alzheimer’s disease (León-Espinosa et al., 2012; Sun et al., 
2014; Marin et al., 2016; Zempel et al., 2017), which have all been shown to be associated 
with CNS oxidative stress through ROS/RNS dysregulation (Lewén et al., 2000; Smith et 
al., 2013; Méndez-Armenta et al., 2014; Islam, 2017). 
 
 
 
ROS/RNS and Ca2+ Entry 
     Our data suggest that ROS/RNS-mediated AIS disruption involves extracellular Ca2+ 
entry through L-type VDCCs, as well as intracellular release from IP3-gated stores. While 
114 
 
the mechanistic link between ROS/RNS application and cytosolic Ca2+ levels is not well 
defined in our system, previous studies examining this link may provide insight. Similar to 
the present study, SIN-1 treatment is known to induce Ca2+ entry through L-type channels 
in CA1 pyramidal neurons, cardiomyocytes, and striatal neurons (Pan et al., 2004; 
Rocchitta et al., 2005; Zhaowei et al., 2014). Peroxynitrite treatment of cerebral cortical 
neurons, the cell type used in the present study, also resulted in increased Ca2+ entry 
through L-type VDCCs (Ohkuma et al., 2001). However, the effects of SIN-1 have been 
shown to vary in other cell types, as treatment resulted in decreased Ca2+ flow through L-
type VDCCs in cerebellar granule cells and vestibular hair cells (Gutiérrez-Martín et al., 
2005; Almanza et al., 2007; Tiago, et al., 2011). While the mechanism of ROS/RNS 
modulation of L-type VDCCs remains unclear for most cell types described, S-
glutathionylation of the L-type VDCCs has been shown to be involved in increased Ca2+ 
flow through these channels in cardiomyocytes (Tang et al., 2011; Johnstone and Hool, 
2014). It remains to be determined if this, or other modifications, could underlie SIN-1-
induced Ca2+ influx through L-type VDCCs in our primary cortical neuron system.   
     In addition to L-type VDCCs, we demonstrate the involvement of IP3-gated intracellular 
Ca2+ stores on ROS/RNS-induced AIS disruption. Similar to the present study, previous 
work has shown SIN-1 and its ROS/RNS products to induce release of Ca2+ specifically 
through IP3-gated stores in neuroblastoma SH-SY5Y cells and cardiomyocytes (Saeki et 
al., 2000; De Simoni et al., 2013). It has been reported, however, that SIN-1 derived 
ROS/RNS can induce intracellular Ca2+ release non-specifically in renal epithelial cells 
and ventral horn spinal cord neurons (Ohashi et al., 2016; Munoz et al., 2017) or 
specifically through ryanodine-sensitive stores in smooth and skeletal muscle cells (Pan 
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et al., 2004; Yamada et al., 2015). Given the cell-type specific effects of ROS/RNS on 
both voltage-dependent and intracellular Ca2+ channel function reported in the literature, 
the mechanistic action of SIN-1 on L-type VDCCs and IP3-gated intracellular stores in our 
system remains to be determined. 
 
How does Calpain Modulate the AIS? 
     In the present study, we have identified ROS/RNS-induced AIS disruption to be 
dependent upon calpain activation. Similarly, calpain activity is shown to drive AIS 
alterations in other model systems including ischemic injury (Schafer et al., 2009), 
glutamate excitotoxicity (Benned-Jensen et al., 2016), and P2X7 purinergic activation 
(Del Puerto et al., 2015). Schafer et al. (2009) demonstrated that proteolytic degradation 
of essential AIS proteins, such as ankyrinG, βIV spectrin, and voltage-gated Na+ 
channels, was the mechanism underlying calpain-mediated AIS modulation following 
ischemic injury. Benned-Jensen et al. (2016) and Del Puerto et al. (2015) did not analyze 
the extent of proteolysis, but speculated that a mechanism similar to that reported by 
Schafer et al. (2009) was most likely involved in their models of AIS injury. It is likely that 
calpain-mediated proteolysis of the AIS complex underlies the alterations observed 
following the ROS/RNS-induced insult presented in this study, as this mechanism is well 
characterized by Schafer et al. (2009). 
     In summary, for the first time, we demonstrate that oxidative stress, stimulated directly 
through exogenously applied ROS/RNS, is capable of reversible structural modulation of 
the AIS. This mechanism involves activity of L-type VDCCs, as well as intracellular IP3-
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gated stores. Additionally, calpain, but not calcineurin, activity is involved in this 
ROS/RNS-induced disruption. These findings provide new insights into the mechanisms 
underlying altered AIS stability in a variety of CNS pathologies.  
 
 
 
 
 
 
 
 
 
 
 
117 
 
 
 
 
 
 
 
 
 
 
 
118 
 
 
 
 
 
Figure 3.1. ROS/RNS generator, SIN-1, induces oxidative stress in vitro. Cortical 
neurons (NeuN+ cells, green) treated with (B-F) and without (A) SIN-1 at increasing 
concentrations reveal no propidium iodide (PI) staining at concentrations of 25 μM and 
below (B-E) 24 hours post treatment; however, robust staining was present at 
concentrations of 50 μM (not shown) and 100 μM (F). Quantitation of percent neuronal 
survival, determined as the percentage of NeuN+ cells that were also PI- (as a percent of 
the untreated cells), revealed significant cell death at SIN-1 concentrations of 50 μM and 
100 μM (M). The CellROX® Green assay for detection of ROS production by the cortical 
neurons revealed baseline levels of ROS at ≤6 hours post SIN-1 treatment (G-I, N) with 
significantly elevated levels at 12 hours (J, N), peak levels at 24 hours (K, N) and a return 
to baseline by 72 hours (L, N). Asterisks represent a significant difference from the SIN-
1 untreated group (*p < 0.05).  
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Figure 3.2. Exogenous ROS/RNS drive disruption of the AIS in vitro. Axon initial 
segments of cultured cortical neurons maintain their integrity with no SIN-1 treatment (A) 
or 3 (B,G), 6 (C,H), or 12 (D,I) hours following exposure to 25 μM SIN-1, a concentration 
that did not induce cell death. However, at this same concentration, a significant dose-
dependent reduction in the number of cortical neurons (NeuN+, green) that presented 
ankyrin-G (red) positive AISs was observed 24 hours after SIN-1 exposure (white arrows; 
E,J). By 72 hours post SIN-1 exposure, AIS integrity was restored (F,K) demonstrating 
the reversibility of AIS disruption and further indicating that AIS loss was not a 
consequence of cell death. Asterisks represent a significant difference from the SIN-1 
untreated group (*p < 0.05). 
 
 
 
 
 
121 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
122 
 
 
 
 
 
 
 
Figure 3.3. ROS/RNS-induced AIS disruption is attenuated following chelation of 
extracellular Ca2+. The loss of AIS labeling (white arrows) following exposure to 25 μM 
SIN-1 (B) was inhibited by the addition of EGTA (C) to the medium prior to SIN-1 
treatment. The extent of AIS maintenance was directly dependent on the dose of EGTA 
(D). An asterisk with an associated bracket indicates significant differences between 
treated groups; asterisks without an associated bracket represent a significant difference 
from the SIN-1 untreated group (A, *p < 0.05). (NeuN, green; AnkG, red) 
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Figure 3.4. L-type voltage dependent calcium channels are required for ROS/RNS-
induced AIS disruption. Similar to SIN-1 treated neurons without inhibitor pre-treatment 
(B), neurons (NeuN+, green) treated with inhibitors directed against T/R- (C,G) or P/N/Q-
type (D,H) calcium channels prior to SIN-1 exposure presented with significant loss (white 
arrows) in AIS labeling (AnkG, red). In contrast, cultured cortical neurons treated with an 
L-type calcium channel inhibitor (E,I) resulted in a significant preservation of the AISs. 
Further demonstrating a role for L-type calcium channels in mediating AIS alterations, 
cortical neurons treated with (S)-(-)-Bay K 8644 also resulted in a significant disruption of 
the AISs (F,J). Asterisks without an associated bracket represent a significant difference 
from the SIN-1 untreated group (A, *p < 0.05).  
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Figure 3.5. IP3-gated Ca2+ stores are required for ROS/RNS-induced AIS disruption. 
AIS labeling (AnkG, red) was lost (white arrows) following exposure of cortical neurons 
(NeuN+, green) to 25 μM SIN-1 (B). This disruption was prevented by pre-treatment with 
an IP3-receptor inhibitor (D,F) but not an inhibitor to ryanodine receptors (C,E). Asterisks 
without an associated bracket represent a significant difference from the SIN-1 untreated 
group (A, *p < 0.05). 
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Figure 3.6. ROS/RNS-induced AIS disruption is mediated by calpain but not 
calcineurin activity. Cultured cortical neurons (NeuN+, green) treated with an inhibitor 
directed against calcineurin (C,E) prior to SIN-1 exposure presented with a significant 
loss (white arrows) of AIS labeling (AnkG, red) similar to the SIN-1 treated neurons 
without inhibitor pre-treatment (B). In contrast, neurons treated with a calpain inhibitor 
displayed a significant preservation of AISs (D,F). A calpain protease activity assay 
revealed significantly elevated activity at 12 hours, peak activity at 24 hours and a return 
to baseline by 72 hours post SIN-1 treatment (25 μM) which is represented as the percent 
increase over untreated neurons (G). Asterisks without an associated bracket represent 
a significant difference from the SIN-1 untreated group (A, *p < 0.05). 
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Supplementary Table S3.1. Neurobasal™ Medium Formulation 
Components Molecular Weight (kDa) Concentration (mg/L) 
Amino Acids   
Glycine 75.0 30.0 
L-Alanine 89.0 2.0 
L-Arginine hydrochloride 211.0 84.0 
L-Asparagine-H2O 150.0 0.83 
L-Cysteine 121.0 31.5 
L-Histidine hydrochloride-H2O 210.0 42.0 
L-Isoleucine 131.0 105.0 
L-Leucine 131.0 105.0 
L-Lysine hydrochloride 183.0 146.0 
L-Methionine 149.0 30.0 
L-Phenylalanine 165.0 66.0 
L-Proline 115.0 7.76 
L-Serine 105.0 42.0 
L-Threonine 119.0 95.0 
L-Tryptophan 204.0 16.0 
L-Tyrosine 181.0 72.0 
L-Valine 117.0 94.0 
Vitamins   
Choline Chloride 140.0 4.0 
D-Calcium Pantothenate 477.0 4.0 
Folic Acid 441.0 4.0 
Niacinamide 122.0 4.0 
Pyridoxal Hydrochloride 204.0 4.0 
Riboflavin 376.0 0.4 
Thiamine Hydrochloride 337.0 4.0 
Vitamin B12 1355.0 0.0068 
i-Inositol 180.0 7.2 
Inorganic Salts   
Calcium Chloride (anhydrous) 111.0 200.0 
Ferric Nitrate 404.0 0.1 
Magnesium Chloride (anhydrous) 95.0 77.3 
Potassium Chloride 75.0 400.0 
Sodium Bicarbonate 84.0 2200.0 
Sodium Chloride 58.0 3000.0 
Sodium Phosphate Monobasic 138.0 125.0 
Zinc Sulfate 288.0 0.194 
Other Components   
D-Glucose (Dextrose) 180.0 4500.0 
HEPES 238.0 2600.0 
Phenol Red 376.4 8.1 
Sodium Pyruvate 110.0 25.0 
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CHAPTER FOUR 
 
DISRUPTION OF THE CISTERNAL ORGANELLE IN EAE AND  
MULTIPLE SCLEROSIS  
 
Clark et al., Cerebral Cortex (Submitted) 
 
4.1 Abstract 
     The axon initial segment (AIS), the neuronal subcompartment responsible for action 
potential generation, is altered through activity-dependent plasticity and pathological 
insult. While there may be many triggers for AIS modulation, all described mechanisms 
converge on calcium (Ca2+) dysregulation which activates enzymes leading to AIS 
destabilization and neuronal dysfunction. Understanding the mechanisms that regulate 
Ca2+ levels at the AIS is therefore critical for addressing AIS alterations that underlie many 
CNS insults. Here, we investigate the cisternal organelle (CO), a poorly understood 
structure located specifically at the AIS and reported to buffer Ca2+ at this domain. Our 
findings of CO disruption in postmortem multiple sclerosis (MS) tissue are the first to show 
pathologically-induced CO alteration. Further characterization in a mouse model of MS 
(experimental autoimmune encephalomyelitis) suggests F-actin depolymerization and 
axo-axonic GABAergic synapse loss is a trigger and consequence of CO disruption, 
respectively.  Importantly, we also demonstrate that F-actin depolymerization, synaptic 
loss, and CO instability are reversible upon treatment with didox, a potent free radical 
scavenger. Overall, these findings identify a novel neuronal insult which may provide 
insight into new therapeutic targets for MS and other CNS pathologies.   
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4.2 Introduction 
     The axon initial segment (AIS) is a specialized axonal subdomain responsible for both 
action potential initiation, and maintenance of neuronal polarity (Kole et al., 2008; 
Rasband, 2010). Consistent with its role as the trigger zone for neuronal firing, voltage 
gated ion channels are clustered at the AIS by the cytoskeletal scaffolding protein 
ankyrinG (AnkG) (Nelson and Jenkins, 2017). Structural and functional stability of this 
domain is heavily dependent on the master regulatory protein AnkG, as its loss at the AIS 
results in complete disassembly of the complex (Hedstrom et al., 2008). Our lab (Clark et 
al., 2016, Benusa et al., 2017, Clark et al., in press), and others (Buffington and Rasband, 
2011; Yamada and Kuba, 2016) have demonstrated alterations to the AIS as a result of 
either activity-dependent plasticity or pathological insult. While the initial triggers of AIS 
modulation may differ, local calcium (Ca2+) dysregulation at this axonal complex is central 
to all established mechanisms of AIS plasticity and injury (Buffington and Rasband, 2011; 
Yamada and Kuba, 2016). To elucidate the mechanisms underlying plasticity- and 
pathologically-induced Ca2+ changes at the AIS, we investigated the cisternal organelle 
(CO), an enigmatic structure localized specifically at the AIS reported to play a role in 
local cytosolic Ca2+ regulation (Benedeczky et al., 1994; Sánchez-Ponce et al., 2011). 
     The CO is a specialized form of smooth endoplasmic reticulum, arranged similarly as 
stacks of electron-dense membranous cisternae (Benedeczky et al., 1994; Bas Orth et 
al., 2007). This structure lies in close apposition to the axolemma while also associating 
with the submembranous cytoskeleton at the AIS (Sánchez-Ponce et al., 2012). 
Surprisingly, the functional role of the CO has not been fully elucidated. In fact, most 
insight into the function of this structure  is derived from the nature of the expressed 
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proteins such as annexin 6 (A6), sarco-endoplasmic reticulum Ca2+-ATPase (SERCA), 
and Inositol 1,4,5-trisphosphate (IP3) receptor type 1 (IP3R1). The functional nature of 
these proteins suggests a role for the CO in the sequestration and release of Ca2+ at the 
AIS (Benedeczky et al., 1994; Sánchez-Ponce et al., 2011). Recently, a role for the CO 
in AIS maturation and plasticity during development was demonstrated in the visual cortex 
(Schlüter et al., 2017). Additional insight into the functional role of the CO is gleaned from 
existing knowledge about a distinct, but structurally analogous organelle found in dendritic 
spines, termed the spine apparatus (Segal et al., 2010). Unlike the CO, the functional role 
of the spine apparatus as a regulator of local Ca2+ levels at the dendritic spine has been 
extensively characterized (Segal et al., 2010). Despite the elusive functional role of the 
CO, evidence for the mechanisms involved in its establishment and maintenance is 
provided by in vitro and in vivo studies (Bas Orth et al., 2007; Sánchez-Ponce et al., 2011; 
Schlüter et al., 2017). Stability of this organelle is dependent on both AnkG localization 
and clustering of filamentous actin (F-actin), as both AnkG silencing and actin 
depolymerization results in the loss of this structure at the AIS (Sánchez-Ponce et al., 
2011). In addition to these extrinsic AIS components, CO integrity is also regulated 
intrinsically by synaptopodin (Synpo), an actin-binding protein critical for stabilizing the 
CO with the F-actin cytoskeleton (Kremerskothen et al., 2004; Sánchez-Ponce et al., 
2011), as Synpo-deficient mice fail to establish COs (Bas Orth et al., 2007). 
     While the mechanisms that establish and maintain the CO are becoming clear, the 
structural and functional vulnerability of this organelle under any pathological condition 
has yet to be demonstrated. Presently, the only study to investigate CO integrity under 
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pathological conditions found the CO to remain structurally intact in a model of 
Alzheimer’s disease (León-Espinosa et al., 2012).  
     Interestingly, we have recently reported that Ca2+ regulation is altered at the AIS 
following inflammatory insults that mimic those present in multiple sclerosis (MS) (Clark 
et al., 2017), a disease classically characterized by demyelination but known to exhibit 
extensive axonal pathology (Trapp et al., 1998; Criste et al., 2014). Based on our previous 
findings, we investigated CO stability in MS and experimental autoimmune 
encephalomyelitis (EAE), an animal model of MS, and found that CO integrity is 
compromised in both the human disease and the animal model. Our findings provide the 
first evidence that the CO is vulnerable to pathologically-induced disruption. Additionally, 
we provide evidence of a potential upstream trigger, and downstream consequence of 
CO instability in the form of F-actin depolymerization and GABAergic axo-axonic synapse 
loss, respectively. Importantly, we show that the CO disruption is reversible following free 
radical scavenger treatment suggesting that this newly described form of neuronal injury 
is potentially amenable to clinical manipulation for novel therapeutic approaches to 
combat MS. 
 
4.3 Materials and Methods 
Animals 
    11 week old female C57BL/6J mice were purchased from Jackson Laboratories (Bar 
Harbor, ME) and maintained in the McGuire Veterans Affairs Medical Center  
(VAMC) vivarium, an AAALAC accredited facility. The EAE model was induced following 
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one week of acclimation post-arrival resulting in induction at 12 weeks of age. Food and 
water were provided ad libitum. All procedures were conducted in accordance with the 
methods outlined in the approved McGuire VAMC IACUC protocols.  
 
The EAE Model and Didox Administration 
     Induction of EAE was performed in 12 week old female C57BL/6J mice as previously 
described (Clark et al., 2016). Briefly, subcutaneous injection of 100 µL of myelin 
oligodendrocyte glycoprotein peptide 35-55 (3 mg/mL; AnaSpec, Fremont, CA) was 
emulsified in complete Freund’s adjuvant (Thermo Fisher Scientific, Waltham, MA) 
containing heat-killed M. tuberculosis (2 mg/mL, Invitrogen Life Technologies, Waltham, 
MA). Intraperitoneal (IP) injection with PBS-diluted pertussis toxin (0.25 µg/µL, List 
Biological Labs, Campbell, California) was performed on the same day, followed by a 
booster injection 48 hours later. Clinical motor symptoms were scored daily and recorded 
as follows: 1.0 = limp tail, 2.0 = loss of righting reflex, 3.0 = paralysis of single hind limb 
and 4.0 = paralysis of both hind limbs consistent with previous reports (Dupree et al., 
2015; Clark et al., 2016). For analysis, EAE mice were grouped into two clinical score 
groups: those presenting with mild scores (1&2) and severe scores (3&4) as previously 
described (Clark et al., 2016). Additionally, these two groups were assessed at two 
different time points along the EAE disease course: an early inflammatory time point (3 
days after peak clinical score presentation) and a late inflammatory time point (9 days 
after peak clinical score presentation). This resulted in EAE groups termed: Early EAE 
1&2, Early EAE 3&4, Late EAE 1&2 and Late EAE 3&4 (Clark et al., 2016). Only animals 
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that maintained consistent scores (whether 1&2 or 3&4) for the duration of their 
designated EAE duration were included in the study.   
     As previously described (Clark et al., 2016), EAE mice presenting with severe clinical 
scores (3&4) were treated with didox, a ribonucleotide reductase inhibitor (Bhave et al., 
2013) which has been shown to dampen the inflammatory response (Matsebatlela et al., 
2015; Clark et al., 2016; Caslin et al., 2017) and act as a potent free radical scavenger 
(Szekeres et al., 1997). Didox was supplied by Molecules for Health, Inc. (Richmond, VA) 
and administered via IP injection based on prior studies optimizing the treatment 
parameters (DeVries et al., 2012, Clark et al., 2016). Didox was dissolved at a 
concentration of 250 mg/kg in a solution containing: 0.5% (w/v) carboxymethylcellulose 
(Sigma-Aldrich Corp., St. Louis, MO), 0.9% (w/v) sodium chloride (Sigma-Aldrich Corp., 
St. Louis, MO), 0.4% (w/v) polysorbate 80 (Sigma-Aldrich Corp., St. Louis, MO), and 0.9% 
(w/v) benzyl alcohol (Sigma-Aldrich Corp., St. Louis, MO) in deionized water. Didox 
treatment was initiated in the Early EAE 3&4 mice and continued once daily for 6 days. 
For analysis, these mice were compared against similarly EAE staged animals treated 
daily with vehicle solution for the same duration (termed Carboxy Veh. group).  
    
Mouse Tissue Preparation      
     Mouse tissue preparation was performed as previously described (Clark et al., 2016). 
Briefly, mice were transcardially perfused with 4% paraformaldehyde (Ted Pella, Inc., 
Redding, CA) and brains cryopreserved in 30% sucrose solution (in PBS), frozen in 
Tissue TEK Optimal Cutting Temperature compound at -80oC, and serially sectioned 
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coronally at 40 µm thickness. Fifteen slides of six sections spanning the region 1.1 mm 
anterior to bregma to 2.5 mm posterior to bregma were collected as described previously 
(Clark et al., 2016).  
 
Human Tissue 
     All human tissue used in this study, including postmortem samples from non-
demented control or MS individuals, was obtained from the Netherlands Brain Bank 
(Amsterdam, Netherlands). Tissue characterization and donor history data are detailed in 
Supplementary Table S4.1.    
 
Antibodies and Immunohistochemistry 
    A complete list of the primary antibodies used in this study is provided in 
Supplementary Table S4.2. All secondary antibodies were obtained from Invitrogen Life 
Technologies (Waltham, MA) (1:500, AlexaTM Fluor). Human and mouse tissue was 
immunolabeled with the appropriate primary and secondary antibodies as described 
previously (Clark et al., 2016; Benusa et al., 2017), and imaged using confocal 
microscopy. 
 
Image Collection and Quantitation 
     Confocal z-stacks spanning an optical distance of 20 m were collected using a Zeiss 
LSM 710 confocal laser scanning microscope (Carl Zeiss Microscopy, Jena, Germany) 
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housed in the VCU Department of Anatomy and Neurobiology Microscopy Facility. 
Imaging parameters described previously (Clark et al., 2016) were used for all 
immunofluorescent analyses in the present study. Twelve fields of view were collected 
for both mouse and human tissue samples, yielding >1000 or >500 AISs per animal or 
donor, respectively. Neocortical layer V, the region previously revealed to exhibit severe 
AIS disruption following EAE induction (Clark et al., 2016), was the area of focus for 
analysis. A minimum of four mice (n=4) were used per treatment group, while the number 
of human tissue samples analyzed was five and 18 for non-demented controls (n=5) and 
MS (n=18), respectively (Supplementary Table S4.1).  
     Z-stack image files were analyzed using Volocity™ 3D Image Analysis Software 
version 6.3 (PerkinElmer, Waltham, MA). For CO, F-actin, and GABAergic axo-axonic 
synaptic analyses, automated measurements in the 3D z-stack allowed for specific 
selection and measurements of the CO through colocalization with AnkG (Supplementary 
Fig. S4.1). Automated exclusion of CO markers (Synpo, αAct, annexin 6, SERCA, IP3R1), 
F-actin (phalloidin) and GABAergic axo-axonic synaptic components (VGAT, gephyrin) 
not colocalized with AnkG was performed in order to restrict analysis to the AIS 
(Supplementary Fig. S4.1). COs were analyzed based on the 1. percent of AISs with COs, 
2. number of COs as a function of AIS length (per 10 µm) and 3. combined CO length as 
a function of AIS length (per 10 µm). Similar automated 3D measurements were used for 
the analyses of F-actin and GABAergic synaptic labeling. Data from these analyses are 
presented as the percent of AISs with F-actin or GABAergic synaptic clustering, as well 
as the number of these clusters as a function of AIS length (per 10 µm). Representative 
images shown for individual AISs are presented as isosurface images (generated in 
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Volocity™ 3D Image Analysis Software) with the raw images provided in Supplementary 
Figures S4.3, S4.4 and S4.5. One way ANOVAs with Tukey’s HSD post hoc tests were 
performed for all analyses using GraphPad Prism version 6.03 (GraphPad Software, Inc., 
La Jolla, CA ). 
     In order to determine the extent of parvalbumin (PV)+ and total neuronal cell death, 
tissue was immunolabeled for PV and NeuN in combination with  TUNEL labeling (Roche 
In Situ Cell Death Detection Kit, Fluorescein, Sigma-Aldrich Corp., St. Louis, MO). Images 
were collected as described above and qualitatively assessed for the presence of 
neuronal death at all EAE disease stages and time points used in this study 
(Supplementary Fig. S4.2). Additionally, TUNEL labeling was utilized in the postmortem 
human tissue to restrict CO and GABAergic synapse analysis to tissue sections 
containing only non-apoptotic neurons (Supplementary Fig. S4.2). 
 
4.4 Results 
The cisternal organelle is disrupted in an inflammatory model of MS 
     Our lab has previously reported disruption of the AIS in EAE (Clark et al., 2016), a 
murine model commonly used to recapitulate the inflammatory environment associated 
with MS (Kipp et al., 2017). Follow-up in vitro studies identified dysregulation of Ca2+ as 
a potential driver of the observed AIS pathology (Clark et al., in press) consistent with all 
previously reported mechanisms underlying AIS modulation (Leterrier et al., 2016; 
Jamann et al., 2017). Since we and others have implicated Ca2+ as a regulator of AIS 
stability, we investigated the integrity of the CO, a Ca2+-storing organelle localized 
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specifically in the AIS which regulates local cytosolic Ca2+ levels (Benedeczky et al., 1994; 
Sánchez-Ponce et al., 2011). Based on our previous findings suggesting Ca2+ 
dysregulation at the AIS in EAE (Clark et al., 2016), CO integrity was first assessed in this 
model at all previously established time points and disease stages (Clark et al., 2016).       
     In the Early EAE 1&2 disease group, no difference in the percent of AISs containing 
COs (identified as synaptopodin, or “Synpo”+ puncta), number of COs per 10 µm of AIS 
or total combined length of COs per 10 µm was observed as compared with Naïve mice 
(Fig. 4.1A&B, 4.1K&M). However, in the Early EAE 3&4 disease group (Fig. 4.1C), the 
percent of AISs with Synpo+ puncta was significantly reduced (Fig. 4.1K) as was the 
number of puncta (Fig. 4.1M) and the combined length of puncta per 10 µm of AISs (data 
not shown). By Late EAE, in both the 1&2 (Fig. 4.1D) and 3&4 (Fig. 4.1E) groups, Synpo 
labeling exhibited a continued and/or progressed reduction with regard to all three 
quantified parameters indicating that CO disruption parallels disease development (Fig. 
4.1K&M). 
     To further analyze CO integrity, we next conducted immunolabeling of α-actinin (α-
Act), a separate actin-binding protein important for CO stabilization (Sánchez-Ponce et 
al., 2012). Similar to the Synpo findings, co-immunolabeling for α-Act and AnkG revealed 
no significant changes in CO integrity in the Early EAE 1&2 clinical group (Figs. 4.1G, L, 
N) as compared to the Naïve (Figs. 4.1F, L, N). In contrast with the results of the Synpo 
analysis, the Early EAE 3&4 mice did not show a significant reduction in the percent of 
AISs containing α-Act+ puncta (Figs. 4.1H, L). However, CO stability was still impaired in 
this disease group as the number and total combined length of αAct-immunoreactive (IR) 
puncta per 10 µm of AnkG labeling were significantly reduced (Figs. 4.1H, N). Also, 
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consistent with the Synpo analysis, both clinical score groups at the late time point 
presented with a significant reduction in the percent of AISs containing αAct-IR puncta 
(Figs. 4.1I, J, L) as well as the number and combined length of puncta per 10 µm of AIS 
(Figs. 4.1I, J, N). Overall, we have identified disruption of the CO following EAE induction 
and confirmed this disruption separately through immunohistochemical analysis of two 
proteins critical for organelle structural stability. 
 
Calcium-regulating proteins at the cisternal organelle are also lost in EAE 
     In order to further characterize the EAE-induced pathological alteration of the CO, we 
next investigated the CO-specific expression of several Ca2+-associated proteins which 
are critical for its proposed function as a regulator of cytosolic Ca2+ at the AIS (Sánchez-
Ponce et al., 2011).  
     Consistent with the CO analysis performed through Synpo and α-Act immunolabeling 
and based on the same parameters of analysis, no change in the expression of Ca2+-
associated proteins (annexin 6, SERCA and IP3R1) on the COs of Early EAE 1&2 mice 
was observed as compared to the Naïve group (Figs. 4.2P-X). Also consistent with Synpo 
and α-Act analysis, mice in the Early EAE 3&4, Late EAE 1&2, and Late EAE 3&4 groups 
exhibited significant reduction in the percent of AISs containing annexin 6+, SERCA+, and 
IP3R1+ COs (Figs. 4.2P-R). Similarly, these groups exhibited significant reductions in the 
number of Ca2+-associated protein+ COs per 10 μm of AIS (Figs. 4.2S-U), as well as in 
the percent of COs positive for these Ca2+-associated proteins (Figs. 4.2V-X). Overall, in 
addition to the EAE-induced structural changes in CO integrity (Fig. 4.1), these data also 
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suggest an impaired function as these Ca2+-associated proteins are vital for the proposed 
role of the CO as a Ca2+-regulating structure (Sánchez-Ponce et al., 2011).  
 
Loss of F-actin clustering precedes cisternal organelle disruption in EAE 
     We have demonstrated significant CO disruption following EAE induction and next 
asked what pathological mechanism could trigger this insult. While very little is known 
about the mechanisms that regulate CO integrity, AnkG and F-actin are both known to 
stabilize this organelle (Sánchez-Ponce et al., 2011). Because we are investigating CO 
stability in the AnkG-intact population of AISs, we focused our analysis instead on the 
integrity of the F-actin clusters at the AIS. To determine if altered F-actin stability could 
act as an upstream trigger of CO disruption, we quantified F-actin puncta associated with 
the AIS, as visualized through fluorescently conjugated Phalloidin staining, at all 
previously described EAE clinical score groups and time points.  
     Interestingly, a significant reduction in the percent of AISs with F-actin puncta, the 
number of F-actin puncta per 10 μm of AnkG labeling, and the combined length of these 
puncta per 10 μm of AnkG labeling (data not shown) was detected in all EAE clinical score 
groups and time points (Figs. 4.3A-E, K&L). In order to temporally correlate this loss of F-
actin clustering with CO integrity at the AIS, double immunolabeling for Synpo and AnkG 
in combination with Phalloidin staining was performed within the same tissue sections. 
While an approximate one-to-one ratio of the number of F-actin puncta to CO (Synpo+) 
puncta  within the AIS was maintained in the Naïve mice (Figs. 4.3F, M), this ratio dropped 
significantly in the Early EAE 1&2 mice (Figs. 4.3G, M) in which the F-actin clustering was 
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lost (Fig. 4.3L) but no change in CO stability was detected (Fig. 4.1). This F-actin to CO 
ratio, however, was not significantly different between the Naïve group and  mice 
belonging to the Early EAE 3&4, Late EAE 1&2, and Late EAE 3&4 disease groups (Figs. 
4.3H-J, M) since these mice also exhibit CO disruption (Fig. 4.1) in addition to F-actin 
loss. Taken together, these data demonstrate that loss of F-actin clustering precedes CO 
disruption along the EAE disease course consistent with F-actin destabilization acting as 
a trigger for this pathological CO insult.   
 
 GABAergic axo-axonic synapse loss follows cisternal organelle disruption in EAE 
     As our findings implicate F-actin destabilization as a potential upstream trigger of CO 
disruption in EAE, we next wanted to identify   downstream consequences of this insult. 
Although not associated with disease, previous studies have suggested that the CO 
provides functional support for inhibitory GABAergic synaptic input on the AIS 
(Benedeczky et al., 1994; Jedlicka et al., 2009; King et al., 2014). This is evidenced by 
strong colocalization between the CO and GABAergic synaptic boutons along the AIS 
(King et al., 2014), as well as a functionally impaired inhibitory network in Synpo-deficient 
mice which fail to establish COs (Jedlicka et al., 2009). In light of these findings, we next 
investigated the structural stability of the GABAergic synaptic terminals on AISs of cortical 
pyramidal neurons of the EAE mice which displayed compromised CO stability. The 
morphological integrity of GABAergic synaptic input at the AIS made by chandelier cells, 
a subset of GABAergic cortical interneurons (King et al., 2014; Wang et al., 2016), was 
determined through co-immunolabeling of AnkG and either vesicular GABA transporters 
(VGAT) or gephyrin to visualize the pre- and postsynaptic compartments, respectively.  
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     No change in either the percent of AISs with VGAT+ puncta or the number of 
presynaptic puncta per 10 µm of AIS was detected at the early time point in either clinical 
score group (Figs. 4.4U&V). In contrast to the early EAE groups, a significant reduction 
in the percent of AISs containing VGAT+ puncta, as well as in the number of these boutons 
per 10 µm of AIS was observed in the Late EAE 1&2 and Late EAE 3&4 groups (Figs. 
4.4U&V). These data demonstrate a loss of the presynaptic component of the GABAergic 
synaptic complex at the AIS in EAE. 
     To determine if the postsynaptic component of the GABAergic synaptic complex was 
also disrupted, immunolabeling for gephyrin, a postsynaptically localized scaffolding 
protein critical for the establishment and maintenance of these axo-axonic synapses 
(Choii and Ko, 2015), was performed on all EAE disease groups. Consistent with the 
VGAT analysis, no significant differences were observed in the percent of AISs containing 
gephyrin+ postsynaptic puncta nor the number of these puncta per 10 µm of AnkG 
immunolabeling between the Naïve and Early EAE 1&2 disease groups (Figs. 4.4X&Y). 
Also consistent with the VGAT analysis, significant loss in the percent of AISs containing 
gephyrin+ synapses and the number of  synaptic puncta as a function of AIS length (per 
10 µm) was observed in both the Late EAE 1&2 and Late EAE 3&4 disease groups (Figs. 
4.4X&Y). Surprisingly, a significant reduction in these parameters was also detected in 
the Early EAE 3&4 group (Figs. 4.4X&Y), which displayed intact VGAT+ presynaptic 
terminals (Figs. 4.4U&V).   
     As shown in Figure 4.4, we then correlated the disruption of the GABAergic synaptic 
complex with the CO integrity within each AIS. Triple immunolabeling for VGAT, Synpo, 
and AnkG revealed the ratio of CO to VGAT+ puncta number to be maintained at a two-
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to-one ratio in the Naïve and Early EAE 1&2 groups (Fig. 4.4W). This ratio is significantly 
reduced only in the Early EAE 3&4 disease group (Fig. 4.4H&W), a point at which VGAT 
immunolabeling is reduced (Fig. 4.4U&V) but CO number is maintained (Fig. 4.1). In 
contrast, the ratio of CO to VGAT+ puncta number was not significantly different from 
Naïve in both clinical score groups at the late time point (Figs. 4.4W) since CO number is 
also reduced at this disease stage (Fig. 4.1). Additionally, triple immunolabeling for 
gephyrin, Synpo, and AnkG and subsequent determination of the CO to gephyrin+ 
postsynaptic puncta ratio revealed similar trends to that of the VGAT-CO correlative 
analysis (Fig. 4.4Z). Overall, these data suggest that instability of the GABAergic synaptic 
complexes at the AIS is a downstream consequence of CO disruption in EAE.  
 
Cisternal organelle disruption in EAE is reversible following anti-inflammatory 
treatment 
     In the present study, we have provided the first evidence for pathological alterations 
to the CO. While we now know that the CO is vulnerable to disruption, we asked whether 
these pathological changes are reversible. Our lab has previously demonstrated, not only 
an alleviation of disease clinical scores, but also an attenuation of AIS pathology in EAE 
through treatment with a novel anti-inflammatory and free radical scavenger known as 
didox (Clark et al., 2016). To investigate whether the loss of the CO in EAE is also 
recoverable, we began treatment in the Early EAE 3&4 mice, a time point and disease 
stage at which significant CO loss is observed (Fig. 4.1). Following didox treatment, we 
first assessed CO integrity through immunolabeling for the two actin-associated markers 
utilized in Figure 4.1: Synpo (Fig. 4.5A-E) and α-Act (data not shown), both of which are 
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important for CO stability (Sánchez-Ponce et al., 2012). CO loss was indeed reversible, 
with the percent of AISs containing Synpo+ or α-Act+ organelles indistinguishable from 
Naïve, and significantly increased compared to the vehicle treated mice (Figs. 4.5A-D). 
Similarly, the number of Synpo- or α-Act-IR puncta was also reduced in the vehicle treated 
mice but significantly attenuated in the didox treated group (Figs.  4.5A-C, E). CO number, 
however, did not completely return to baseline when compared to the Naïve mice (Figs. 
4.5A, C, E).   
     We next investigated whether the CO integrity was also reversible based on 
immunolabeling of the functional Ca2+-regulating proteins assessed previously (Fig. 4.2). 
Triple immunolabeling with AnkG (βIV-spectrin in the case of the SERCA analysis), 
Synpo, and either annexin 6 (data not shown), IP3R1, or SERCA revealed a decrease in 
the percent of AISs containing COs positive puncta for these markers and a significant 
recovery following didox treatment (Figs. 4.5F-I, K-N). Didox treated mice, however, did 
display mixed results when assessing the percent of COs positive for each of the three 
Ca2+-associated proteins. Only the IP3R1 but not annexin 6 (data not shown) or SERCA 
(Figs. 4.5K-M, 5O) analysis revealed a significant return to Naïve levels for this 
measurement. SERCA labeling, however, reminiscent of the IP3R1 analysis, displayed 
significant recovery when compared to vehicle treated mice (Figs. 4.5K-M, O). Taken 
together, these findings reveal at least a partial, but potentially incomplete, recovery of 
CO proteins important for Ca2+ regulation at the AIS.  
       Finally, we investigated the reversibility of the F-actin and GABAergic synaptic 
complex loss at the AIS, a potential trigger (Fig. 4.3) and consequence (Fig. 4.4) of this 
pathological CO insult, respectively. As expected, phalloidin staining revealed significant 
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F-actin loss in the vehicle treated mice (Figs. 4.5P-T). Interestingly, this loss was also 
reversible with didox treatment (Figs. 4.5P-T). Immunolabeling for both the presynaptic 
(VGAT) and postsynaptic (gephyrin, data not shown) GABAergic complex components 
revealed a similar attenuation following didox treatment as compared to the loss observed 
in vehicle treated EAE mice (Figs. 4.5U-Y). Overall, these findings demonstrate that loss 
of CO integrity and GABAergic synaptic complexes at the AIS are reversible insults in 
EAE.  
 
The cisternal organelle and GABAergic axo-axonic synapses are lost in multiple 
sclerosis 
     The findings in the EAE model suggest that CO and axo-axonic synaptic loss at the 
AIS may represent previously unidentified insults associated with MS pathogenesis. In an 
effort to investigate the relevancy of these observations to the human disease, 
postmortem MS tissue was analyzed for each of these potential neuronal pathologies. As 
shown in Figure 4.6, double immunolabeling for AnkG and Synpo was performed to 
quantify the percent of AISs containing COs, the number of COs as a function of AIS 
length (number of COs per 10 µm of AIS) and the combined CO length as a function of 
AIS length (combined CO length per 10 µm of AIS). While no change in the percent of 
AISs containing the CO was detected between MS and control tissue (data not shown), 
significant reductions in CO number and total CO length per 10 µm of AnkG 
immunolabeling, as compared to the non-demented control tissue, were observed (Fig 
4.6). These findings are the first to demonstrate CO pathology in any human disease.      
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     As demonstrated in Figure 4.4, loss of the CO in EAE was observed preceding that of 
GABAergic axo-axonic boutons at the AIS. To investigate this relationship in the 
postmortem MS tissue, immunolabeling for VGAT was used to identify the axo-axonic 
GABAergic presynaptic terminals formed by chandelier cells (King et al., 2014; Wang et 
al., 2016). Similar to the findings of CO stability, a significant reduction in the number of 
VGAT+ synaptic terminals was also observed in postmortem MS tissue (Fig. 4.6). AISs in 
MS tissue presented with significantly fewer GABAergic boutons per 10 µm of AnkG 
immunolabeling, as compared to non-demented control tissue. Overall, these findings 
reveal a loss of both the CO and GABAergic axo-axonic synapses at the AIS, two 
previously unidentified neuronal insults associated with MS pathogenesis. 
 
4.5 Discussion 
     In the present study, we have identified the first pathological alterations to the CO, an 
organelle critical for the regulation of Ca2+ levels at the AIS (Benedeczky et al., 1994; 
Sánchez-Ponce et al., 2011). Additionally, the loss of this structure, as well as the 
GABAergic synaptic complexes on the AIS, represent previously unidentified neuronal 
insults associated with MS pathogenesis (Fig. 4.6). Investigating CO integrity in the 
inflammatory EAE model provided a more complete characterization of this novel 
pathology. Loss of F-actin clustering at the AIS presents before detectable changes to 
CO stability during EAE progression (Fig. 4.7B). In contrast, loss of the axo-axonic 
GABAergic synaptic complexes appear to occur downstream of the CO insult along the 
disease course (Fig. 4.7D). Importantly, the morphological alterations to the GABAergic 
synaptic terminals are consistent with the functional impairment of the GABAergic 
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inhibitory network previously reported in the Synpo deficient mice (Jedlicka, et al., 2009). 
Finally, structural disruption of the CO as well as its potential downstream pathology are 
reversible upon  anti-inflammatory and free radical scavenger treatment  (Figs. 4.5, 4.7) 
suggesting that these novel MS pathologies are clinically subject to therapeutic 
modification.  
 
How does cisternal organelle integrity affect AIS stability? 
     While our lab has previously identified extensive AIS disruption in EAE (Clark et al., 
2016), here we demonstrate loss of the CO in the population of AISs that remain 
morphologically intact (AnkG+). It remains unclear how CO and AIS loss may correlate 
mechanistically, but previous work in vitro and in vivo provides some insight. AIS stability 
is required for both the establishment and maintenance of the CO (Sánchez-Ponce et al., 
2011). Not only does AIS maturation precede that of the CO, but AnkG silencing in 
cultured hippocampal neurons results in complete destabilization of this organelle 
(Sánchez-Ponce et al., 2011). While these findings provide strong evidence for the 
dependence of the CO on AIS stability, the reciprocal relationship is not as clearly defined. 
Initial findings from Synpo deficient mice, in which the CO is not established, revealed no 
consequence on structural or functional integrity of the AIS with respect to AnkG 
localization and action potential generation (Bas Orth et al., 2007). The authors, however, 
acknowledged the possibility that the CO could play a role at the AIS distinct from the 
basic electrophysiological parameters tested (Bas Orth et al., 2007). A recent study 
suggested a role for the CO in modulating developmental plasticity of the AIS. Schlüter 
et al. (2017) demonstrated altered AIS length in the visual cortex of mice lacking the CO 
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following dark rearing. In addition to its role in AIS development, the CO may also play a 
role in maintaining GABAergic axo-axonic synaptic complexes based on 
immunocytochemistry colocalization (Benedeczky et al., 1994; King et al., 2014). 
Consistent with this possibility, electrophysiological studies in the Synpo deficient mice, 
which lack the CO and spine apparatus, revealed an impaired local inhibitory network 
(Jedlicka et al., 2009). Therefore, the apparent downstream consequence of CO loss, as 
observed in both previous (Jedlicka et al., 2009; King et al., 2014) and our present studies, 
is impaired structural and functional AIS stability, since the AIS is a highly plastic structure 
heavily regulated by neuronal activity (Yamada and Kuba, 2016; Jamann et al., 2017).  
     In addition to activity-dependent AIS alterations as a potential consequence of CO 
disruption, it is also likely that dysregulation of cytosolic Ca2+ at the AIS could lead to 
proteolytic modulation of this domain. Previous studies demonstrated cleavage of critical 
AIS components including AnkG, βIV-spectrin, and voltage-dependent sodium channels 
by calpain, a Ca2+-activated protease (Schafer et al., 2009). Calpain activation is central 
to a wide array of pathological AIS insults including those induced by ischemia (Schafer 
et al., 2009; Hinman et al., 2013), purinergic receptor activation (Del Puerto et al., 2015), 
glutamate excitotoxicity (Benned-Jensen et al., 2016), LPS-mediated inflammation 
(Benusa et al., 2016), and oxidative stress (Clark et al., in press). Because regulation of 
local Ca2+ is crucial for AIS stability, it is possible that alterations to the CO could underlie 
many of these previously identified AIS pathologies.  
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Is F-actin destabilization mediated by the inflammatory environment? 
     Here we show loss of F-actin clustering at the AIS of EAE-induced mice which 
precedes CO disruption (Fig. 4.3). This finding is consistent with other studies in which F-
actin is revealed to stabilize and maintain CO integrity at the AIS (Sánchez-Ponce et al., 
2011). Although loss of F-actin could be mechanistically upstream of CO disruption in 
EAE, the trigger for F-actin destabilization in this model remains unclear. It is likely that 
the inflammatory environment of EAE is responsible for the alterations of F-actin, as actin 
dynamics are modulated by a variety of inflammatory components (Cross and Woodroofe, 
1999; Delbro et al., 2009; Munnamalai and Suter, 2009; Tong et al., 2012; Munnamalai 
et al., 2014). Previous studies demonstrated loss of F-actin clustering in a variety of cell 
types as a result of an LPS-induced inflammatory insult and more specifically by cytokines 
such as IL-1β (Cross and Woodroofe, 1999; Delbro et al., 2009; Tong et al., 2012). 
Additionally, it is possible that oxidative stress plays a role in the F-actin alterations 
observed in this study, since clustering was recovered following free radical scavenger 
treatment (Fig. 4.5). Supporting this idea, reactive oxygen species (ROS) disassemble 
the F-actin cytoskeleton at the neuronal growth cone during normal neurite outgrowth 
(Munnamalai and Suter, 2009; Munnamalai et al., 2014). These changes are believed to 
be due to ROS-mediated activation of various kinases that regulate actin remodeling 
(Munnamalai and Suter, 2009). While these mechanisms are important for neural 
development, they may become pathological when overstimulated, as F-actin 
destabilization mediated through oxidative stress has been attributed to the pathogenesis 
of other neurodegenerative diseases such as Alzheimer’s disease (Bamburg and 
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Bernstein, 2016). The specific trigger of F-actin destabilization in the EAE model requires 
further investigation.  
 
Impairment of the GABAergic network in multiple sclerosis 
     In the present study, we have identified loss of the CO and GABAergic synaptic 
complexes localized at the AIS (Figs. 4.4, 4.6), two previously undescribed axonal insults 
in MS pathogenesis. These findings are consistent with the hypothesized role for the CO 
in maintaining these axo-axonic inputs at the AIS (Benedeczky et al., 1994; Jedlicka et 
al., 2009; King et al., 2014), and provide a possible explanation for the impaired 
GABAergic network reported in MS and its animal models (Dutta et al., 2006; Rossi et al., 
2011; Falco et al., 2014; Mosayebi et al., 2016). Western blot, as well as 
immunohistological analysis on postmortem MS and EAE cortical tissue, previously 
revealed decreased overall expression of pre- and postsynaptic components of the 
GABAergic complex (Dutta et al., 2006; Falco et al., 2014). These morphological findings 
are consistent with functional studies performed in the EAE model demonstrating loss of 
the hippocampal paired-pulse inhibitory effect (Mosayebi et al., 2016), as well as impaired 
striatal GABAergic transmission (Rossi et al., 2011). Though the triggers of structural and 
functional impairment of the inhibitory network in EAE are not clearly defined, loss of PV+ 
interneurons may contribute (Falco et al., 2014). In the present study, we reveal structural 
changes to the GABAergic axo-axonic synapses in the absence of PV+ interneuron cell 
death (Supplementary Fig. 4.2), at a much earlier disease stage than those examined in 
previous studies (Falco et al., 2014). This suggests that these effects are not, at least 
initially, consequences of neuron cell death. In addition to the animal studies suggesting 
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a functionally impaired GABAergic network, Arpin et al. (2017) used 
magnetoencephalography (MEG) to record neural responses following paired-pulse 
stimulations showing similar functional abnormalities in MS patients consistent with a loss 
of GABAergic synaptic complexes.  
     Overall, we provide the first evidence of CO disruption under pathological conditions, 
an insult that would have profound effects on local Ca2+ regulation at the AIS. Additionally, 
we report the disruption of the CO as well as the axo-axonic GABAergic synaptic terminals 
at the AIS in postmortem MS tissue. Characterization of CO insult in EAE revealed this 
disruption to be preceded by loss of F-actin clustering at the AIS and followed by structural  
impairment of the GABAergic network, which is consistent with previous studies that 
reported  compromised CO integrity and a disrupted CNS inhibitory network (Jedlicka et 
al., 2009; Sánchez-Ponce et al., 2011; King et al., 2014). Importantly, these changes are 
reversible upon free radical scavenger treatment in EAE, indicating that these neuronal 
MS deficits are potentially amendable to therapeutic approaches. 
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Figure 4.1. The cisternal organelle is disrupted in early and late EAE. Representative 
immunolabeling for the CO using antibodies directed against two structural CO proteins 
(Synpo (A-E) and α-Act (F-J), green; white arrows) in Early EAE 1&2 mice (B,G) reveals 
no change in either the percent of AISs containing these structures (K,M), or the number 
of these organelles per 10 µm of AnkG labeling (L,N) as compared to the Naïve group 
(A,F). Significant reductions in both of these values were detected in mice belonging to 
the Early EAE 3&4 (C,H), Late EAE 1&2 (D,I), and Late EAE 3&4 (E,J) groups. Isosurface 
insets of individual AISs are shown below the low magnification representative images. 
Asterisks without an associated bracket represent a significant difference from the Naïve 
group (*p < 0.05). 
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Figure 4.2. Calcium-regulating proteins at the cisternal organelle are compromised 
following EAE induction. Representative isosurface AISs immunolabeled with AnkG 
(grey), Synpo (green; white arrows), and either Annexin 6 (A-E), SERCA (F-J), or IP3R1 
(K-O) (red; white arrows) demonstrate no change in the expression of these Ca2+-
associated proteins on the CO in Naïve (A,F,K) and Early EAE 1&2 mice (B,G,L). Loss of 
each of these proteins on the CO is present in the Early EAE 3&4 (C,H,M), Late EAE 1&2 
(D,I,N), and Late EAE 3&4 (E,J,O) groups. Yellow arrows denote COs that are negative 
for Annexin 6 (C-E), SERCA (H-J), or IP3R1 (M-O) on the composite images. Data are 
presented as the percent of AISs containing COs positive for each of these Ca2+-
associated markers (P-R), the number of theses COs per 10 µm of AnkG labeling (S-U), 
and the percent of COs positive for each Ca2+-associated protein (V-X). Asterisks without 
an associated bracket represent a significant difference from the Naïve group (*p < 0.05). 
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Figure 4.3. Loss of F-actin clustering at the AIS precedes cisternal organelle 
disruption. Staining of F-actin with phalloidin (green; A-E) in representative images 
collected from Naïve mice (A) display numerous AIS-localized (AnkG, red; A-E) clusters 
(white arrows). Significant reduction in F-actin clustering at the AIS is first observed at 
Early EAE 1&2 (B), which persists at the Late EAE time point for both clinical score groups 
(D,E). Data for this analysis are presented as the percent of AISs containing F-actin 
puncta (K), as well as the number of these puncta as a function of AIS length (per 10 µm; 
L). Isosurface insets of individual AISs are shown below the low magnification 
representative images (A-E). Staining of F-actin (green; white arrows) with simultaneous 
double immunolabeling for Synpo (CO, red; white arrows) and AnkG (AIS, grey) allow for 
correlation between F-actin and CO loss (F-J). The ratio of F-actin to CO number at the 
AIS is only significantly reduced in the Early EAE 1&2 group (H), the clinical stage where 
F-actin loss precedes CO disruption. The F-actin/CO ratio returns to baseline level in the 
Early EAE 3&4 (H), Late EAE 1&2 (I), and Late EAE 3&4 (J) groups as subsequent CO 
loss is also observed. Yellow arrows (most prevalent in G merged) denote COs not 
colocalized with F-actin. Representative AISs are depicted as isosurface images (F-J). 
Asterisks without an associated bracket represent a significant difference from the Naïve 
group (*p < 0.05). 
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Figure 4.4. Axo-axonic GABAergic synaptic complexes are lost following cisternal 
organelle disruption. Immunolabeling of GABAergic presynaptic (VGAT, green; A-J) 
axo-axonic terminals in representative images collected from Naïve (A,F), Early EAE 1&2 
(B,G), and Early EAE 3&4 (C,H) mice display numerous AIS-localized (AnkG, red; A-E) 
GABAergic terminals (white arrows). Significant loss of these presynaptic axo-axonic 
synapses is observed, however, at the Late EAE time point of both clinical score groups 
(D,E). Similarly, postsynaptic (gephyrin, green; white arrows; K-T) GABAergic terminal 
labeling reveals no change in AIS localization (AnkG, red; P-T) in Early EAE 1&2 (L) mice 
as compared to the Naïve (K). This postsynaptic component of the GABAergic complex 
is, however, significantly disrupted in the Early EAE 3&4 (M), Late EAE 1&2 (N), and Late 
EAE 3&4 (O) groups. Isosurface insets of individual AISs are shown below the low 
magnification representative images (A-E). Data from these analyses are presented as 
the percent of AISs with either VGAT+ (U) or gephyrin+ (X) puncta, and the number of 
these GABAergic synaptic components (VGAT, V; gephyrin, Y) per 10 µm of AnkG 
labeling. Furthermore, the ratio of CO to pre- (VGAT; F-J, W) or postsynaptic number 
(gephyrin; P-T, Z) at the AIS (AnkG, grey) demonstrates a significant reduction beginning 
in the Early EAE 3&4 group, as CO disruption is observed to precede GABAergic axo-
axonic synaptic loss at this point (yellow arrows). Representative AISs are depicted as 
isosurface images (A-E; P-T). Asterisks without an associated bracket represent a 
significant difference from the Naïve group (*p < 0.05). 
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Figure 4.5. Cisternal organelle and axo-axonic GABAergic loss is reversible 
following free radical scavenger treatment. Immunolabeling for the CO (Synpo, green; 
A-C) in didox treated mice (C) reveals significant recovery in both the percent of AISs 
(AnkG, red; A-C) containing the CO (D), and the number of these structures per 10 µm of 
AnkG labeling (E) as compared to the Naïve (A) and vehicle treated (B) groups. 
Isosurface insets of individual AISs are shown below the low magnification representative 
images (A-C). Representative isosurface AISs immunolabeled with AnkG (grey; F-H), 
Synpo (green; F-H), and either IP3R1 or SERCA (red; F-H) demonstrate recovery of CO-
expression of these Ca2+-associated proteins in didox treated mice (H,M) as compared to 
the Naïve (F,K) and vehicle treated (G,L) groups. Data from these analyses are presented 
as the percent of AISs containing either IP3R1 or SERCA+ COs (I,N) and the percent of 
COs that are positive for these markers (J,O). Yellow arrows denote COs without 
colocalization of either Ca2+-associated proteins IP3R1 (F-H) or SERCA (K-M). Finally, 
both F-actin clustering (phalloidin, green; P-R) and GABAergic axo-axonic synaptic 
puncta (VGAT, green; U-W) recovered following didox treatment (R,W) with respect to 
both the percent of AISs (red, P-W) positive for each of these markers (S,X), and the 
number of these puncta as a function of AIS length (T,Y), as compared to the Naïve (P,U) 
and vehicle treated (Q,V) groups. Isosurface insets of individual AISs are shown below 
the low magnification representative images (P-R; U-W). Asterisks without an associated 
bracket represent a significant difference from the Naïve group (*p < 0.05). 
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Figure 4.6. The cisternal organelle and axo-axonic GABAergic synaptic terminals 
on the AIS are lost in postmortem MS tissue. Representative AISs (AnkG+, grey) 
immunolabeled in non-demented control (A,B) and multiple sclerosis (MS) (C,D) tissue 
reveal significant  fewer Synpo+ COs (red) and VGAT+ GABAergic synaptic terminals 
(green) in disease.  Quantitation of the number of these Synpo+ (E) and VGAT+ (F) 
structures, as a function of AIS length (per 10 µm), revealed significant reductions in MS 
tissue. Asterisks represent a significant difference from the control group (*p < 0.05). 
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Figure 4.7. Summary of findings for F-actin, cisternal organelle, and GABAergic 
synaptic disruption along EAE disease progression. Naïve mice present with intact 
filamentous actin (F-actin), cisternal organelle (CO), and an axo-axonic synaptic complex 
(composed of post synaptic density (PSD) and GABAergic Bouton) at the AIS. 
Destabilization of F-actin clustering is first observed in the early stages of the disease 
(Early EAE 1&2 (B)) preceding CO and axo-axonic GABAergic complex disruption. As 
the disease progresses, initial signs of CO loss are detected (Early EAE 3&4 mice (C)) 
preceding loss of axo-axonic GABAergic presynaptic clustering (VGAT), but coincident 
with reduced postsynaptic density (PSD) clustering at the AIS. In the later and more 
severe stages of disease (Late EAE (D)), loss of F-actin, COs, and axo-axonic GABAergic 
terminals is prevalent. Encouragingly, F-actin depolymerization, CO disruption, and loss 
of the GABAergic axo-axonic complex may be reversible (blue arrow); however, the 
therapeutic window for recovery has not been determined.  
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Supplementary Figure S4.1. Methodology of 3D automated image analysis. A 
representative raw image with immunolabeling for synaptopodin (Synpo;green) and the 
AIS (AnkG, red) shows Synpo+ puncta localized both at the AIS (termed the cisternal 
organelle), and outside the AIS (located on dendritic spines – termed the spine apparatus) 
(A). To focus our analysis specifically on the COs, Volocity™ 3D Image Analysis Software 
was used to select only those Synpo+ puncta colocalized with AnkG (D’, yellow arrows) 
in an automated fashion. This is performed through initial selection of total Synpo+ (B) and 
AnkG+ (C) positive objects, followed by exclusion of those Synpo+ objects not colocalized 
with AnkG+ structures (D, white arrows). Although Synpo is depicted as an example in 
this figure, all CO, F-actin, and GABAergic synapse analyses were performed using this 
quantifying approach.  
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Supplementary Figure S4.2. Neuronal loss was not detected in EAE or analyzed 
postmortem human MS tissue. Representative images of triple labelling for NeuN 
(green; total neurons), Parvalbumin (red; interneurons) and TUNEL (cyan) qualitatively 
show no apoptotic neurons in Naïve (A) or Late EAE mice (B). In contrast, some of the 
post mortem human Control (not shown) and MS (E; white arrows) samples revealed 
NeuN (green) and TUNEL (cyan) labelling indicative of apoptosis. These samples were 
excluded from analyses.  All analyses were restricted to postmortem control (C) and MS 
tissue (D) that did not contain apoptotic neurons.  
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Supplementary Figure S4.3. Non-isosurface images from Figure 4.2. Non-isosurface 
raw images of triple labelled synpo, AnkG and either annexin 6, SERCA, or IP3R1 from 
Figure 4.2. 
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Supplementary Figure S4.4. Non-isosurface images from Figures 4.3 and 4.4. Non-
isosurface raw images of triple labelled synpo, AnkG and either phalloidin (F-actin), 
VGAT, or gephyrin from Figures 4.3 and 4.4. 
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Supplementary Figure S4.5. Non-isosurface images from Figure 4.5. Non-isosurface 
raw images of triple labelled synpo, AnkG and either SERCA, or IP3R1 from Figure 4.5. 
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Supplementary Table S4.1. Summary of donor history and tissue characterization 
Tissue ID Sex 
Age 
(years) 
Diagnosis 
MS Duration 
(years) 
Postmortem 
Delay (hrs:min) 
Brain Region 
S11/044 M 51 Non-Demented Control NA 7:45 Medial Temporal Gyrus 
S95/056 F 86 Non-Demented Control NA 13:30 Inferior Temporal Gyrus 
S96/057 M 73 Non-Demented Control NA 6:00 Superior Temporal Gyrus 
S96/238 F 87 Non-Demented Control NA 8:00 Inferior Temporal Gyrus 
S96/251 M 84 Non-Demented Control NA 9:00 Inferior Temporal Gyrus 
S09/054 F 68 Multiple Sclerosis 4 8:25 Medial Temporal Gyrus 
S10/085 F 57 Multiple Sclerosis 27 8:40 Medial Temporal Gyrus 
S10/273 M 56 Multiple Sclerosis 14 9:50 Medial Temporal Gyrus 
S11/048 M 53 Multiple Sclerosis 24 10:00 Medial Temporal Gyrus 
S08/240 F 40 Multiple Sclerosis 6 8:55 Medial Temporal Gyrus 
S08/302 F 77 Multiple Sclerosis 24 10:00 Medial Temporal Gyrus 
S10/334 F 60 Multiple Sclerosis 7 10:40 Medial Temporal Gyrus 
S11/080 F 56 Multiple Sclerosis 32 8:25 Medial Temporal Gyrus 
S04/114 F 56 Multiple Sclerosis 20 6:35 Medial Temporal Gyrus 
S96/102 F 74 Multiple Sclerosis 24 5:30 Inferior Temporal Gyrus 
S96/115 F 57 Multiple Sclerosis 19 5:45 Inferior Temporal Gyrus 
S07/127 F 48 Multiple Sclerosis 23 11:40 Medial Temporal Gyrus 
S08/047 M 49 Multiple Sclerosis 25 8:00 Medial Temporal Gyrus 
S09/251 M 75 Multiple Sclerosis 39 7:45 Medial Temporal Gyrus 
S09/317 F 59 Multiple Sclerosis 24 4:45 Medial Temporal Gyrus 
S10/052 M 44 Multiple Sclerosis 22 10:15 Medial Temporal Gyrus 
S12/056 M 78 Multiple Sclerosis 33 8:45 Medial Temporal Gyrus 
S96/232 F 40 Multiple Sclerosis 4 7:00 Medial Temporal Gyrus 
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Supplementary Table S4.2. Summary of markers used 
Marker Target Structure Species/Isotype Dilution Manufacturer 
Ankyrin-G (AnkG) Axon Initial Segment Mouse/IgG2a 1:500 NeuroMab 
βIV-Spectrin Axon Initial Segment Rabbit/IgG 1:500 Gift from Dr. Matthew Rasband 
Synaptopodin (Synpo) Cisternal Organelle Mouse/IgG1 1:100 OriGene 
α-Actinin (α-Act) Cisternal Organelle Mouse/IgG1 1:500 Thermo Fisher Scientific 
Annexin 6 (A6) Cisternal Organelle Rabbit/IgG 1:500 Thermo Fisher Scientific 
Sarco-endoplasmic reticulum 
Ca
2+
-ATPase (SERCA) 
Cisternal Organelle Mouse/IgG2a 1:250 Abcam 
Inositol 1,4,5-trisphosphate 
receptor type 1 (IP
3
R1) Cisternal Organelle Rabbit/IgG 1:250 Thermo Fisher Scientific 
Vesicular GABA Transporter 
(VGAT) 
Presynaptic  
GABAergic Synapses 
Rabbit/IgG 1:500 Synaptic Systems 
Gephyrin 
Postsynaptic 
GABAergic Synapses 
Mouse/IgG2b 1:500 NeuroMab 
Parvalbumin 
PV+ Neocortical 
Interneurons 
Mouse/IgG1 1:1000 MP Biomedicals 
NeuN Neuronal Nuclei Rabbit/IgG 1:1000 Abcam 
Phalloidin 
Filamentous actin 
 (F-actin)  
NA 1:100 Thermo Fisher Scientific 
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CHAPTER FIVE 
DISCUSSION 
5.1 Synopsis 
     The focus of these studies was to better understand the stability and vulnerability of 
the axon initial segment in MS. While nodal disruption in MS was well characterized 
(Dupree et al., 2004; Coman et al., 2006; Howell et al., 2010; Pomicter et al., 2010; Zoupi 
et al., 2013), much less was known about the AIS, a compositionally similar axonal 
domain critical for neuronal function (Buttermore et al., 2013). To more effectively 
investigate the extent of AIS stability under hallmark conditions of MS pathogenesis, 
animal models of the disease were utilized and presented in Chapter 2. AIS integrity was 
assessed in both the cuprizone and EAE murine models, which are commonly used to 
recapitulate the demyelinating and inflammatory aspects of the disease, respectively 
(Kipp et al., 2017). Unlike the nodal domains, no changes in AIS stability were observed 
in the demyelinating cuprizone model. Extensive loss of AIS protein clustering was 
detected, however, following EAE induction. This disruption closely correlated with the 
inflammatory environment specifically with increased microglial reactivity and AIS contact 
(Figure 5.1). Treatment with a novel anti-inflammatory drug dampened the microglial 
response, attenuated AIS loss and restored AIS structure. This study revealed, for the 
first time, that the AIS, unlike the node of Ranvier, does not require myelin contact to 
maintain its integrity. This finding provides valuable insight into the pathogenesis of MS, 
as most neuronal insults in the disease are demonstrated to be consequential to myelin 
damage rather than primary pathogenic events. Furthermore, AIS alterations were found 
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to be driven by the local inflammatory environment suggesting that this mechanism of 
neuronal injury may not be restricted to MS pathogenesis.   
          While the study presented in Chapter 2 implicated the inflammatory environment in 
driving alterations at the AIS, the underlying mechanism remained unclear. The strongest 
insight was that oxidative stress was a key contributor as treatment with a free radical 
scavenger was capable of attenuating this insult. In order to investigate this further, we 
established an in vitro model that allowed us to more easily manipulate this AIS injury 
mechanism. In Chapter 3, AIS integrity was assessed in an in vitro primary cortical neuron 
system of oxidative stress induced through the application of SIN-1. The addition of this 
spontaneous ROS/RNS generator resulted in the loss of AIS stability, which was reversed 
upon resolution of the oxidative insult. ROS/RNS-induced AIS loss involves increased 
cytosolic Ca2+ entry specifically through L-type voltage-dependent Ca2+ channels and 
from IP3-gated intracellular stores (Figure 5.1). These AIS alterations are also dependent 
upon activation of calpain, a Ca2+-activated protease whose substrates include critical 
AIS components (Schafer et al., 2009) (Figure 5.1). Overall, we uncovered a mechanism 
of AIS injury driven by oxidative stress, a finding that could have implications for a variety 
of CNS pathologies. 
          Our lab and others have demonstrated that elevated levels of intracellular Ca2+ 
drive the pathologic mechanisms responsible for AIS disruption associated with ischemia, 
traumatic brain injury, Alzheimer’s disease, epilepsy, and MS (Schafer et al., 2009; 
Baalman et al., 2013; Greer et al., 2013; Harty et al., 2013; Hinman et al., 2013; Hamada 
and Kole, 2015; Clark et al., 2016; Vascak et al., 2017). Therefore, elucidating the 
mechanisms that regulate local Ca2+ levels at the AIS is therefore vital to addressing the 
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AIS alterations associated with these pathologies. This led us to investigate the cisternal 
organelle (CO), an AIS-specific Ca2+-storing organelle thought to regulate local cytosolic 
Ca2+ levels. Although this organelle may be central to AIS modulation, very little is known 
about the mechanisms regulating its stability and no pathological alterations have ever 
been described. To determine if CO integrity is altered coincident with AIS disruption, we 
performed morphological assessments in the EAE model in which severe AIS loss was 
previously observed. As presented in Chapter 4, extensive CO loss was detected and 
found to precede the AIS alterations in EAE (Figure 5.1). These changes were preceded 
by destabilization of F-actin at the AIS signifying a potential upstream trigger of CO 
instability under inflammatory conditions (Figure 5.1). Additionally, loss of GABAergic 
synapses at the AIS followed CO disruption consistent with the CO playing a critical role 
in stabilizing AIS axo-axonic synapses (Figure 5.1). Finally, CO disruption and loss of 
inhibitory synaptic complexes at the AIS were also detected in postmortem MS tissue. 
This study provided the first evidence of a pathologically-induced insult to the CO. 
Collectively, these studies provide crucial insight into the pathogenesis of not only MS, 
but an array of CNS insults in which axonal Ca2+ regulation is impaired. 
 
5.2 The AIS and CO: Inflammatory Mediated Modulation 
     Findings from EAE and the in vitro system of oxidative stress implicate the 
inflammatory environment in modulation of AIS and CO stability. As described in the 
Introduction, the MS inflammatory environment involves immune mediators including 
peripheral lymphocytes and resident CNS microglia with the peripheral lymphocytes 
believed to prime and drive the microglial response (Larochelle et al., 2011). For this 
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reason, the present studies have largely focused on the contribution of microglia, rather 
than peripheral lymphocytes to AIS and CO instability under these inflammatory 
conditions. As described above, microglia have biphasic roles in MS pathogenesis 
exhibiting reactivity states that are either pro-inflammatory or resolving depending on the 
stage of CNS damage (Luo et al., 2017). Fortunately for the characterization of MS driven 
AIS insult, these phenomena are recapitulated separately in the cuprizone and EAE 
models in which microglia exhibit reparative or destructive reactivity profiles respectively 
(Gao and Tsirka, 2011; Clemente et al., 2013). While microglia make close associations 
with the AIS in the non-inflamed state (Baalman et al., 2015), increased AIS-contacts 
were made by microglia displaying both types of reactivity profiles in the two models as 
presented in Chapter 2. The increased AIS associations by pro-inflammatory microglia in 
EAE, however, likely have destructive rather than protective consequences for the AIS 
providing a possible explanation for the differential outcomes on AIS stability seen 
between the cuprizone and EAE models.  
     While microglia appear to be the modulators of AIS and CO disruption in EAE, 
oxidative stress is the likely downstream contributor to AIS and CO instability, as free 
radical scavenger treatment prevented and/or reversed these insults. As presented in 
Chapter 3, further characterization in an in vitro model of oxidative stress revealed that 
exogenously applied ROS/RNS was sufficient to induce changes to the AIS complex. This 
is likely contributing to the AIS disruption observed in EAE since microglia produce 
ROS/RNS (Guemez-Gamboa et al., 2011) in close proximity to the AIS. Due to the lability 
of ROS/RNS (Forkink et al., 2010), the most destructive effects would likely be observed 
in microglial-contacted rather than uncontacted AISs. While AIS disruption, as detected 
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through AnkG and βIV spectrin localization, closely correlated to microglial reactivity and 
contact in EAE, the present studies did not make this correlation for the CO. As presented 
in Chapter 4, CO disruption was first detected at the Early disease stage in mice exhibiting 
severe clinical scores (3 & 4), a time point and disease stage following detectable 
microglial reactivity and contact with the AIS (Chapter 2). Therefore, it is possible that 
microglia also drive CO disruption in EAE. Additionally, using the same free radical 
scavenger treatment paradigm as in Chapter 2, CO loss was attenuated much like that of 
disrupted AnkG localization. This implies that CO disruption can occur through ROS/RNS-
induced insult as well. As discussed in Chapter 3, previous studies demonstrated 
oxidative stress-induced alterations to F-actin polymerization (Munnamalai et al., 2014), 
a component of the AIS cytoskeleton that is essential for proper CO maintenance 
(Sánchez-Ponce et al., 2011). Therefore, to further understand the mechanisms 
underlying these insults it would be important to investigate F-actin and CO stability 
following exogenous ROS/RNS treatment with SIN-1 in vitro and correlate the timing of 
this potential disruption to AnkG loss.  
 
5.3 The AIS and CO: Calpain Mediated Modulation 
     As described in the Introduction, calpain protease activation underlies AIS disruption 
in a variety of CNS insults (Buffington and Rasband, 2011), including the ROS/RNS-
induced insult presented in Chapter 3. Additional work in our lab revealed attenuation of 
LPS-induced AIS disruption following in vivo administration of a calpain inhibitor (Benusa 
et al., 2017) further implicating this protease in AIS modulation under inflammatory 
conditions. Previous studies have implicated calpain in MS pathogenesis with a proposed 
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role in myelin proteolytic breakdown (Rosenberger, 2014). Here, we propose an 
additional role for calpain under the inflammatory conditions associated with MS in 
targeting the AIS complex for disruption. Interestingly, calpain inhibition in the EAE model 
results in alleviation of clinical scores (Rosenberger, 2014); AIS stability, however, 
remains to be assessed. 
     In addition to AIS protein clustering, the relationship between CO stability and calpain 
activity remains elusive, but interesting. While no study has investigated this relationship 
specifically, calpain activation may occur both upstream and downstream of CO 
disruption under inflammatory conditions. For example, drebrin, an actin binding and F-
actin stabilizing protein, is a known target of calpain mediated proteolysis, resulting in F-
actin depolymerization (Chimura et al., 2015). This supports a role for calpain upstream 
of CO disruption since depolymerization of F-actin results in loss of CO stability (Sánchez-
Ponce et al., 2011). In contrast, because calpain activation requires large Ca2+ influx, it is 
also likely that protease activation would be a downstream consequence of CO loss, since 
this organelle is responsible for regulation of cytosolic Ca2+ levels (Benedeczky et al., 
1994; Sánchez-Ponce et al., 2011). Supporting this possibility, Chapter 3 demonstrates 
the involvement of IP3-gated intracellular Ca2+ stores in ROS/RNS-induced AIS 
disruption. We propose that the receptors contributing to Ca2+ release at the AIS following 
this insult were those present on the CO which releases Ca2+ in an IP3-gated manner 
(Benedeczky et al., 1994; Sánchez-Ponce et al., 2011). Because calpain requires 
micromolar to millimolar levels of Ca2+ for activation, cell death cascades could be 
activated if threshold levels are achieved cell-wide (Baudry and Bi, 2016). Perhaps the 
CO, instead, allows for local Ca2+ release at these levels specifically at the AIS to restrict 
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calpain activation to this axonal compartment. Further investigation in the SIN-1 in vitro 
model is required to elucidate the relationship between the CO and calpain during 
ROS/RNS-induced AIS disruption. 
 
5.4 Implications for MS Pathogenesis and Treatment 
     Here, we describe two previously unidentified neuronal insults in MS: disruption of the 
CO and loss of axo-axonic GABAergic synaptic complexes at the AIS (Chapter 4). We 
propose that these pathologies have detrimental effects on neuronal function since Ca2+ 
dysregulation at the AIS leads to a dysfunctional trigger zone and loss of neuronal polarity 
(Buffington and Rasband, 2011). Additionally, loss of GABAergic input at the AIS could 
also impair neuronal firing capabilities (Jamann et al., 2017) and contribute to the 
impaired GABAergic network seen in the EAE model and MS patients (Falco et al., 2014; 
Arpin et al. 2017).  
    Since we believe these insults have the potential to contribute to MS disability, and 
have demonstrated them to be driven by the inflammatory environment, it remains to be 
determined why currently prescribed immunomodulatory MS therapies are not effective. 
All currently approved MS therapies, while acting through slightly different mechanisms, 
aim to suppress the inflammatory response in a widespread fashion (Dargahi et al., 2017). 
Targeting the inflammatory response in this manner has proven more beneficial for the 
early phases of disease rather than later progressive stages (Torkildsen et al., 2016). It 
is possible that the AIS and CO insults highlighted in the present study are far more 
extensive in patients upon clinical presentation, and potentially beyond reversibility 
through anti-inflammatory treatment alone. In this case, it would be important to target 
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downstream of the inflammatory response. One such potential therapeutic target is 
calpain, the proteolytic effector of AIS disruption (Schafer et al., 2009; Del Puerto et al., 
2015; Benned-Jensen et al., 2016), which may exhibit high levels of activation at the 
chronic stages of MS pathogenesis that is unaffected by dampening of the inflammatory 
response. Encouragingly, the SIN-1 in vitro study presented in Chapter 3 demonstrates 
repair of the AIS complex once calpain activity is reduced. Additionally, calpain inhibition 
in EAE has shown promise as mentioned above (Trager et al., 2014; Cagmat et al., 2015). 
Selectivity may be an issue, however, since calpain is required for certain endogenous 
neuronal functions (Cagmat et al., 2015). 
 
5.5 Recommendations for Future Studies 
     While the present studies effectively characterize disruption of the AIS in EAE, 
technical challenges have prevented investigation of AIS protein clustering in postmortem 
tissue. As shown in Chapter 4, postmortem samples vary widely in collection time. This 
appears to have severe consequences on AnkG localizations since the AIS responds 
very rapidly to changes in neuronal activity (Evans et al., 2015) resulting in substantial 
AIS disruption (through AnkG localization) in the non-demented control in addition to the 
MS samples. In contrast, significant alterations to CO and GABAergic synaptic stability 
were detected in postmortem samples despite varying collection times (Chapter 4). These 
structures may be more resistant to the tissue processing issues seen with AnkG. 
Ultimately, in order to effectively investigate AIS disruption through AnkG immunolabeling 
in postmortem human tissue, it is important to obtain control and MS tissue that have 
much more consistent and reduced post-death collection times. Outside of collection 
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issues, differential AIS stability due to inconsistently affected CNS regions should be 
accounted for by pairing AIS assessments with lymphocytic and microglial markers to 
assess infiltration and activation, respectively. This would allow for a more effective 
correlation between AIS disruption and the varying degrees of inflammatory conditions 
with MS pathogenesis. 
     As described above, it would also be important to follow up the SIN-1 in vitro study 
with an investigation into the effects of exogenously applied ROS/RNS on the cisternal 
organelle. Correlating the CO disruption with that of the AIS is difficult in the EAE model 
since the first signs of insult appear concurrently at the Early 3&4 disease stage (Chapters 
2 and 4). Since these structures exhibit mutual dependence for stability, understanding 
the order of events mechanistically is crucial for identifying therapeutic strategies. This 
study would involve application of SIN-1 followed by morphological assessments such as 
those performed in Chapter 4. Additionally, F-actin should be investigated as a potential 
target of ROS/RNS-induced insult since its stability is critical for CO maintenance at the 
AIS (Sánchez-Ponce et al., 2011). If F-actin depolymerization is targeted by oxidative 
stress, as hypothesized (Munnamalai and Suter, 2009; Munnamalai et al., 2014), an F-
actin stabilizer such as jasplakinolide (Zhang et al., 2012) could be used to confirm F-
actin’s mechanistic positioning upstream of CO and AIS disruption under ROS/RNS-
induced insult. 
     Finally, although we have demonstrated reversibility of AIS and CO disruption in EAE, 
it would be important to examine a more chronic disease state for more relevant 
therapeutic potential. Our designation of “late” disease is only nine days following 
achievement of peak clinical scores, a far cry from the chronic inflammatory conditions of 
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the human disease. It would be important to know if free radical scavenging is a viable 
therapeutic target for late stage disease. Additionally, as mentioned above, examining the 
therapeutic potential of targeting calpain, a downstream mediator of AIS complex 
destabilization (Schafer et al., 2009; Del Puerto et al., 2015; Benned-Jensen et al., 2016), 
is also critical for addressing reversibility of AIS insults following the chronic inflammatory 
conditions associated with MS.  
 
5.6 Concluding Remarks 
     These studies identify disruption of the AIS and CO under the inflammatory 
environment of MS adding to the growing number of neuronal insults independent of 
myelin loss. Further characterization in EAE implicate microglia and the inflammatory 
environment of MS as drivers of AIS alterations. An in vitro primary neuronal system of 
oxidative stress allowed for elucidation of the mechanism underlying ROS/RNS-induced 
AIS insult revealing Ca2+ dysregulation to be central to these changes. Investigation of the 
CO, an important regulator of local Ca2+ levels at the AIS, in EAE and MS revealed the 
first described pathologically-induced alterations. CO loss was preceded by F-actin 
destabilization and followed by loss of GABAergic axo-axonic synaptic terminals at the 
AIS. Importantly both AIS and CO insults are reversible upon free radical scavenger 
treatment. Overall, these findings highlight the importance for the inclusion of primary 
neuronal insults, such as AIS and CO disruption, in future therapeutic strategies for MS.  
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Figure 5.1. Proposed mechanism of inflammatory-induced AIS and CO disruption. 
Reactive microglia make increased associations with the AIS in EAE. These cells release 
ROS/RNS in close approximation to the neuron. L-type VGCCs and IP3 receptors are 
both involved in ROS/RNS-induced AIS disruption. We hypothesize that the IP3 receptors 
involved in this mechanism are located at the CO. The CO is also a target of ROS/RNS 
resulting in Ca2+ dysregulation locally at the AIS. This can lead to calpain activation and 
proteolysis of critical AIS complex protein such as AnkG. CO destabilization also results 
in loss of GABAergic axo-axonic synapses at the AIS. These presumed changes in 
activity level may also contribute to structural modification of the AIS complex. 
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APPENDIX ONE 
Primary Cortical Neuron In Vitro System Methodology 
Media Recipes for Primary Cortical Neuron Culture 
Neurobasal Media w/out B27 (500 mL) NB w/ B27 (50 mL)   
500 mL  Catalog # 
Neurobasal Media 500-7.55 mL  Gibco 21103-049 
Anti-Anti 5 mL  Gibco 15240-096 
B-27* (50X) - 1 mL Gibco 17504-044 
L-Glutamine (200 mM) 1250 µL  Gibco 25030-149 
Glutamate (10mM) 1300 µL  Sigma G8415-100G 
*Will need with and without B-27* (Thaw frozen B27 at 4oC) 
            NB Media + B27 with anti-oxidants – for initial plating (100 µL/coverslip) 
            NB Media + B27 without anti-oxidants – for long term maintenance media (600 µL/well)   
Sterilize via vacuum filtration! 
Store at 4o C 
Poly-D-Lysine Coating 
Preparing the Solution 
1. Prepare Borate Buffer  
2. Dissolve 100 mg of Poly-D-Lysine (Sigma P0899) in 1 mL Borate Buffer and 
aliquot to 100 µL, store at -20oC. 
3. For each 10 mL Borate Buffer, add 100 µL of Poly-D-Lysine stock solution, filter 
through 0.22 µm filters. 
Preparing the coverslips 
Note: coverslips should be acid washed in 1 M HCl for at least 5 hours in 60oC water 
bath then rinsed thoroughly with DI H2O and stored long-term in EtOH.  
Borate Buffer  
 1 L Catalog # 
Water 1 L  
Boric Acid 3.1 g Sigma B6768-500G 
Sodium Borate 4.75 g Sigma 221732-500G 
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1. Place desired # of coverslips on Whatman paper and let dry under UV in the hood 
2. Put 100 µL of diluted Poly-D-Lysine solution on each coverslip and let sit in the 
hood for 1 Hr 
3. Transfer to 24-well plates containing DI H2O (keep coated side up) 
4. Dump and replace DI H2O at least 6 times (6 washes in DI H2O) (keep coated 
side up) 
5. Transfer washed coverslips to Whatman paper and let dry overnight under UV in 
the hood (keep coated side up!) 
6. Once completely dry, transfer to sterile 24 well plates for cell plating (keep coated 
side up) 
 
Neuronal Culture Preparation and Plating 
Pre-preparation 
- Make sure the incubator is set to 37oC and 5% CO2 
- Prepare 500 mL Neurobasal media (w/out B-27) and keep on ice  
- Put 10 mL of NB media (w/out B-27) in 6 petri dishes and keep on ice 
- Prepare Neurobasal media w/ B-27 + AO and keep on ice  
- Prepare Neurobasal media w/ B-27 - AO and keep in 37oC water bath 
- Thaw 2 mL accutase aliquot at RT and keep on ice once thawed 
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Removal of Embryos 
1. Euthanize the mother (containing E16 pups) 
2. Remove the embryonic sac 
- Apply ethanol to belly 
- pull up skin and cut open to reveal the embryonic sac 
- remove embryonic sac and place in a petri dish containing NB media (w/o B-27) 
to wash off excess blood 
3. Remove the individual embryos, decapitate with scissors, and place heads in a 
separate dish w/ NB media (w/o B-27) 
 
Dissection of Brains       ****From here on out, do all steps on ice!**** 
4. Place one head on a gauze pad soaked in ethanol under a dissecting 
microscope 
5. Using two very fine forceps peel off the skin - pinch in the center and pull in 
opposite directions to rip it away from the brain 
6. Using the same method, peel off the skull (it should be soft enough) 
7. Pick up the brain with the forceps (pinch underneath and lift) and place it into an 
empty dish containing NB media (w/o B-27) - do this for all brains 
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8. Place one brain in a separate dish w/ NB media (w/o B-27) under the dissecting 
microscope and using forceps and micro-scissors; remove and discard the 
cerebellum 
9. Separate the two hemispheres and turn them downward (midbrain on the 
bottom) - do not cut, pull them apart 
10. Using two forceps method, remove the meninges from both hemispheres 
(separately) - meninges need to be removed to prevent blood cells and other cell 
types from contaminating your culture  
11. Turn hemisphere back over (midbrain facing up) and cut out the midbrain w/ 
micro-scissors or with forceps– leaving only the cortex behind 
- place all cortex tissue in a separate dish containing NB media (w/o B-27) 
12. Transfer cortices (using a transfer pipette) into 2 mL of accutase in a 15 mL 
conical tube 
13. Let sit on ice for 10 minutes  
- do not close the conical tube lid - the cells need airflow 
- mix around every 5 minutes to break up clumps 
 
Neuronal Isolation       ****From here on out use NB media WITH B-27+AO**** 
14. Centrifuge the accutase/neuronal conical tube for 5 min at 900 RPM 
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15. Aspirate and discard supernatant w/ pipette-man and add 7 mL of complete NB 
media (w/ B-27+AO) – should use less than 7 mL if fewer you have fewer than 5 
cortices   
16. Homogenize (by trituration) w/ 10 mL pipette (until it flows smoothly) 
17. Homogenize (by trituration) w/ 10 mL pipette + 1000 µL sterile tip attached (until 
it flows smoothly) 
18. Homogenize (by trituration) w/ 10 mL pipette + 200 µL sterile tip attached  
(20 times up/down or until it flows smoothly) 
19. Pass homogenate through a 70 µm cell strainer in a 50 mL conical tube. 
20. Pass again through a second filter on another 50 mL conical tube = single cell 
solution 
 
Neuronal Counting & Plating 
21.      Dilute 30 µL of single cell solution into 270 µL of trypan blue in a hemocytometer 
and count.     
22.      Dilute to desired cell concentration (30,000 neurons per coverslip) in complete 
NB media (w/ B-27+AO) and plate (100 µL of cell solution) 
Desired plating concentration:  (30,000 cells)/(100 µL )=300,000 cells⁄mL 
23. 1 hour after plating (after cells have adhered to the coverslip): add 600 µL of NB 
media w/ B27 - AO with a multi-channel pipette  
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24. Leave the cells in the incubator without changing media. Treatments can begin at 
10 days after plating (the point at which the AIS is mature in vitro).  
 
Neuronal Culture Preparation and Plating 
The following steps are for treating one 24-well plate – do this for each plate separately 
1. Prepare necessary amount of media with B27 (–AO)  
(Depends on number of plates to be treated – need ~11 mL per plate) – do not 
prepare less than 50 mL since B27 (-AO) cannot be re-frozen 
2. Warm media to 37oC in water bath  
(do not treat cells until it has sat at least ~15 min in the water bath) 
3. Weigh out 1 mg of SIN-1 into a micro-centrifuge tube on an analytical balance 
4. Prepare two 15 mL centrifuge tubes – each with the appropriate amount of media 
ready to use immediately upon dilution of SIN-1 
- 1 tube with 6.05 mL media (Tube 1) 
- 1 tube with 3.75 mL media (Tube 2) 
 
5. Make sure all necessary pipettes are set and ready to use for treatment 
6. Use ~1 mL from Tube 1 to dissolve and rinse the tube containing 1 mg SIN-1 – 
quickly transfer this back to Tube 1 and vortex 
SIN-1 Dilution Final Concentration 
800 µM = 1 mg in 6.05 mL  
200 µM = 1.25 mL of 800 µM in 5 mL 100 µL added = 25 µM 
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7. Immediately add 1.25 mL of Tube 1 to Tube 2 and vortex 
8. Quickly remove plate to be treated from incubator and add 100 µL of Tube 2 to 
each well – dip the tip and add directly into the existing media so none of it is lost 
(keep using the same tip for every well to save time)  
9. Place plate back into incubator to be taken at desired time point 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
233 
 
VITA 
     Kareem Clark was born in Louisville, Kentucky in 1989. He was raised in North 
Carolina and received a Bachelor’s in Science Degree with a concentration in 
biochemistry from North Carolina State University in 2011. After college, Kareem was 
accepted into the Biomedical Sciences Doctoral Portal at the Virginia Commonwealth 
University School of Medicine, where he completed his neuroscience graduate training 
under the mentorship of Jeffery Dupree, PhD. This thesis was defended on October 30th, 
2017 before the PhD committee. 
 
